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Abstract
In this work a distributed computing system (RTGrid) has been configured and
deployed to provide a statistically robust comparison of Monte Carlo (MC) and
analytical dose calculations. 52 clinical oesophageal radiotherapy plans were
retrospectively re-calculated using the Pencil Beam Enhanced (PBE) and Col-
lapsed Cone Enhanced (CCE) algorithm within the Oncentra v4.3 radiother-
apy (RT) Treatment Planning System (TPS). Simulations were performed using
the BEAMnrc and DOSXYZnrc codes. The Computing Environment for Radio-
therapy Research (CERR) has been used to calculate Dose Volume Histogram
(DVH) parameters such as the volume receiving 95% Dose for the Planning Tar-
get Volume (PTV) for the PBE, CCE and MC calculated dose distributions. An
initial sample of 12 oesophageal radiotherapy treatment plans were simulated us-
ing the RTGrid system. The differences in the DVH parameters between the
dose calculation methods, and the variance in the 12 cases, were used to calculate
the sample size needed. The required sample size was determined to be 37, so
a further 40 oesophageal cases were simulated, following the same method. The
median difference in the PTV V95% between CCE and MC in the group of 40
cases was found to be 3%. To choose a suitable test for the statistical significance
of the difference, the Shapiro-Wilk test was performed, which showed that the
differences between the two sets of PTV V95% values did not follow a Gaussian.
Therefore the Wilcoxon matched pairs test was indicated, which showed that the
null hypothesis (i.e. that the distributions are the same) was rejected with a
p-value less than 0.001, so there is very strong evidence for a difference in the two
sets of values of PTV V95%. Similar statistical analyses were performed for other
DVH parameters, as well as Conformance Indices used to describe the agreement
between the 95% dose and the PTV, and estimates of the Tumour Control Prob-
ability (TCP). From the results, the use of MC simulations are recommended
when non-soft tissue voxels make up > 60% of the PTV.
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1Chapter 1
Introduction
1.1 Cancer
1.1.1 What is cancer?
Cancer is the term given to a disease in which cells of the body grow in an
uncontrolled way, potentially spreading to different parts of the body, and the
various illnesses caused by cancerous cells invading other tissues. There are over
200 different forms of cancer, relating to cells of different types and locations
(Peedell, 2005). A neoplasm (literally, new growth) is an abnormal growth of
tissue, due to rapidly proliferating cells, and may be malignant or benign (Seeley
et al., 2000). A malignant (from the Latin malignant, ‘with malice’) neoplasm
is a growth that can grow and spread. Benign (from the Latin benignus, ‘kind’,)
neoplasms are unlikely to continue to grow or spread. The common term ‘tumour’
can refer to any swelling, but is most commonly used to refer to a neoplasm.
Specific terms may be used depending on the type of tissue from which the tumour
has grown. For example a malignant neoplasm growing from epithelial cells (type
of cells lining surfaces, including the outside of the body, and the lining of cavities,
digestive tract etc.) is often called a carcinoma. A malignant neoplasm growing
from connective tissue cells is called a sarcoma.
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Hanahan and Weinberg (2000) describe six ‘hallmarks’ of cancer, which distin-
guish most and perhaps all cancer cells from normal cells.
1. Self sufficiency in growth signals: Normals cells will only divide and
proliferate when they receive a biochemical ‘signal’ to do so from the body.
Cancer cells are able to signal themselves to proliferate.
2. Insensitivity to anti-growth signals: Within normal tissue, there are
various mechanisms to prevent excessive growth by preventing proliferation.
Cancer cells are able to ignore signals to stop proliferating.
3. Evading apoptosis: apoptosis is a term for ‘programmed’ cell death, a
process used by the body to kill cells. Cancer cells are able to avoid apop-
tosis.
4. Limitless Replicative Potential: In order for a single cancerous cell to
grow to a macroscopic tumour, it must replicate at a rate far greater than
that of normal tissues.
5. Sustained angiogenesis: In order to proliferate, the tumour needs a blood
supply, to provide oxygen and nutrients. Cancer cells have the ability to
encourage new blood vessel growth, termed angiogenesis.
6. Tissue invasion and metastasis: Most tumours are able to produce
‘pioneer’ cells that spread, typically to nearby tissues and lymph nodes,
and then to further sites.
These differences are due to mutations in genes that regulate cell proliferation
and division. These mutations are predominantly acquired, rather than inherited
(Peedell, 2005), and may be caused by chemical, radiological or biological factors.
1.1 Cancer 3
1.1.2 Cancer statistics
The number of people being diagnosed with cancer is increasing. The lifetime risk
of cancer for people born in the UK since 1960 is now greater than 1 in 2 overall
(53.3% for men, 47.5% for women) (Ahmad et al., 2015). This is an increase
from the figure of 1 in 3 for those born since 1930. The lifetime risk of cancer,
as defined by Ahmad et al. (2015), means that as average lifespans increase there
will be a corresponding increase in the lifetime risk of cancer. The proportion of
the population living to at least 65 in the UK is expected to reach 24% in 2040,
compared with 16% in 2009 (Maddams et al., 2012). There are other factors
that lead to the observed increase in lifetime risk of cancer diagnosis, such as
increasing obesity, women having fewer children and having children later in life,
increases in red meat consumption, and better screening for certain cancers, e.g.
Prostate Specific Antigen (PSA) screening for prostate cancer, leading to more
cancers being diagnosed (from Ahmad et al. (2015) and references therein).
There are two related, but different ways of looking at death from cancer: mor-
tality rate, which is the proportion of people dying from cancer per 100,000; and
cancer deaths, which is the total number of deaths from cancer, usually expressed
as deaths within a calendar year. Mortality rates from cancer have decreased
since 1990, and are expected to continue to decline (Olsen et al., 2008). However,
the absolute increase in cancer diagnoses outweighs the decrease in mortality, so
that the number of cancer deaths is still increasing (Olsen et al., 2008).
The chances of surviving cancer are steadily increasing. Quaresma et al. (2015)
have analysed cancer survival rates in terms of a survival index, which is in-
dependent of changes in population age and prevalence of cancer in groups of
different age and gender. This survival index shows an increase in 10 year post-
diagnosis survival for both genders combined from 1 in 3 (34.4%) for 1990-1991
to 1 in 2 (49.8%) in 2010-2011. Quaresma et al. (2015) caution that this does
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not mean that half of patients will have their cancers cured, rather that half will
not die from their cancer. The survival at 10 years for different cancers varies
dramatically, from 1% for pancreatic cancer to 94% for testicular cancer.
Furthermore, the absolute number of people surviving cancer is increasing. Mad-
dams et al. (2012) expect that the number of cancer survivors in the UK will
increase by one million per decade from 2010 to 2040, so that by 2040 1 in 4
people in the UK will be a cancer survivor.
There are currently three main treatments for cancer, surgery, radiotherapy (RT)
and chemotherapy. These may be used on their own, or in a combination. It is
estimated that radiotherapy contributes to the cure of 40% of patients diagnosed
with cancer who survive five years or more, second only to surgery in its curative
effectiveness (Bentzen et al., 2005). RT is the use of ionising radiation to treat
cancer. The majority of RT is External Beam Radiotherapy (EBRT), in which
a beam of radiation from a treatment machine is directed at the cancer from
outside the body. However, the term includes brachytherapy, in which radioactive
sources are placed into the body, and unsealed source therapy, in which radioactive
chemicals in liquid form are introduced into the body. There is increasing interest
in immunotherapy, which aims to either enhance the body’s natural immune
response to cancer, or to help the immune system identify cancer cells, so that
they will be attacked1.
1.2 Oesophageal cancer
Oesophageal cancer was the eighth most commonly occurring cancer worldwide
in 2012 (Stewart and Wild, 2014), and the thirteenth most commonly occurring
1Immunotherapy. Available at: http://www.cancer.net/blog/2016-02/immunotherapy-
2016-clinical-cancer-advance-year (Accessed: 16 December 2016).
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cancer in the UK in 20132. The 8,784 new cases of Oesophageal cancer diagnosed
in the UK in 2013 accounted for 2% of the total cancer cases in the UK that
year. However, oesophageal cancer accounted for 5% of the deaths from cancer in
the UK in 20143. These trends are similar for Wales, where oesophageal cancer
accounted for 2,181 cancer diagnoses between 2010 and 2014, out of a total of
93,976 (2.3%). However, oesophageal cancer accounted for 2,091 deaths from
cancer between 2010 and 2014 in Wales, out of a total of 43,323 deaths (4.8%) in
the same period4.
Oesophageal cancer commonly presents with locally advanced or metastatic dis-
ease (Mukherjee et al., 2015). Survival rates for oesophageal cancer in the UK for
2010-2011 were 42% at one year after diagnosis, 15% at five years after diagnosis
and 12% at ten years after diagnosis5.
Stewart and Wild (2014) state that the two most common types of oesophageal
cancer are squamous cell carcinoma and adeno-carcinoma. These are cancers of
squamous cells (which are found in the skin, and linings of certain organs) and
cancers of the epithelial tissue (which lines the oesophagus, as well as other or-
gans), respectively. According to Peedell (2005), 65%-70% of oesophageal cancer
cases are adeno-carcinomas, although 20-30 years ago the majority of cases were
squamous cell carcinoma. Risk factors for squamous cell carcinoma of the oeso-
2Cancer Research UK. Oesophageal Cancer Incidence Statistics. Available at:
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/oesophageal-cancer/incidence#heading-Zero (Accessed: 18 November 2016).
3Cancer Research UK Oesophageal Cancer Mortality Statistics. Available at:
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/oesophageal-cancer/mortality (Accessed: 18 November 2016).
4Welsh Cancer Intelligence and Surveillance Unit, Welsh Cancer Statistics. Available at:
http://www.wcisu.wales.nhs.uk/officical-statistics-exel-files-of-trend (Accessed: 13 December
2016).
5Cancer Research UK. Oesophageal Cancer Incidence Statistics. Available at:
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/oesophageal-cancer/incidence#heading-Zero (Accessed: 18 November 2016).
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phagus include alcohol consumption, smoking or chewing tobacco, and drinking
hot beverages. Squamous cell carcinoma of the oesophagus tends to arise in low
resource regions of the world.
The most significant risk factors for adeno-carcinoma of the oesophagus are
obesity, gastro-oesophageal reflux disease, and smoking or chewing tobacco. An-
other risk factor is Barratt‘s Oesophagus, a complication of gastro-oesophageal
reflux disease in which the lining of the oesophagus begins to resemble that of the
intestine. However, only 5% to 10% of patients with Barratt‘s Oesophagus go on
to develop adeno-carcinoma of the oesophagus. The UK has the highest incidence
of adeno-carcinoma of the oesophagus in the world (Stewart and Wild, 2014), and
the highest age-standardised incidence of oesophageal cancer in Europe (Gatenby
et al., 2011). The incidence of oesophageal cancer has increased in men over the
last 35 years (Figure 1.1), whereas in women, after a peak incidence in 1990s,
rates have slightly declined. According to Parkin et al. (2011), 89% of cases of
oesophageal cancer in the UK are preventable, i.e. due to lifestyle factors.
Quaresma et al. (2015) grouped the 21 most common cancers into three clusters,
based on survival. The first cluster has the best prognosis, and includes breast,
prostate and testicular cancer. The second group has poorer prognosis, and in-
cludes bladder cancer and leukaemia. Oesophageal cancer falls into the cluster
with the poorest prognosis, with pancreatic and lung cancer.
The most common symptom of oesophageal cancer is difficulty swallowing, ini-
tially solids, and later liquids, which is also known as progressive dysphagia.
Patients may also suffer from weight-loss. If the oesophagus is blocked, this may
cause coughing, regurgitation of food, choking on food, and pneumonia (Peedell,
2005).
Screening using endoscopy has proved to be expensive and error-prone (Stew-
art and Wild, 2014). Non-endoscopic methods involve threading a deflated bal-
loon through the oesophagus, inflating the balloon, then pulling the balloon back
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Figure 1.1: Age-standardised incidence rates of oesophageal cancer
per 100,000 population, by sex, for Great Britain.
through the oesophagus. Cells from the lining of the oesophagus adhere to the
surface of this balloon, which can be tested for cancerous cells. Developing a
blood test for oesophageal cancer is the subject of significant current research
interest in Wales6.
Surgery is the most common treatment for early stage oesophageal cancer. Med-
ical Research Council (MRC) trial OE02 (Allum et al., 2009) showed an advantage
to neo-adjuvant chemotherapy (N.B. no radiotherapy) and surgery compared to
surgery alone. Chemo-radiotherapy (CRT) is commonly used if the cancer has
spread, or the patient is too unwell to tolerate surgery (Gwynne et al., 2011). CRT
may be used in two main ways, as the sole treatment, known as definitive CRT, or
prior to surgery, called neo-adjuvant CRT. Survival at two years from definitive
6Cancer Research Wales. New Smoke Detector Test For Oesophageal Cancer. Available
at: https://www.cancerresearchwales.co.uk/blog/new-smoke-detector-test-for-cancer/ (Ac-
cessed: 28 November 2016).
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CRT was reported by Gwynne et al. (2011) as over 40%, which is comparable
to surgery alone. Gwynne et al. (2013) discussed that most relapses following
definitive CRT are due to local progression or local recurrences, suggesting that
the standard doses of CRT are not high enough.
1.2.1 SCOPE1 Trial for oesophageal cancer
SCOPE1 (Hurt et al., 2011) was a multi-centre randomised controlled trial to
compare CRT with and without a chemotherapy agent called Cetuximab. The
trial closed early due to the research arm (CRT plus Cetuximab) showing higher
than expected toxicity, poorer completion (completing the whole course of ther-
apy), and poorer survival. However, the control arm (CRT only) showed better
overall survival (56%) compared with the prediction of 35% (Crosby et al., 2013).
This was attributed to the radiotherapy protocol design and quality assurance
used for SCOPE1. However, the authors also cite other positive contributory
factors such as patient selection and improvements in the organisation of cancer
services, access to Positron Emission Tomography (PET) and the role of Multi-
Disciplinary Teams (MDTs) in the management of oesophageal cancer. The trial
is considered a watershed in the design of radiotherapy trials, and the import-
ance of quality assurance within such trials - this despite the main trial aim being
related to the effect of an additional chemotherapy agent.
The details of the protocol, as they relate to this project, will be discussed in
section 3.2.1.
As part of the SCOPE1 trial, test cases were sent to the prospective centres,
which required all clinicians to delineate the diseased tissue on an anonymised
Computed Tomography (CT) scan. A RT treatment plan had to be prepared
on this test case, and the outlines, plan and doses returned to the Radiotherapy
Trials Quality Assurance (RTTQA) centre for assessment. RTTQA are a group
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funded by the National Cancer Research Institute (NCRI), which ensures that
patients in all NCRI radiotherapy trials are treated in accordance with the trial
protocol, and are treated according to nationally accepted standards. RTTQA are
responsible for the quality assurance of radiotherapy in clinical trials. A centre
was only able to enrol patients in the trial if the outlining, planning and dose
calculation were deemed to have passed the quality checks by the RTTQA team.
1.3 Radiobiological rationale for radiotherapy
It is common to deliver radiotherapy in a series of ‘fractions’, with each fraction
typically delivered on separate weekdays, over a period of weeks. However, some
fractionation schemes may involve multiple fractions per day, or no breaks for
weekends, or a single fraction per week. Radiotherapy kills cells by damaging the
deoxyribonucleic acid (DNA) in cells. Due to the famous double helix structure
of DNA, the damage to it can be classified as a Single Strand Break (SSB) or a
Double Strand Break (DSB). The aim of the fractionation schedule is to make the
radiation more damaging to the cancerous cells than the surrounding tissue. The
five factors, known at the ‘5 Rs’, which affect the choice of fractionation schedule
identified by Steel (1997) are Radio-sensitivity, Re-oxygenation, Redistribution,
Re-population and Recovery.
1.3.1 Radio-sensitivity
Radio-sensitivity is the amount of damage done by a standard dose of radiation.
The ability of the cell to rejoin DSBs in DNA, and the fidelity of such repairs
determine the sensitivity of a cell to radiation. (SSBs are easy for the body to
repair, as the double helical structure will not alter; a DSB, or many breaks in a
small area can cause sections of DNA to become detached, which is hard to repair
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correctly. Mis-repair can lead to cell death or mutation; mutation can then lead
to carcinogenesis) .
1.3.2 Re-oxygenation
Since 70% of the body is comprised of water, the most common molecule for
radiation to interact with is water, or H2O, commonly producing a positively
charged H2O+ molecule, and a negatively charged electron, e−. There follows a
series of interactions, leading to various highly reactive ions with unpaired elec-
trons, known as free radicals. Oxygen reacts with these free radicals to produce
hydro-peroxy radicals, such as HO−2 , which are highly toxic to biological struc-
tures such as DNA. Therefore damage due to RT is affected by the availability of
oxygen. The Oxygen Enhancement Ratio (OER) is the ratio of doses needed to
produce a given effect in the presence and absence of oxygen. The OER is 2.5-3
for low Linear Energy Transfer (LET) radiation, such as x-rays or gamma rays
(for the higher LET values found in particle therapies, OER values are lower,
approaching unity for carbon ion beams). Some regions of tumours have a very
low oxygenation level, which makes them resistant to radiation compared to the
rest of the tumour and normal tissue.
Re-oxygenation is important as cells that are Hypoxic during the first treatment
may become oxygenated for subsequent fractions, increasing their sensitivity to
radiation-induced damage.
1.3.3 Redistribution
The sensitivity to radiation damage varies over the cell cycle, the sequence of
changes in a cell in which it splits into two cells (Figure 1.2). The cell cycle can
broadly be split into:-
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• Gap 0 or G0: a resting phase, after the previous division has completed
and before a new division starts;
• Gap 1 or G1: cell increases in size;
• Synthesis or S: DNA is replicated, resulting in two copies of the DNA
molecule;
• Gap 2 or G2: further increase in cell size;
• Mitosis or M: Cell splits into two, each with one of the DNA molecules.
Mitosis
Gap 2
Synthesis
Gap 1
Gap 0
Figure 1.2: Graphic of the phases of the cell cycle, showing Gap 0,
Gap 1, Synethsis, Gap 2 and Mitosis phases.
A given cell is relatively more resistant in the late S phase, when the DNA mo-
lecule is being replicated, compared to the G2 or M phases. At irradiation, tu-
mour cells will be in different stages of the cell cycle. A cell in the S phase
during the first fraction may be in the G2 or M phase for subsequent fractions,
so may be killed by the radiation - this effect is known as Redistribution. This
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re-assortment means that fractionating the treatment will kill more cells. This
effect is complicated by checkpoints in the cell cycle, which slow down the cycle
in cells with damaged DNA.
1.3.4 Re-population
Tumours undergo Re-population between fractions by cell proliferation. The
rate of cell division in treated tumours can be accelerated, possibly due to the
increased abundance of nutrients. This limits the total time a treatment can last.
1.3.5 Recovery
Cells can also undergo Recovery from radiation damage, which reduces the
number of cells killed during prolonged treatments, or following missed fractions.
1.4 Therapeutic window
The aim of radiotherapy is to give enough radiation to the cancerous cells to
produce a desired effect , while keeping the effect on healthy tissue to acceptable
levels. The desired effect is to kill enough cells so that the body can deal with
the remainder, or reducing tumour size to alleviate symptoms. The proportion
of cells in a sample that is killed by a dose of radiation can be approximated by
a sigmoid (’S’-shaped) curve. Up to a certain dose of radiation, virtually no cells
are killed; as the dose is increased, the proportion of cells rises rapidly at first,
as the more radio-sensitive cells are killed. As the dose is further increased, the
proportion of cells killed begins to slow, as only the more radio-resistant cells are
left. Assuming healthy and cancerous cells exhibit this behaviour leads to the
concept of the ‘therapeutic window’, illustrated in Figure 1.3. If the curves are
close together, with the curve for the cancerous cells to the left of the healthy
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Figure 1.3: Illustration of the concept of the therapeutic window in
radiotherapy.
cells, there will be a small range of suitable radiotherapy doses that can satisfy
both the requirement to treat the tumour, and to spare healthy tissue. If the
curve for the cancerous cells is to the right of the the curve for the healthy cells,
there will be no therapeutic window, as is the case for stomach cancer. Different
fractionation schedules (or the use of more advanced radiotherapy techniques,
to shield healthy tissue better) may widen the therapeutic window. It should
be noted that the therapeutic window is essentially an illustrative concept - the
curves in Figure 1.3 cannot be determined for an individual patient.
1.5 Reactions to radiotherapy
The reactions to RT can be divided into three categories:
• acute or early reactions: Occur within a few weeks of treatment, and
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are associated with damage to rapidly dividing cells, and include reactions
such as hair loss and reddening of the skin, known as erythema;
• sub-acute reactions: Occur between one and six months after radiother-
apy, and include inflammation of lung tissue, known as radiation pneumot-
itis, and fatigue;
• late reactions: are usually the reactions that prevent higher doses of radi-
ation being used, and vary between irradiation site, but include tissue death
(necrosis), ulceration, nerve damage (neuropathy), inflammation of the sac
surrounding the heart (pericarditis) and dry mouth due to damage to the
salivary glands (xerostomia).
1.6 Radiotherapy planning and delivery
1.6.1 Treatment Planning Systems
Modern-day RT may be radical (aiming to cure the disease) or palliative (aiming
to provide relief from the symptoms of the disease). The RT may involve simple
irradiation conditions, or more complex radiation dose distributions, tailored to
the individual patient‘s anatomy. This more complex form of RT is called Con-
formal Radiotherapy (CFRT). CFRT is recommended by the National Institute
for Clinical Excellence for RT of many sites, including Urological, Breast and
Head and Neck cancers7.
In CFRT, a CT scan is taken of the patient and images loaded into specialised
software, called a 3D Treatment Planning System (TPS). Oncologists will outline
the cancerous tissue they wish to treat, and Organs At Risk (OARs) to which
they wish to limit the dose, and state the total radiation dose they want to deliver.
7NICE website. Available at: https://www.nice.org.uk/ (Accessed: 21 November 2016).
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Treatment planning staff then use the 3D TPS to model the radiation treatment
to be delivered by a medical Linear Accelerator (linac). Treatment planning staff
choose suitable beam entry angles, sizes and shapes to deliver the required dose
of radiation to the target volume, while avoiding healthy tissue as far as possible.
The TPS calculates the dose that will be absorbed by the patient anatomy from
the chosen beam arrangement, and displays the dose distributions overlaid on the
CT scans, using visualisation tools such as Isodoses and Dose Volume Histograms
(DVHs). Isodoses are lines (often coloured) that indicate regions getting the same
dose (c.f. isobars, lines of equal pressure on a weather map). The isodoses can be
used to see regions of the target that may not be getting enough dose, or regions
of healthy tissue getting too much dose. DVHs are a type of histogram used to
show the volume of a target or OAR that is received a given dose. Commonly,
cumulative histograms are used, so the histogram shows the volume getting up to
and including a specified dose. Commonly, for a given treatment site there will
be objectives given in terms of DVH parameters, i.e. at least 99% of the target
volume must receive at least 95% of the prescription dose. The planning staff
then adjust the beam arrangement and parameters to maximise the tumour dose,
and minimise the sensitive tissue dose, based on the isodoses and DVH.
The decisions made to optimise the dose distribution assume that the dose calcu-
lated by the TPS is accurate. However, the two current dose calculation methods
used in the TPS used at Velindre Cancer Centre, Cardiff, Elekta Oncentra8,
known as the Pencil Beam (PB) and Collapsed Cone Algorithm (CC) algorithms
(Ahnesjö and Aspradakis, 1999), each involve assumptions and approximations
to allow dose calculation in a reasonable time. These assumptions may cause
the calculated dose to deviate from the true dose at interfaces between tissues
of different densities (IAEA, 2013). It is generally accepted that CC is the more
accurate algorithm, but it is not always used due to the longer calculation times,
8Oncentra. Available at: https://www.elekta.com/software-solutions/#treatment-
management (Accessed: 21 November 2016).
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or poorer resolution for comparable calculation times. There is also the com-
plicating factor that CC reports dose to material, not dose to water as PB does
(Ahnesjö, 1989).
There are several advantages of using an algorithm that reports dose to water.
Clinical experience is based on calculations that yield dose to water. There may be
uncertainties in deducing the material involved in the dose to material calculation.
In cases where bone is contained within the Planning Target Volume (PTV),
it may not be possible to deliver sufficient radiation to treat the bone to the
prescription dose if the dose is reported as dose to medium. The advantages
of reporting dose to material are that it is more closely related to the energy
absorbed by the physical matter in the patient. There is some discussion on
whether the dose to water is a better surrogate for the radiobiological effects on
bony tissue (Liu et al., 2002).
The gold standard of dose calculation in radiotherapy is the Monte Carlo (MC)
method, which involves simulating radiation transport through the linac and the
patient on a particle by particle basis (Verhaegen and Seuntjens, 2003). It is
therefore intrinsically very accurate, but very computationally intensive; the dose
deposited in a patient from a CFRT treatment may take days of CPU time to
calculate by MC, using current computational methods and technology.
1.6.2 Linear accelerators
The majority of EBRT is delivered by linacs (Figure 1.4). A linac is a medical
device that accelerates electrons through an evacuated wave-guide to a potential
of several million volts. Generally, this wave-guide will not be directed at the
patient. Due to the length of the wave-guide, if it were directed at the patient,
the assembly would not be able to be positioned under the patient without the
patient being suspended several meters above the floor. Therefore, the electron
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Figure 1.4: Photograph of a Varian 2100CD linac at Velindre Cancer Centre, aka
‘LA6’.
beam must be deflected by beam steering magnets towards the patient. As the
electron beam is poly-energetic, different energies would be deflected by different
angles in a simple magnetic field, so different manufacturers have devised different
methods to perform this bending in a way that does not lead to dispersion, known
as achromatic bending. The electron beam is then incident on a heavy metal
target, typically tungsten or tungsten-alloy, whereby photons are produced by a
process called Bremsstrahlung. As this is the origin of the photons this is termed
the ‘source’. Distances are defined relative to the plane containing this source, for
example the ‘source to skin’ distance is the distance the patient’s skin surface is
from the source plane. The generation of photons in this way produces a photon
beam that is more intense in the centre of the beam than at the edges, which is not
generally suitable for treating patients. Therefore a shaped piece of metal, known
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as a flattening filter, is placed in the beam, which absorbs more radiation on the
beam axis than at the edges to produce a relatively flat beam profile at a specific
depth. This flattening filter causes differential beam hardening across the beam,
resulting in a more energetic beam on the central axis than off axis. Currently
there are two main linac manufacturers, Varian (Varian Medical Systems, Palo
Alto, CA, USA)9 and Elekta (Elekta Limited, West Sussex, UK)10. A specific
model of Varian linac, known as a Varian 2100CD has been used throughout this
work. Where the design details of a Varian 2100CD differ from a generic linac,
this will be highlighted.
A lead block with a cone cut from it, known as the primary collimator, confines
the beam to a cone. If the secondary collimators are opened fully the corners of
the field will be missing, due to the shape of the primary collimator.
Secondary collimators or jaws are blocks that move in and out of the beam to
define the size of the radiation beam (Figure 1.5). There are upper collimators
that define the field size in one direction, and lower collimators mounted below
them to define the field in the perpendicular direction. Due to the finite radiation
source size, there will not be a drop in dose from 100% to 0% at a single point at
the edge of the field. There will be a penumbral region in which the collimator
blocks part of the source (the effects of scatter blur the beam edge further). The
size of the penumbra region depends on the source to skin distance, and the
distance between the collimator and the point halfway between the source and
the patient surface. Therefore, the upper collimators have a larger penumbra
than the lower collimators. To reduce the penumbra, in some linacs such as
the Varian Clinac 2100CD, the edge of the collimator can be aligned with the
beam divergence (Figure 1.5). For this the collimator must move along an arc,
9Varian Linacs. Available at: https://www.varian.com/oncology/products/treatment-
delivery (Accessed: 3 December 2016)
10Elekta Linacs. Available at: https://www.elekta.com/radiotherapy/treatment-delivery-
systems.html (Accessed: 3 December 2016)
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which increases the height of the treatment head. When radiation is incident
on the face of the collimator, rather than the upper surface, the radiation will
not be attenuated by the full thickness of the collimator. Radiation entering the
collimator near the lower edge will have a shorter path length, and be attenuated
Target
Primary collimator
Flattening filter
Ionisation chamber
Y jaws
X jaws
MLCs
Patient
Patient invariant
Patient specific
Electron beam
Figure 1.5: Block diagram of Varian 2100CD linac. Y jaws, X jaws and Multi-Leaf
Collimators (MLC) shown as moving in same plane for illustrative purposes only. The
target, primary collimator and flattening filter are fixed for a given energy, and are
referred to as the patient invariant portion of the linac head. The jaws and MLCs are
positioned depending on the patient, so are referred to as the patient specific portion
of the linac head.
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less, than radiation entering near the upper edge. This contributions to the size
of the penumbra; Figure 1.6 illustrates that angling the face of the collimator
to align with the beam divergence reduces the size of the penumbra. On Varian
machines, only the upper collimators move in an arc, to save on isocentric height.
Non angled Y-jaw Angled Y-jaw
Finite focal spot
Figure 1.6: Diagram illustrating how aligning the face of the collim-
ator with the beam divergence reduces the beam penumbra.
A hard wedge is a physical piece of metal, shaped to give an isodose angled at
15o, 30o, 45o or 60o to a plane at right angles to the central axis at a specified
depth. For Varian hard wedges, this depth is 5 cm along the the central axis,
following the approach of Hughes et al. (1972). The varying thickness of metal
produces differential beam hardening and scatter across the field.
A flying wedge is a motorised 60o physical wedge in the linac head, which can be
driven into and out of the beam. If for example the flying wedge is in the beam
for a given fraction of the treatment time, a similar profile will be produced as if
a 30o wedge had been used. These wedges still have differential beam hardening
and scattering across the beam. Varian 2100 linacs do not use flying wedges.
For machines in which the collimators move asymmetrically, one jaw can be driven
across the beam during irradiation, such that a wedged isodose will be produced.
On a Varian linac, the wedge angle is defined at 10 cm deep, following the ap-
proach of ICRU (1976). This means there is no differential beam hardening or
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scatter across the beam. Any wedge angle up to 60o could be produced in theory,
but profiles would have to be measured, and quality assurance performed, on
each. Only 15o, 30o, 45o and 60o Enhanced Dynamic Wedges (EDWs) are used
at Velindre Cancer Centre.
An MLC consists of scores of pairs of thin leaves (40, 60 and 80 are common
configurations), which can be moved to produce an irregular field shape, to im-
prove conformity
(
Figure 1.7(a)
)
. Due to restrictions on isocentric height, the
leaves cannot move in an arc to keep their edges at the divergence angle of the
field, so are rounded, to produce as low a penumbra as possible at all positions(
Figure 1.7(b)
)
.
One of the most important components of the linac is the monitor chamber.
This is a thin, transmission ionization chamber, positioned below the flattening
filter, and above any beam shaping collimators. While most radiation will pass
through the chamber (it is constructed from low attenuation materials) some
will cause ionisation in the gas within the ionization chamber. The chamber has
parallel plate electrodes, which collect the charge. The resultant signal will be
proportional to the amount of radiation passing through the chamber, so can be
used to monitor (hence the name) the radiation fluence above the beam shaping
collimators.
The chambers are divided into segments, and analysing the relative signal from
different segments can be used in feedback loops to correct problems with the
beam generation. For example, changes in the electron beam energy incident on
the target will affect the relative intensity in the centre of the beam compared to
the edge of the beam. If the electron beam hits the tungsten target off centre,
the beam will be more intense on one side of the beam than the other. It is also
common to have two chambers, one ‘downstream’ of the other, where the second
acts as a backup to the first. The linac will be calibrated in terms of Monitor
Units (MU), a way of linking the signal from the monitor chamber to a radiation
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dose. The MU will be calibrated in such a way that 100 MUs will deliver 1 Gray
(J/Kg) of dose, under reference conditions. Measuring under reference conditions
involves measuring at 10 cm deep in a water phantom at standard temperature
and pressure, placed with its surface 90 cm from the source of the radiation (the
tungsten target), when the collimators define a 10 cm by 10 cm field. When
delivering 100 MU, the dose given to a patient, or test phantom, can be altered
by altering the collimator settings or MLC shape, or moving the patient closer
or further from the linac. The MU is designed to take account of fluctuations in
the intensity of the radiation beam, but to be independent of how the patient is
set up, or how the collimators are configured. However, some linacs are affected
by backscatter from collimators into the monitor unit chamber (section 3.2.4.6).
Calculating the number of MUs to deliver the required dose in a patient is usually
performed by a TPS.
1.6.3 Radiotherapy computer systems
The planning, delivery and monitoring of RT involves the use of many computer
systems, which must communicate with one another. Medical images and certain
other data are often transferred between computer systems in Digital Imaging and
COmmunications in Medicine (DICOM) file format, which is an international
standard for the transfer of medical images. DICOM is used to transfer CT,
PET and many other medical images, each known as a modality in DICOM
terminology. Digital Imaging and COmmunications in Medicine, Radiotherapy
Supplement (DICOM-RT) is an extension to the DICOM standard for data used
in radiotherapy, and defines seven additional modalities: -
• RTSTRUCT, which describes the details of the OARs, target volumes and
the external contour;
• RTPLAN, which describes details about the treatment plan;
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• RTIMAGE, for a type of image peculiar to radiotherapy, called a Digit-
ally Reconstructed Radiograph (a prediction of a 2D image based on a 3D
dataset);
• RTDOSE, which describes the dose calculated for a plan, in a matrix of
voxels;
• RTRECORD, to record the parameters used during external beam treat-
ment delivery;
• RTBRACHYRECORD, to record the parameters used during delivery of
Brachytherapy;
• RTSUMMARYRECORD, to record dose delivered during a course of treat-
ment
Due to the extensive use of DICOM and DICOM-RT as a transfer standard, it
is very common to store files that follow the formatting defined by the DICOM
and DICOM-RT standards, so the transfer standards have become de facto file
format standards too. There are therefore a number of tools available to read,
manipulate and save DICOM and DICOM-RT files.
1.7 Summary
Cancer is one of the leading causes of death in the world. While oesophageal
cancer is not the most prevalent form of cancer, it does have significant mortal-
ity rates in Wales, UK and across the world. Many forms of cancer are treated
with radiotherapy, either as the sole treatment or in conjunction with other treat-
ments, such as chemotherapy or surgery. The SCOPE1 trial demonstrated the
importance of RTTQA for oesophageal radiotherapy, and established a protocol
for delineation and treatment planning that is still the standard for oesophageal
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treatments in Velindre Cancer Centre. These treatments are designed on TPS,
and delivered by linacs. If the TPS employs an algorithm with too many approx-
imations or assumptions, the treatment delivery parameters produced may not
result in the delivery of the required dose, which may compromise the efficacy of
the treatment.
1.8 Thesis objectives
The aim of this study is to establish whether MC methods provide significantly
different results to conventional analytical dose calculations used in conformal
photon radiotherapy treatment planning for oesophageal cancer. MC calcula-
tions are much slower than the algorithms used in TPS. Using MC clinically will
require additional resources, and determining whether MC is important will allow
appropriate and effective deployment of resources in the future.
Over the last 10 years, work has been undertaken at Velindre Cancer Centre to
develop a system known as RTGrid (Downes et al., 2009) to perform MC dose
calculations for CFRT, on a variety of computational resources. These resources
include those at the Welsh e-Science Centre (WeSC)11 which can be controlled by
RT physicists at Velindre Cancer Centre, or computational resources at Velindre
Cancer Centre itself. The development of RTGrid was originally funded by a
£400,000 grant from the Engineering and Physical Sciences Research Council12.
Expected plan turnaround is a few hours, rather than the several days required
for the same task on a single PC. These resources have been utilised for this
research. This study will compare PB, CC and MC, for a large number of clinical
cases to determine in which cases each mode of dose calculation is appropriate.
11WeSC. Available at: http://www.cs.cf.ac.uk/wesc/ (Accessed: 21 November 2016).
12EPSRC grant. Available at: http://gow.epsrc.ac.uk/NGBOViewGrant.aspx?
GrantRef=EP/C538641/1 (Accessed: 21 November 2016).
1.9 Thesis outline 25
This will allow effective deployment of clinical resources to the situations where
they are most needed.
The study cohort will be conventional clinical CFRT plans calculated using PB,
on the clinical TPS, Elekta Oncentra, at Velindre Cancer Centre. These can be
re-calculated using CC, also using the clinical TPS, and using MC on the RTGrid.
Differences between MC, CC and PB calculations can then be determined in the
required regions of interest. These will inevitably include the PTV, which includes
the tumour plus a margin for clinical spread, and a further margin for set-up
uncertainties (ICRU, 1993, 1999) together with any clinically important radiation-
sensitive normal structures, or OARs. Over 2500 CFRT plans are prepared per
annum in Velindre Cancer Centre, including approximately 50 oesophageal plans
per annum, which can be used for the study. The RTGrid system will be used to
export the necessary parameters from the clinical plan and return the MC dose
distributions to the PTV and OARs for comparison. Data analysis and reduction
will be performed using a variety of systems including analysis software previously
developed in Velindre Cancer Centre for comparing MC calculated doses and doses
from commercial treatment planning systems (Spezi et al., 2002).
1.9 Thesis outline
The structure of the thesis is as follows: -
• Chapter 1: Introduction
• Chapter 2: Overview of dose calculation methods in external beam Radio-
therapy. Distributed computing for MC calculations. Clinical relevance of
dose calculations.
• Chapter 3: The use of the RTGrid system, including changes required to
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allow simulation of oesophageal plans. Pilot study and sample size calcula-
tion.
• Chapter 4: Main study, analysis of differences between calculation methods.
• Chapter 5: Conclusions.
• Appendix: Dissemination
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(a) Millenium 120-leaf MLC, defining the field according to a standard test
shape.
(b) Millenium 120-leaf MLC, in which the curved leaf ends can be seen.
Figure 1.7: Photographs of Millennium 120-leaf MLC on a Varian
2100CD linac.
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Chapter 2
Dose calculation for external
beam radiotherapy
2.1 Introduction
This chapter will provide an overview of dose calculation methods for EBRT,
starting with a discussion of the interaction of radiation with matter. Superposi-
tion and convolution dose calculation methods will be discussed, and the PB and
CC algorithms used in Oncentra v4.3 will be described. An overview of the MC
method will be presented, with a focus on the BEAMnrc package. To conclude
the chapter, a review of MC simulations on distributed computing platforms will
be presented.
2.2 Photon interactions with matter
The attenuation of photon beams passing through an absorber is due to five major
types of interactions of photons with matter (Khan, 2003):
1. Coherent scattering;
2. Photo-electric effect;
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3. Compton scattering;
4. Pair production;
5. Photo-disintegration.
Photo-disintegration only occurs above a threshold, which is over 10 mega-electron
volts (MeV) for most nuclei (but is approximately 2 MeV for beryllium and deu-
terium). Even above the threshold, it has a low probability of occurring, and will
not be discussed further.
Neglecting photo-disintegration, the total mass energy attenuation co-efficient for
a photon beam, µ/ρ, is given by Equation 2.1:
µ/ρ = σcoh/ρ + τ/ρ + σc/ρ + κ/ρ (2.1)
where σcoh, τ , σc and κ are the attenuation coefficients for coherent scattering,
photoelectric effect, Compton scattering and pair production respectively. These
four processes will be discussed below.
In EBRT, the range of energies encountered is 625 MeV (Velindre Cancer Centre
uses energies of 6 MeV and 10 MeV). The effective atomic number (Z) is 7.4
for muscle and water and is 13.8 for bone, although higher Z values may be en-
countered in metal implants - hip prostheses commonly contain titanium (Z = 22).
Figure 2.1 shows the most probable interaction for a range of Z values and en-
ergies. It follows that Compton scattering is the most probable interaction for
EBRT, while Photo-electric effect (PE) is most probable for the lower energies
used in medical imaging, and pair production is important in EBRT for materials
with high Z.
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Figure 2.1: Illustration of the relative importance of the three prin-
cipal types of photon interaction in an absorber of atomic number Z,
for a photon with energy hν in the range 0.01-100 MeV, where τ , σ and
κ are the probability of photoelectric, Compton and pair interaction
occurrence, respectively.
Short M. (2015) Photoelectric Effect[Online]. Available at:
https://www.flickr.com/photos/mitopencourseware/3706466731 (Accessed: 25 July 2017).
2.2.1 Coherent scattering
In coherent scattering, also known as classical scattering or Rayleigh scattering,
no energy is converted to kinetic energy, but photons are deflected (Figure 2.2).
Considering the radiation beam as an electro-magnetic wave (or a superposition
of waves), the wave induces oscillations in the electrons bound to atoms (c.f.
induced oscillations of electrons in an antenna). Coherent scattering leads to a
broadening of radiation beams below 100 kilo-electron volts (keV), such as those
used in diagnostic radiology (Johns and Cunningham, 1983). It is not shown in
Figure 2.1 as it is not the most probable interaction for any energy range or value
of Z encountered in radiotherapy.
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E = hν
E = hν
Figure 2.2: Illustration of a photon undergoing coherent scattering. The scattered
photon has the same energy, hν, as the incident photon, and no energy is transferred.
2.2.2 Photo-electric effect
PE is the process in which a photon interacts with an atom and causes a bound
electron to be ejected (Figure 2.3). The energy of the electron is entirely absorbed
by the atom, and is then transferred to the ejected electron. If the photon energy
is given by E = hν, where h is Planck‘s Constant and ν is the frequency of the
photon, the ejected electron will have an initial energy of hν − EB, where EB is
the binding energy of the electron. If hν is less than EB for the lowest energy
electron state, PE is not possible. If the electron is ejected from an inner shell,
an electron from an outer shell can drop down to fill the hole. A photon will then
be emitted with a characteristic energy, EChar, equal to the difference between
the energy levels of the two shells (Figure 2.4).
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E = hν
E = hν − EB
Figure 2.3: Illustration of the photo-electric effect, in which an electron is emitted
with E = hν − EB.
Figure 2.1 shows that the photo-electric effect is the most probable interaction
photons of energy0.1 MeV for the ranges of Z naturally occurring in the human
body, so is most relevant in imaging rather than EBRT.
2.2.2.1 Auger electrons
Instead of a characteristic photon being emitted, the photon can be reabsorbed
by the atom, and an electron from a higher shell is emitted to carry away the
excess energy from the atom. This electron is known as an Auger electron. It
the electron emitted is due to transitions within sub-shells of the same shell, the
electron is known as a Coster-Kronig electron.
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EChar
Figure 2.4: Characteristic photon emitted following photo-electric event.
2.2.3 Compton scattering
Compton (or incoherent) scattering is the process in which a photon, of energy
E = hν, collides with an electron, and is deflected at an angle θ, leaving the
photon with a lower energy, E ′. The energy lost by the photon is converted to
the kinetic energy of the electron, which is deflected at an angle φ (Figure 2.5).
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E = hν
E′ = hν ′
φ
θ
Electron
Figure 2.5: Illustration of Compton scattering.
The greatest energy transfer from the photon to the electron occurs when the
photon is scattered backwards, i.e. θ = 180o, and the electron is scattered in
the forwards direction, i.e. φ = 0o. Zero energy is transferred from the photon
to the electron where θ = 0o and φ = 90o, so the photon is not deflected, and
the electron is scattered at right angles to the photon. Figure 2.1 shows that
Compton scattering is the most probable interaction the energies encountered in
EBRT, given the range of Z naturally occurring in the human body.
2.2.4 Pair production
If a photon of energy > 1.022 MeV, i.e. twice the rest mass of an electron, interacts
with the strong Coulomb field of a nucleus, the photon may be converted into an
electron-positron pair, following E = mc2 (Figure 2.6). While the threshold for
pair production is 1.022 MeV, Figure 2.1 shows that it is only the most probable
interaction for much higher energies, particularly in higher Z materials such as
titanium, so pair production is significant in hip prostheses.
The energy of the photon above 1.022 MeV is transferred into the kinetic energy
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of the electron and positron, although the kinetic energy may not be distributed
equally between the particles (Khan, 2003). The nucleus will recoil, and carry
away some energy too, so momentum is not conserved between the photon, elec-
tron and positron. The positron will annihilate when it collides with an electron,
releasing two 511 keV photons (Figure 2.7).
e−
e+
Figure 2.6: Illustration of pair production.
2.2.4.1 Triplet production
A related process to pair production is triplet production, which occurs in the
Coulomb field of an electron rather than a nucleus. In triplet production, an
electron-positron pair is produced, and energy is imparted to the original electron.
The threshold for triplet production is twice that for pair production.
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E = 511 keV
E = 511 keV
Figure 2.7: Illustration of production of annihilation photons, arising from the
positron created during a pair production event.
2.2.5 Charged particle interactions with matter
Charged particles such as electrons interact with matter via ionisation and excit-
ation, which are mediated by the Coulomb force between the electrons and the
bound electrons or nuclei of atoms making up the material (Khan, 2003). For
electrons in water or soft tissue, the collisions may be:
• inelastic collisions with bound electrons (ionisation and excitation);
• inelastic collisions with nuclei (which leads to Bremsstrahlung);
• elastic collisions with bound electrons;
• elastic collisions with nuclei.
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For elastic collisions, no kinetic energy is lost (but may be re-distributed between
particles). As electrons move through a material, they continually lose energy
(which is deposited in the medium) until they reach thermal energies, and are
captured by the atoms of the material. In higher Z materials, such as lead,
electrons may interact via the Bremsstrahlung process, giving rise to new photons.
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(a) Percentage depth dose curves at 6 MV.
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(b) Percentage depth dose curves at 10 MV.
Figure 2.8: Percentage Depth Dose curves for Varian 2100CD at Velindre Cancer
Centre.
Figures 2.8(a) and (b) show the variation of absorbed dose, normalised to the
maximum value and expressed as a percentage, as a function of depth along the
central axis of a photon beam from a Varian 2100CD linac at Velindre Cancer
Centre. These Percentage Depth Dose (PDD) curves were acquired during linac
commissioning, a process that involves taking measurements of the photon beams
generated by the linacs, to allow the dose to be calculated by TPSs. Absorbed
dose is defined as the energy absorbed per unit mass in a material, in this case
water. The interactions between photons and materials outlined in sections 2.2.2,
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2.2.3 and 2.2.4 describe the photon imparting energy to the medium (often the
electrons of the medium). Considering PE, energy is removed from the photon
beam when the electron is ejected from the atom, but the energy is only absorbed
by the media when the electron interacts with other atoms, depositing energy.
This leads to two related but distinct concepts:
1. kerma is the kinetic energy released per unit mass, and relates to energy
leaving the photon beam due to interactions that set charged particles in
motion;
2. absorbed dose is the energy absorbed per unit mass, and related to energy
being deposited into tissue by electrons
Kerma may be separated into two parts, KCol due to inelastic collisions (i.e.
ionisation and excitations); and KRad due to radiative transfers.
Figures 2.8 (a) and (b) show that the absorbed dose near the surface is relatively
low (60% for 6 MV and approximately 40% for 10 MV), before climbing to a
maximum dose at a depth denoted DMax. This is an effect called build-up, and
is due to the electrons that are set in motion near the surface not being absorbed
until they have travelled a finite distance in the water. At DMax, the energy im-
parted to electrons by the photon beam is balanced by the energy absorbed by the
medium from the electrons, a condition known as Charged Particle Equilibrium
(CPE). Once CPE has been established, absorbed dose and KCol are equal to each
other. Strictly, this is not possible due to the attenuation of the beam, so the
absorbed dose is greater than KCol, this is termed transient CPE. In situations
where (transient) CPE is not present, i.e. at surfaces, or interfaces between two
materials of different densities, KCol and absorbed dose are not equal; it is often
harder to calculate absorbed dose in such regions.
After DMax, the PDD curves shown in Figures 2.8 (a) and (b) fall, due to at-
tenuation by the water phantom, and the effect of the inverse square law. As
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the radiotherapy beams are poly-energetic, the lower energy components will be
preferentially attenuated, and the mean energy of the beam will shift towards
higher energy with increasing depth. It can also be seen that 10 MV beams are
more penetrating than 6 MV beams are, due to their higher energy (Figure 2.8
(b) shows a higher value at 400 mm deep than Figure 2.8 (a) does). Also, the
larger field sizes show higher PDD values at depth than the smaller field sizes,
due to radiation scattering from regions off the central axis onto the central axis
at depth, and increases in head scatter and backscatter with increasing field size.
Figures 2.9 (a-d) show ‘profiles’, plots of the variation in absorbed dose across
the width of a 20 cm by 20 cm field, for 6 MV and 10 MV, either normalised
at each depth separately, or normalised to a common dose. It can be seen that
at 5 cm deep, the beams have pronounced ‘horns’, i.e. the profile has a local
minimum in the centre of the beam, and the profile has higher readings off axis.
For the 10 cm deep profiles, this effect is much smaller, and the beam is almost
flat in the central region. At 20 cm deep, the profile has pronounced ‘shoulders’,
with the measurement falling off away from the central axis. This effect is due
to the production of photons via Bremsstrahlung and the flattening filter. The
beam leaving the target is much more intense on the central axis than off axis.
The flattening filter attempts to remove this effect by preferentially absorbing
photons on the central axis. As the photon beam is poly-energetic, lower energy
photons are absorbed preferentially in the flattening filter, and this effect is more
pronounced on the central axis where the filter is thickest. Therefore the condition
that the beam is flat can only be satisfied at one depth, usually chosen to be 10 cm.
At approximately ±10 cm laterally, there is a sharp fall off in all profiles, i.e.
the beam edge, due to the position of the collimators. It can be seen that the
beam falls to approximately 5% over a few millimetres. This is partly due to the
finite source size, so that the edge of the collimators is blurred out, and partly
due to lateral scatter blurring the edge of the beam. This region is known as the
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penumbra of the beam. The region outside the beam is called the umbra, and dose
here is due to the small portion of radiation passing through collimators, scatter
radiation from the directly irradiated portion of the phantom, and indirect head
scatter.
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(a) Un-normalised beam profiles at 6 MV.
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(b) Un-normalised beam profiles at 10 MV.
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(c) Normalised beam profiles at 6 MV.
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(d) Normalised beam profiles at 10 MV.
Figure 2.9: Beam profiles for Varian 2100CD at Velindre Cancer Centre.
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2.4 Analytical dose calculation methods
2.4.1 Factor based dose calculations
The dose at a point on the central axis of radiotherapy beam can be calculated
by Equation 2.2, where PDD is the PDD at depth d, MU is the number of MU
delivered, K is the calibration factor, typically 1 Gy per 100 MU, SC(rC) is the
collimator scatter factor of a field size rC defined at the source to axis distance,
SP (r) is the phantom scatter factor of a field size for r defined at the patient
surface, SCD is the source to calibration distance, SSD is the source to surface
distance, and t0 is the reference depth (Khan, 2003).
Dose = PDD(d)×MU ×K × SC(rC)× SP (r)×
(
SCD
SSD + t0
)2
(2.2)
Equation 2.2 does not account for the presence of wedges, heterogeneities, or
allow for the calculation of dose off axis. The dose on the central axis in the
presence of a wedge (hard or dynamic) may be accounted for using a Wedge
Factor (WF). The WF is defined as the ratio of doses at a reference depth with
and without a wedge in the beam; the reference depth is often taken to 10 cm
deep. The WF depends on energy of the beam, angle of wedge, and for dynamic
beams the field size. Calculating the dose off-axis may be achieved using an Off
Axis Factor (OAF), which is the ratio of absorbed dose at a point away from the
beam axis, to the absorbed dose at a point on the beam axis at the same depth.
The OAF depends on energy of the beam, depth, and the field size. Accounting
for heterogeneities is more complex, but may be achieved using a Power Law
approach, as outlined in section 2.4.2.
In modern radiotherapy, factor based dose calculations are primarily used to check
more complicated dose calculation methods, but illustrate that:-
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• absolute dose changes with jaw size and source to surface distance;
• variation of dose with depth depends on depth, collimator sizes, and source
to surface distance;
• energy and dose change with depth and off axis position;
• wedges change absolute dose, as well as the shapes of isodoses;
• scatter from the head of the linac and scatter from the phantom behave
differently, and should be considered differently.
2.4.2 Power Law corrections
Consider calculating the dose in a water-like medium, in which there is an irregu-
larly shaped region of low density material (e.g. a lung). Clearly, the dose within
the low density material will be different to the dose at the same point in a homo-
geneous water phantom. The dose in the region ‘downstream’ of the radiotherapy
beam will also be different to the dose in a similar homogeneous water phantom.
This situation is too complex to have a series of pre-defined factors to correct for
the presence of the heterogeneity. The dose will be affected by the size and shape
of the heterogeneity, as well as the proximity of the dose calculation point to the
heterogeneity. Johns and Cunningham (1983) describe a power law correction,
based on the method of Batho, later extended by Sontag, for correcting the dose
at a point in or ‘downstream’ of a heterogeneity. This method is encapsulated in
Equation 2.3, in which:
• TAR is the Tissue Air Ratio (TAR), where the TAR at a point in a water
phantom is the ratio of the total absorbed dose at that point, divided by
the total absorbed dose at a point with the same distance from the source,
but measured with the phantom shifted so that this point is at the depth
of maximum dose (British Institute of Radiology, 1996);
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Z1
Z2
Calc Point
Figure 2.10: Diagram depicting an inhomogeneous region, in which
a Batho type calculation may be employed. Z1 is the distance from the
point at which the beam enters the inhomogeneity to the calculation
point, and Z2 is the distance from the point at which the beam exits
the inhomogeneity to the calculation point.
• z1 is the distance along the ray line from the calculation point to the point
where the beam enters the heterogeneity;
• z2 is the distance along the ray line from the calculation point to the point
where the beam exists the inhomogeneous region (Figure 2.10);
• fd is the field size defined at a depth d;
• ρ1 is the density of the heterogeneity;
• ρ2 is the density of the outer material (i.e. the water phantom).
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This correction still does not account for lack of CPE close to boundaries between
tissues, or the shape of the heterogeneities.
C = TAR(z1, fd)
ρ1−ρ2
TAR(z2, fd)1−ρ2
(2.3)
2.4.3 Type A and type B algorithms
Dose calculation methods can be divided into two types, those that cannot model
lateral electron scatter, termed type A algorithms, and those that can, termed
type B algorithms. In those algorithms that cannot model lateral electron scatter,
there will be errors in regions without Charged Particle Equilibrium, i.e. at the
surface of the patient, or near interfaces between tissues of different densities.
Also, the width of the penumbra in low density media, such as lungs, will be
incorrectly modelled in type A algorithms.
Examples of type A include PB in Oncentra, the Pencil Beam algorithm in Eclipse
and any factor based method that does not account for lateral scatter. Examples
of type B include CC in Oncentra, and the Anisotropic Analytical Algorithm in
Eclipse, which accounts for lateral scatter within a plane only, so is sometimes
referred to as ‘2.5D’, as it does not account for heterogeneities in 3D.
2.4.4 Kernel based methods
Modern TPS dose calculation algorithms use dose deposition kernels in the cal-
culation, which are matrices or analytical functions describing the dose deposited
around the point at which a photon interacts with matter. These kernels may
be combined with the photon fluence via convolution or superposition methods.
Convolution is a mathematical operation to describe the overlap of two functions
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as one function is moved over the other. The modifying function must be in-
variant over the space in which the convolution takes place. In convolution-based
dose calculations, the dose D(~r) at a point ~r may be given by Equation 2.4, where
µ
ρ
is the mass attenuation co-efficient, Ψp(~r′) is the primary photon energy fluence
at a point ~r′, A(~r−~r′) is the convolution kernel. This convolution kernel is a mat-
rix or function describing the dose distribution deposited by scatter photons and
electrons set in motion at the primary interaction site. This may be expressed as
a function of total energy released per unit mass (terma), Tp(~r′), a concept ana-
logous to kerma, but which includes all energy released, not just kinetic energy,
i.e. radiative energy is included. In practice, Fast Fourier transforms may be used
to perform convolution calculations quickly.
D(~r) =
∫ µ
ρ
Ψp(~r′)A(~r − ~r′)d3~r′ (2.4)
D(~r) =
∫
Tp(~r′)A(~r − ~r′)d3~r′ (2.5)
Convolution is only valid if the modifying function (the kernel, in dose calcula-
tions) is spatially invariant, so convolution is not always applicable. If the kernel
varies with depth, or off axis distance, superposition must be used in place of con-
volution. In superposition, the function describing the incoming radiation and
the function describing the spread of dose must be evaluated at each point, then
the resulting doses summed together, or super-imposed - hence the name. Super-
position is mathematically much less efficient than convolution, but convolution-
based methods cannot take account of variations in dose deposition behaviour
that superposition methods can.
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2.4.5 Oncentra MasterPlan algorithms
Oncentra has two algorithms for photon dose calculation, the PB algorithm, which
uses convolution of pencil, point and planar beam kernels, and the CC algorithm
that uses superposition of point kernels. The PB algorithm does not account
for the lateral transport of secondary particles in heterogeneous materials, and is
therefore a type A algorithm. CC does model this lateral transport, so is a type
B algorithm.
The algorithms are designed to be general enough to handle all linac beam geo-
metries, i.e. regular fields shaped by collimators, irregular fields defined by MLCs,
the presence or absence of wedges (either dynamic or physical wedges) and mod-
ulated or dynamic fields such as Intensity Modulated Radiotherapy (IMRT) and
Volumetric Modulated Arc Radiotherapy (VMAT).
Both algorithms calculate the absolute dose per MU, using the dose per MU under
reference conditions. The calculation of dose per MU takes account of the signal
scattered backwards from the collimators into the MU chamber, which reduces
the dose per MU for small field sizes, above that which would be expected due
to the reduction in phantom scatter. Each algorithm can be divided into two
steps: the initial step involves calculating the energy fluence exiting the head of
the linac; and the ‘dose engine’, which calculates the dose to the patient. Both
PB and CC use the same energy fluence modelling. What distinguishes the PB
and CC algorithms is the dose calculation engine they use.
2.4.5.1 Energy fluence modelling
The energy fluence is the amount of radiant energy per unit area traversing a
plane perpendicular to the beam, at a given position, and is a quantity that is
independent of the patient or phantom. Energy fluence is determined wholly by
the linac configuration, including beam energy, collimator and MLC positions and
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presence of wedges. The energy fluence model is produced from PDD, profiles
and Field Size Factor (FSF) measurements taken for different energies and col-
limator sizes, and knowledge of the linac head design for different manufacturers.
Parameters in the general model are adjusted until the PDD, profiles and FSF
calculated by the model agree with the measured values. The energy fluence from
the linac includes contributions from:
• direct photons, which do not undergo scattering in the linac head;
• photons scattered from the flattening filter and primary collim-
ator, which are generally the main sources of scattered energy fluence;
• photons scattered from the collimators and MLCs, which varies with
collimator and MLC positions;
• photons scattered from physical wedges and any auxiliary modulators;
• contaminant photons and electrons, which are low energy photons and
electrons that affect the dose near the surface of the patient or phantom.
Each of these contributions follows a different form, and are calculated in differ-
ent ways. The direct fluence is obtained by modulating the fluence for an ‘open’
(un-collimated) beam by the attenuation from the collimators and MLCs. The
calculation of the photons scattered from the flattening filter and primary col-
limator involves a two step process. Firstly, these components are divided into
a grid, to determine which elements of this grid are ‘visible’ to each calculation
point, using a ‘virtual light source’ approach (visible meaning not hidden by col-
limators or MLCs). Secondly, an integration is performed of the energy fluence
over these visible elements. The collimator scatter is not calculated from scratch
for each collimator and MLC position; rather the scatter kernels are calculated
for a standard geometry, and then shifted and scaled based on the actual beam
defining geometry.
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2.4.5.2 Dose calculation engines
Oncentra represents the patient (or phantom) geometry as a 3D density matrix.
The density of each voxel in the matrix is determined either from the pixel values
of the CT scan, or from user specified values of mass or electron density. The
resolution of this density matrix can be varied; the smaller the voxel size, the
more accurate the calculation, but the calculation time increases linearly with
the number of voxels. (In practice, the voxel size in one direction is set by the
CT slice thickness; within a plane, it is common to use the same resolution in
both directions, so the calculation time varies as the inverse of the square of the
voxel side).
A dose engine is an algorithm that calculates the absorbed dose in this density
matrix from the incident energy fluence, calculated in the first step. The Oncentra
photon dose engines are based on energy deposition kernels, which describe the
deposition of dose around a elementary radiation beam. Three different types of
kernels are used. The first kind are point kernels, relating to the energy deposition
around a point interaction. The second kind are pencil kernels, relating to the
energy deposition from a mono-directional ‘beamlet’, known as a pencil beam
(hence the name of the algorithm). The third kind are planar kernels, relating to
the energy deposition from a broad parallel beam.
Primary dose is defined as the energy imparted per unit mass due to photons
interacting with the medium for the first time. Head scatter dose is the energy
imparted per unit mass due to photons that have been scattered in the head of
the linac (i.e. in the flattening filter, collimators, wedges etc.). Phantom scat-
ter dose is defined as the energy imparted per unit mass due to photons that
have interacted in the medium more than once, as well as Bremsstrahlung and
annihilation photons from pair production.
There are two types of kernels used in this calculation. Firstly, there will be
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kernels to describe the deposition of energy from the energy fluence from the
linac head - this leads to primary and head scatter dose. There will also be
kernels to describe the deposition of energy from energy fluence that has been
scattered in the patient or phantom - this leads to phantom scattered dose.
2.4.5.3 Pencil Beam dose engine
The PB (Ahnesjö et al., 1992) dose engine performs a ‘pre-convolution’ step, in
which point kernels are integrated over the depth co-ordinates, to produce pencil
beam kernels. This saves computation time, but precludes any way to include
density scaling for lateral heterogeneities, as the pencil kernels are then fixed, and
cannot be adapted for the presence of lateral heterogeneities.
The variation of energy with depth is accounted for by using two mono-energetic
pencil kernels, which are combined with a different weighting at different depths.
This produces a poly-energetic pencil kernel, which is integrated with the incident
energy fluence. This creates a dose distribution that reproduces the variation of
beam profile with depth described in section 2.3, without the need to vary the
point kernels with depth, which would lead to a loss in calculation efficiency.
Contaminant photons and charged particles are produced as the direct photons
pass through the air between the linac and the patient, and any auxiliary beam
modulators near the patient. This is modelled using a Gaussian pencil beam
kernel. The contamination dose falls rapidly with depth.
The effect of inhomogeneities along a pencil beam for primary dose and contam-
inant dose is accounted for by scaling the pencil beam kernels by the radiological
depth. The radiological depth is defined as the depth of water that would give
the same attenuation as the path through the inhomogeneous region.
Ahnesjö et al. (1992) describe a correction factor that is applied to the phantom
scatter to account for heterogeneities, which is a function of an ‘effective attenu-
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ation coefficient’. From the definition of this correction factor, it follows that the
final dose is relatively insensitive to the actual value of this effective attenuation
coefficient. A value of 0.8 is used in the Pencil Beam Enhanced (PBE) algorithm.
Using a constant value enables the scatter dose to be corrected for heterogeneities
using a 1D convolution with a planar kernel performed along the beam path. A
planar kernel is used as the kernel does not vary across the width of the beam. It
is noteworthy that the PBE uses point, pencil-beam and planar kernels at differ-
ent stages of its calculation of dose. It is not a simplistic algorithm as it is often
described; rather it is an algorithm that applies approximations in order to allow
efficient calculation methods to be exploited.
Another consequence of the production of pencil beam kernels via the ‘pre-
convolution’ step is that the absorbed dose in a voxel is calculated as if the voxel
were water (even if it is not). This is because the pencil beam kernels describe
dose deposition in water, and this cannot be altered on a voxel by voxel basis if
convolution is to be used.
2.4.5.4 Collapsed Cone dose engine
The CC algorithm (Ahnesjö, 1989) uses the same inputs to the beam model as
PB. Older versions of Oncentra limited the resolution that CC was performed at
to decrease execution time. However, advances in computing, particularly imple-
mentation of the CC algorithm on the Graphics Processing Unit (GPU), allows
calculations to be run faster than the PB algorithm on the Central Processing
Unit (CPU) for all but the simplest calculations. For very simple cases the losses
in the overhead involved in transferring data to and from the GPU outweigh the
speed advantages of the GPU itself.
The CC algorithm uses pre-calculated point kernels, which describe the deposition
of energy from a photon interaction site as a function of direction and distance.
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As with the PB algorithm, a 3D density matrix is used to describe the patient or
phantom geometry. Raytracing is used to calculate the amount of radiant energy
released in each voxel from the incident beam; considering the direct radiation
and head scattered radiation separately. The variations in beam energy along the
beam axis, and across the beam profile, are accounted for during the raytracing.
There are two sets of point kernels used, one to calculate primary dose from direct
and head scattered energy fluence; and one to calculate phantom scattered dose
from the phantom scattered energy fluence. The point kernels for the primary
dose are tilted such that the axis of the kernel is aligned to the beam divergence
angle.
In a homogeneous, water equivalent medium the dose deposition will be the radi-
ant energy released at each point, convolved with the point kernel at each point.
However, in order to account for inhomogeneities, the dose deposition kernel is di-
vided into a number of cones, with the cones being closely packed in the direction
of higher energy deposition, i.e. along the beam axis. In the initial paper describ-
ing the CC algorithm (Ahnesjö, 1989) between 48 and 384 cones were used for
different cases, but 27 was the preferred number; the Collapsed Cone Enhanced
(CCE) as implemented in Oncentra uses 106. The energy deposited within a cone
is assumed to be deposited along the axis of the cone, and the energy deposition
is scaled according to the density of the media along this axis. This allows for
heterogeneities lateral to the beam axis to be accounted for. Since the energy
deposition is performed for the voxel medium, the dose calculated by the CC
algorithm is the dose to the medium, rather than the dose to water as reported
by the PB algorithm. The name of the algorithm comes from the assumption
that the dose deposited in a cone can be ‘collapsed’ onto the axis of the cone, as
an approximate representation of actual dose deposition within that cone.
The dose from contaminant photons is calculated separately, using the same Gaus-
sian pencil beam based method as in the PB algorithm.
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2.4.6 Enhanced algorithms in Oncentra
In Oncentra v3.1, ‘enhanced’ versions of the PB and CC algorithms were intro-
duced. These algorithms include changes to the energy fluence modelling. The
fluence grid is aligned with the beam collimation system, and a higher resolu-
tion grid is used to describe the fluence than in the non-enhanced versions of the
algorithms.
For multi-segment beams, such as IMRT beams, the energy fluence for all seg-
ments is calculated, and the dose engine performs the dose calculation once for
that beam, not once per segment as for the non-enhanced versions of the al-
gorithms.
The enhanced PB algorithm includes further increases in speed due to use of an
interpolation scheme. The energy fluence is convolved with primary and scatter
kernels; this is done at two depths for the primary dose, and three depths for the
scattered dose. The depths are determined during the calculation, as a function of
beam spectrum. The calculation point in the patient is transformed onto a water
phantom, where the point has the same radiological depth and lateral position.
Lateral interpolation is performed in kernel space to calculate the dose deposition
throughout the patient; i.e. the kernels required at other depths are interpolated,
rather than the dose itself being interpolated.
The enhanced versions of the PB and CC offer better calculation accuracy that the
standard versions, due to the higher resolution grid used for the energy fluence,
and its alignment with the beam collimation system. Efficiencies in the way the
fluence matrix is used allow for faster calculations (for same beam and patient
geometry, on the same computer), particularly for IMRT beams.
Throughout this work the enhanced versions of the algorithms from Oncentra
v4.3 have been used, and will be termed PBE and CCE.
2.5 Monte Carlo methods 53
2.5 Monte Carlo methods
The MC method solves equations or calculates integrals using random number
sampling (Seco and Verhaegen, 2013). Early examples include solutions to nu-
merical problems such as a method to calculate the value of pi. However, MC
is perhaps best suited to problems such as those in particle and nuclear physics
in which the random nature of fundamental interactions can be accurately rep-
resented by MC methods. Point kernels describing the spread of energy around
the point of a primary photon interaction, as used in the CCE algorithm were
calculated from MC simulations (Mackie et al., 1988). Simulating radiation trans-
port using MC methods is, in principle, simple; the microscopic interactions are
simulated, using the interaction cross-sections for the radiation energy and type,
and the material under investigation. Consider pair production, discussed in
section 2.2.4: a photon passing near a nucleus may or may not lead to a pair
production process, with a probability that is dependent on the Z of the nuc-
leus. If pair production does occur, the angles at which the electron and positron
travel at will be random, as will be the share of the energy carried away by each
particle, and the nucleus. MC and a knowledge of the relevant interaction cross-
sections should allow radiation transport to be simulated. MC is conceptually
simpler than, for example, the PB algorithm with its use of point, pencil beam
and planar beam kernels at different stages of the calculation.
However, full simulation of all interactions is prohibitively time consuming. For
the energies associated with radiotherapy beams, electrons undergo a large num-
ber of interactions, making the simulation of one electron track much more compu-
tationally expensive that simulating a photon track, to the extent that simulating
electron tracks is not feasible. While MC for particle transport was proposed by
Stanisław Ulam (Metropolis and Ulam, 1949), it was the work of Martin Berger
in Alder et al. (1963) that led to MC for photon and electron transport. Due
2.5 Monte Carlo methods 54
to the small amount of energy transferred from an electron to the tissue and the
small scattering angles that the electron is deflected through, an approach known
as the Condensed History (CH) technique was proposed by Berger. Interactions
are divided into ‘hard’ and ‘soft’ collisions, by use of a parameter, EC . Collision
events with an energy transfer greater than EC are hard collisions, and are sim-
ulated explicitly, as for photons; collisions with an energy transfer less than EC
are termed soft collisions. Soft collisions are modelled by assuming a continuous
energy transfer into the surrounding medium, and a single large scattering angle
rather than a series of small scattering angles. If this large angle deflection is
applied only at the start, the distance travelled by the electron may be overes-
timated. Using a second scattering angle, known as a ‘random hinge’ can be used
to correct for this effect (Figure 2.11).
The parameter EC can be selected by the user, to decrease the time required for
a MC simulation; but choosing too high a value may lead to inaccurate results.
Real electron path
Simulated path
Simulated path with Random Hinge
Figure 2.11: Use of the random hinge method, to avoid over-estimation of particle
range.
The continuous energy loss and random hinge approach for soft interactions has
limitations. For example, all electrons with an initial energy E modelled using a
step length of s will reach the end of the step with the same energy, whereas in
reality the electrons should have a spread of energies. Many implementations of
the random hinge angle use Fermi-Eyges multiple scattering theory (Eyges, 1948)
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to compute a distribution of scattering angles to sample from. However, this the-
ory uses a 2D Gaussian distribution that underestimates the probability of large
scattering angles. Another issue is that the random hinge method assumes that
all soft scattering occurs within the same medium; therefore the CH technique
can only be applied if a single step will not lead to the particle crossing a bound-
ary into another medium. Commonly, the step size is decreased near boundaries
such that it is much less than the distance to a boundary, but this will increase
calculation times.
Variance Reduction techniques are techniques to reduce the calculation time re-
quired to reach the same statistical uncertainty (or increase efficiency) without
altering the result produced (Verhaegen and Seuntjens, 2003). Common methods
include:
• Transport Cut-offs: An energy below which electrons or photons will not
be transported, but will be assumed to deposit all energy where they are.
Due to the higher range of photons compared with electrons, photon cut-
offs are usually lower than electron cut-offs. Since cut-offs can introduce
bias, they are not strictly a variance reduction technique;
• Bremsstrahlung splitting and Russian Roulette: For particles of
particular interest, such as Bremsstrahlung photons in a target, for every
Bremsstrahlung event many Bremsstrahlung photons will be modelled, each
with a reduced weight. Russian Roulette involves removing a proportion of
secondary charged particles, due to the large numbers produced.
• Electron Range Rejection: For electrons that do not have high enough
energy to reach a plane of interest, the electrons are terminated, for example
electrons with insufficient energy to escape the linac head. As electrons may
give rise to Bremsstrahlung photons, a energy threshold must be set, above
which no rejection is performed. As with cut-offs, this method can introduce
bias, so is strictly not a variance reduction technique;
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• Interaction Forcing: Interactions that are relatively uncommon, but
give rise to particles of interest, such as contaminant electrons near pa-
tient/phantom surfaces, may be under-sampled even in long simulations. If
the interactions are forced to occur, but the resulting particles have lower
weight, the statistics in these situations can be improved.
2.5.1 Monte Carlo codes
2.5.1.1 ETRAN, ITS and MCNP
The electron gamma modelling code developed by Berger and others was released
as a package called ETRAN. This underwent many developments, before becom-
ing the ITS code. The ITS electron transport code now lives on in MCNP (Brown,
2003), maintained by group at Los Alamos National Laboratory. In their review
of MC codes for radiotherapy, Spezi and Lewis (2008) found that MCNP was, at
the time of publication, the most commonly cited MC code in the field of nuclear
science and technology, and in all fields combined. This was due to its ability
to model neutrons, and photo-nuclear reactions. It is also the second most com-
monly used code in the field of radiology, nuclear medicine and medical imaging.
However, it is not as fast as other codes, due in part to its ability to model so
many situations.
2.5.1.2 EGS, BEAM and EGSnrc
Spezi and Lewis (2008) reported that the electron-gamma-shower (EGS) code,
or MC packages based on it, were used in more papers in the subject areas of
radiology, nuclear medicine and medical imaging between 1985 and 2007 that
any other MC code, with approximately 500 papers in this period. EGS can
trace its history back to Oak Ridge National Laboratory in the 1960s. Early
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versions of what would become EGS were developed for shielding design, and
to assist with the interpretation of experiments at Stanford Linear Accelerator
Centre. Since the 1980s development of EGS has focussed on medical physics
applications, starting with improvements in transport in the energy range 10 keV
to 30 MeV, which were included in EGS4/PRESTA.
Rogers (2006) highlights the difficulties of modelling the response of a parallel
plate chamber accurately. Kawrakow and Rogers (2000) used a version of EGS,
EGSnrc, which included improvements to particle transport in order to resolve
some issues seen when using EGS4/PRESTA for this purpose. EGSnrc included
improvements in the CH technique, including a new electron step algorithm, often
called PRESTA-II, and an exact boundary crossing algorithm. It also included
improvements in physical processes, such as improvements to the electron elastic
scattering mechanism to include relativistic spin effects, and inclusion of National
Institute of Standards and Technology (NIST) Bremsstrahlung cross sections as
recommended by the International Commission on Radiation Units and Measure-
ment (ICRU) (ICRU, 1984).
The BEAM code was produced by the Ottawa Madison Electron Gamma Al-
gorithm (OMEGA) project, which was set up in response to many users of EGS
wanting to apply EGS to linac modelling (Rogers et al., 1995). It is a tool to
allow clinical physicists to perform MC simulations with EGS, by being more ac-
cessible than EGS. Although it was possible to specify the components of a linac
head in EGS, due to its flexibility, it was not easy to do so. BEAM is written in
MORTRAN3, a preprocessor for Fortran77 (i.e. MORTRAN3 macros can be used
to generate Fortran77 code). BEAM uses Component Modules (CMs) to describe
each component of the linac head as an independent ‘building block’, in which
the geometry and composition of the part of the linac is described. For example
the CM SLABS can be used to model any rectangular object in the linac head,
by specifying the material and certain co-ordinates of the slab to be modelled.
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The boundaries and materials required by the EGS code will be generated from
the parameters supplied to the CM. BEAM allows generation of ‘phase space
files’, which are files containing the type, energy, position and direction of travel
of particles at a plane, at any level of the linac. A simulation may be performed
of the radiation transport through the ‘patient invariant’ portion of the linac, i.e.
the portion excluding wedges, jaws and MLCs, which does not change for a given
energy, to generate a phase space file above the ‘patient specific’ portion of the
head, i.e. the wedges, jaws and MLCs. This phase space file can then be used
as an input to many different simulations of the patient specific portion of the
head, which avoids repeatedly simulating invariant situations. The BEAM code
was also well documented to help users understand the system. The BEAM code
could be extended by users who wanted to add new CMs (such as DYNVMLC,
used to model dynamic MLC motion for the Varian Millennium 120-leaf MLC, by
Heath and Seuntjens (2003)). BEAM also provided a number of source routines,
such as a simple isotropic point source, simple parallel beams, elliptical beams
to represent an electron beam incident on the target in a typical linac, and more
complex sources. Again, users have written their own sources for specific pur-
poses, some of which have been incorporated into the BEAM distribution (Lobo
and Popescu, 2010).
2.5.1.3 PENELOPE
PENetration and Energy LOss of Positrons and Electrons (PENELOPE) is a
general purpose MC code for modelling electron-photon interactions in complex
geometries (Baró, 1995). It allows regions to be specified by quadric surfaces (i.e.
surfaces described by second order equations), and provides a ‘visual debugger’
to visualise the surfaces and resolve issues with the geometry specified. It is well
suited to simulation of low energy particles, due to detailed cross-sections for low
energy interactions.
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PENLINAC (Rodríguez, 2008) is an extension to PENELOPE, which provides a
simple way for users to define the geometry of a linac, in much the same way as
BEAMnrc does for EGSnrc. PENLINAC does not require the user to interact with
the quadratic surfaces directly, and can be considered as a layer of abstraction
between the powerful but complex geometrical modelling of PENELOPE and the
user.
PRIMO (Rodríguez et al., 2013) is a tool-kit built on top of PENELOPE, which
simplifies the simulation process for new users. PRIMO is unique in that is
includes details of Varian and Elekta linac geometry in its code. The advantage
of this approach is that once a user has the code, a realistic simulation can be run
almost straight away with no configuration required. The downside is that the
user cannot add linacs, components and techniques not yet included in PRIMO,
but must wait for the authors to update PRIMO, whereas uses of the underlying
PENELOPE system could configure new geometries themselves (with sufficient
time, effort and expertise). PRIMO has some variance reduction techniques tuned
for simulating linac based treatment plans. PRIMO also has a number of graphical
tools for the evaluation of doses calculated from MC, such as isodoses and DVH
plots.
2.5.1.4 GÉANT
GÉANT was developed at CERN for particle physics applications (Agostinelli
et al., 2003). It is comprised of a series of C++1 toolkit libraries, containing
functions for simulating different processes. All the MC codes discussed above use
Fortran2. GÉANT4 is able to include the effects of external electromagnetic fields,
so is used in proton beam radiotherapy. Earlier versions implemented the hadron
1C++. Available at: http://www.open-std.org/jtc1/sc22/wg21/ (Accessed: 8 December
2016).
2Fortran. Available at: http://www.nag.co.uk/sc22wg5/index.html (Accessed: 8 December
2016).
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event generator from Fluka (section 2.5.1.5). Along with MCNP, GÉANT4 is
one of the few codes to include simulation of photo-nuclear reactions. It is very
flexible, but this flexibility means it is slower than EGSnrc unless much effort
is devoted to adapt it for the energy ranges and materials of interest in medical
physics. Seco and Verhaegen (2013) state that the number of publications using
GÉANT for medical applications is approaching the number of publications using
MCNP for medical applications (note MNCP is used extensively in non-medical
applications).
2.5.1.5 Fluka
FLUKA is another general purpose code from CERN (Ferrari et al., 2005). As
with GÉANT4, it has the ability to include the effects of external electromagnetic
fields on charged particle transport which makes it suitable for proton beam
radiotherapy, as well as photon or electron beam radiotherapy. This ability will
also be advantageous with advent of MRI-linacs. FLUKA can transport photons
and electrons over an energy range of 1012, 1 keV to 1 peta-electron volts (PeV).
It has detailed cross-section data at very low and very high energies, and is well
suited to shielding calculations for linacs and proton accelerators, due to ability
to model radionuclide production (Fassó et al., 2000).
2.5.1.6 Accelerated codes
There are a number of ‘accelerated’ MC codes, which aim to reduce computation
time while not significantly altering the doses calculated. They achieve this by
employing approximations and simplifications for processes that are less import-
ant for energies and materials relevant to radiotherapy. One of the best known
of these is the Voxel Monte Carlo (VMC) program by Kawrakow et al. (1996),
which was written for electron dose calculations only. This targeted the energy
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range 1-30 MeV, and densities in the range 0-3 g/cm3, and sacrificed accuracy
outside these ranges for efficiency savings within them. Further efficiencies were
found by only supporting dose deposition in rectangular grid geometries - as found
in CT scans. This enabled a decrease in calculation time of 35 compared with
EGS4. VMC is available in commercial treatment planning systems, e.g. it is
implemented in Oncentra as the eMC dose calculation method.
The VMC code was extended to include photon dose calculations, in a code called
XVMC (Fippel, 1999). This demonstrated a increase in calculation speed of 15-20
compared to EGS4, without significant loss in accuracy except in lung substitute.
XVMC is available within the BrainLab iPlanNET3 TPS.
XVMC, which was written in Fortran, was re-implemented in C++ by Kawrakow
and Fippel (2000), as VMC++. The Object Oriented nature of C++ allows Sim-
ultaneous Transport of Of Particle Steps (STOPS), in which particles with the
same energy but different positions, directions and even statistical weights are
transported simultaneously, to increase efficiency. VMC++ has a reported speed
up compared to EGS4 of 150 times, while agreeing to within 1% with EGSnrc.
Other accelerated codes include DPM by Sempau et al. (2000), PEREGRINE
by Hartmann Siantar et al. (2001) and MCDOSE by Ma et al. (2002). DPM
and PEREGRINE use a method in which transport through a number of voxels
can be modelled in a single step, increasing calculation speed. PEREGRINE
uses a source model in which a phase space file is produced by modelling the
patient invariant portion of the linac head. The distribution of energies, direc-
tions and positions is then approximated by histograms. Particles are generated
by sampling data from the histograms, which produces similar data to the phase
space file without having to store a large phase space file. VMC++ remains the
fastest accelerated MC code, although MCDOSE uses extensive variance reduc-
tion techniques to achieve calculation speeds within a factor of two of VMC++
3BrainLab (2013) BrainLab Physics Technical Reference Guide rev 1.7. Germany.
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(Chetty et al., 2007).
The DMLC code (Keall et al., 2001; Siebers et al., 2002) is notable in that it only
models the MLCs. It takes a phase space file positioned above the MLCs as it
input. It then creates a phase space file beneath the MLCs, having simulated the
passage of the radiation through the MLCs using a simplified transport method,
but which is capable of accounting for the dynamic motion of the MLCs. This
approach has been superseded by BEAMnrc CMs that are capable of including
MLC motion, e.g. DYNVARMLC, or source models capable of accounting for
motion in the linac head (Lobo and Popescu, 2010).
2.5.2 High Performance or High Throughput Computing
Due to the computationally demanding nature of MC, many workers have used
High Performance Computing (HPC) or High Throughput Computing (HTC) to
reduce the execution time for MC simulations. HPC is the field devoted to ex-
ecuting tightly coupled computing tasks, often requiring a high number of Float-
ing Point Operations Per Second (FLOPS). Examples of HPC hardware include
supercomputers and clusters. Supercomputers are computers with a high level
of computational capacity compared to a consumer computer. They are fre-
quently large, expensive, and have a large number of processors, which generally
share memory and a filesystem (e.g. Sunway TaihuLight4, currently the record
holder for the number of FLOPS, has 40,960 64-bit RISC processors and cost
over $270M). Computer clusters are sets of computers, which may be loosely or
tightly coupled, which are used together and may be viewed as a single system.
An example of a type of cluster is a Beowulf cluster5, which is a computer cluster
built from standard, consumer-grade computers that share a filesystem, and act
4Sunway TaihuLight. Available at: http://demo.wxmax.cn/wxc/soft1.php?word=soft&i=46
(Accessed: 9 December 2016).
5Beowulf Clusters. Available at: http://www.beowulf.org/ (Accessed: 9 December 2016).
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as a single system in which processing tasks are shared amongst the constituent
computers.
In contrast, HTC systems are not designed for tightly coupled problems, and
may not use hardware that is faster than consumer hardware. In HTC the key is
performing many calculations at once, often utilising many computers, which may
or may not be distributed over a large area. Examples include the Folding@home6
and SETI@home7 projects, which both involve volunteers downloading analysis
programs and data to their computers; the analysis program is configured to run
while the computer is idle. Once a batch of data has been analysed, the results
are uploaded for the researchers to access. The ‘virtual supercomputer’ formed by
participant computers in the SETI@home project holds the record for the largest
number of total floating point operations in a computation (1021). This is despite
Sunway TaihuLight being capable of performing floating point operations at 50
times the rate of SETI@home.
To illustrate when HPC and HTC are appropriate, consider the simulation of
many coupled oscillators; a change in the position of one oscillator will affect
the forces experienced by other oscillators. Therefore the simulation cannot be
separated into independent tasks, as all nodes involved will need to be able to
access information on all oscillators as the simulation progresses. Communication
between calculation processes will be required, therefore shared resources such as
common memory and/or a shared filesystem will be required, so a supercomputer
or cluster would offer a significant advantage over HTC resources. In contrast,
MC has been described as an ‘embarrassingly parallel’ computational problem,
i.e. not only can simulations be separated into different dependent ‘batches’ and
run on different computers, but the task is so well suited to this approach that
it would be embarrassing not to do so. HTC is therefore a more natural fit for
6Folding@home. Available at: https://folding.stanford.edu/ (Accessed: 9 December 2016).
7SETI@home. Available at: https://setiathome.berkeley.edu/ (Accessed: 9 December
2016).
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MC, as the parallel nature of HPC is not needed or used in MC simulations - but
HPC has been used.
2.5.3 Monte Carlo on HPC or HPC resources
A number of authors have published work involving running MC simulations on
clusters or distributed resources or other non-standard computing architecture in
order to reduce the time needed to perform a simulation.
2.5.3.1 MCRTV
The Monte Carlo for Radiotherapy Treatment plan Verification (MCRTV) is a
system to perform MC on a Linux cluster consisting of 14 nodes, with two 3.2 GHz
Intel Xeon CPUs per node (Yamamoto et al., 2007). MCRTV takes DICOM-RT
files from the TPS, and produces input files for the EGS4 simulations. The
simulations are parallelized via the Message Passing Interface (MPI), a set of
library routines for programming a variety of parallel computing architectures.
An initialisation command from the MPI library is used to send the EGS4 input
files to the nodes, with different random numbers for each input file. The nodes
execute the EGS4 programs, and further MPI commands are used to collect and
sum the outputs. The simulation is generally split into three parts, each using
EGS4 - the patient invariant portion of the head, the patient specific portion of
the head and the patient/phantom geometry. Phase space files may be used in
place of the simulation of the patient invariant portion of head. The voxel size
in the simulation is matched to that of TPS resolution, to facilitate comparisons.
Analysis of MC calculated dose and and comparison with TPS dose is performed
within MCRTV, using tools written for this purpose.
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2.5.3.2 VIMC
The Vancouver Island Monte Carlo (VIMC) system (Zavgorodni et al., 2007) is
used to run simulations on an HTCondor pool8, consisting of nine single-core
2.2 GHz computers, which has been extended for RapidArc treatments (Bush
et al., 2008). The simulation is divided into three parts, the head of the linac ex-
cluding the MLCs, the MLCs alone, and the patient/phantom geometry. BEAM-
nrc is used for the linac head simulation, DMLC is used for the MLC simulation,
and either DOSXYZnrc or VMC++ may be used for the patient/phantom geo-
metry. Batch files are created to perform a simulation for each beam, or each
control point for arcs, individually. These batch files are then submitted to an
HTCondor pool for execution. Simulations are performed based on the required
statistical uncertainties, rather than a set number of histories. VIMC can convert
dose to medium into dose to water, before converting the data into DICOM-RT
format, which can be imported into a TPS, to utilise the analysis tools of the TPS.
The system is fully automated, and is suitable for routinely verifying doses for
RapidArc plans. The system has been developed in recent years to incorporate
the ability to perform Electronic Portal Imaging Device (EPID) image predic-
tions. Further developments added the ability to perform simulations based on
the linac parameters used during delivery, using the positions recorded by the
linac into files known as Dynalog files or Trajectory Log files (Popescu et al.,
2015).
8HTCondor. Available at: https://research.cs.wisc.edu/htcondor/ (Accessed: 21 November
2016).
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2.5.3.3 SMCP
Swiss Monte Carlo Plan is a framework for performing MC on a Linux based
cluster (Fix et al., 2007). It is interfaced to research version of the Varian Eclipse9
TPS, so can benefit from tools such as outlining, isodose visualisation, and DVH
comparisons. In Eclipse, the SMCP is chosen as a calculation type, which launches
a Graphical User Interface (GUI) written in QT4. This GUI is used to specify
the many options available - the details of the plan and patient geometry are
provided by Eclipse; SMCP is registered as a dose calculation, and may be selected
within Eclipse just as the AAA algorithm is. The MC simulation is split into
three parts, the plan-independent portion of the linac head, the portion of the
linac head comprising the beam modifiers and the patient geometry. For each
of these, different MC transport methods for can be used, depending on the
requirements for accuracy or speed. For the plan-independent portion of the
linac head, options for the transport method include phase space files, histogram
based source models and full simulation using VMC++. The results of the source
modelling may be used to write a phase space file to input to the beam modifier
simulation. However, the particles are more commonly passed in memory to the
next stage of the simulation, thanks to the use of interface classes. SCMP can run
simulations for a given number of histories or a required statistical uncertainty,
and can continuously sample linac positions, and correlate these to MU delivery,
for dynamic applications. The beam modifier simulation may be performed using
EGSnrc, VMC++ or an in-house transport code called Photon Interaction (PIN),
which allows beam modifiers to be modelled as:-
• completely absorbing
• absorbing based on attenuation only
9Varian Eclipse Treatment Planning System. Available at: https://www.varian.com/en-
gb/oncology/products/software/treatment-planning/eclipse-treatment-planning-system (Ac-
cessed: 19 December 2016).
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• absorbing using attenuation and first order Compton
• absorbing using attenuation including all Compton
• ‘flat’ geometry, in which modifiers are collapsed onto a single plane, and
assumed to be completely absorbing.
The patient/phantom simulation maybe performed using EGSnrc or VMC++. An
in-house algorithm is used to re-sample the CT to the desired resolution. The
advantages of SMCP include the range of transport methods, the minimal user
input required to perform a simulation so the simulations are robust, and the use
of isodose visualisation and DVH tools within Eclipse for plan comparisons.
SMCP has been used to facilitate a variety of research projects. These projects
include investigating the effective dose rate throughout irradiated volume from
VMAT plans (Mackeprang et al., 2016), and an investigation of Modulated Elec-
tron Beam Therapy, in which the photon MLC is used to modulate electron beams
(Henzen et al., 2014).
2.5.3.4 MMCTP
The McGill Monte Carlo Treatment Planning (MMCTP) system runs on multiple
operating systems (Windows, Linux, Macintosh), and provides a GUI written in
REALBasic (now called Xojo10) to facilitate the execution of MC simulations on
a computing cluster (Alexander et al., 2007). The GUI runs on a standard com-
puter, can import from TPS data in DICOM-RT and standard TPS file formats,
and generate input files for the MC simulations. It also acts as an abstraction
layer, to simplify the control of the jobs on the cluster using Secure SHell (SSH)11
10Xojo, new name for REALBasic. Available at: https://en.wikipedia.org/wiki/Xojo (Ac-
cessed: 16 December 2016).
11SSH. Available at: http://www.snailbook.com/protocols.html (Accessed: 5 November
2016).
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commands, and provides functions such as contouring and DVH analysis to com-
pare the MC doses with TPS calculated dose distributions; the paper stresses the
importance of comparing DVHs on the same platform, to avoid the influence of
implementation details. The data is described as being anonymised prior to trans-
mission to the cluster, although it is not clear if the anonymisation is performed
by converting data to input files that hold no Personally Identifiable Information
(PII). Internally, the system uses a custom file storage format, dubbed the Mc-
Gill RT format (which is an extension of the Radiation Therapy Oncology Group
(RTOG) format). The MC simulation is divided into a linac simulation using
BEAMnrc, and a patient/phantom simulation using XVMC. The simulations are
run for a large number of histories, rather than a specified statistical uncertainty,
using nodes in the cluster to run batches of histories.
MMCTP has been used as a platform to facilitate various research topics. Con-
neely et al. (2013) used MMCTP to automatically tune MC linac parameters,
performing multiple simulations with different electron beam energies. The agree-
ment with measured data was used to select the optimum electron beam energy.
Conneely et al. (2014) used MMCTP to simulate the delivery of IMRT to a
Farmer chamber in a phantom, in two situations: firstly, with all beams with
the gantry angle set to zero; and secondly, with the real planned gantry angles.
This showed that using the real gantry angles was the preferred method, and
highlighted factors such as dose heterogeneity in the Farmer chamber must be
considered if performing verification measurements with all gantry angles set to
zero.
2.5.3.5 RTGrid
RTGrid is a project to enable MC simulations to be run on a variety of distributed
computing resources, including HTCondor pools, or the UK e-Science National
Grid Service (NGS) (Yaikhom et al., 2008; Downes et al., 2009). It is implemented
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using the Gridsphere portal framework, and aims to be an accessible interface for
Clinical Scientists unaccustomed to distributed computing to access distributed
computing resources. RTGrid may be run on a Linux or Windows server, but the
soft links used by Linux file-systems allows files used by many jobs to be stored
once per simulation, saving file space. The MC simulations may in principle be
performed on Windows PCs via HTCondor, Linux clusters, or other computing
resources, through the use of profiles to describe the simulation details, and the
interaction with the computing resources. In practice the executable programs
involved in the MC simulation need to be compiled for either Windows or Linux,
so a profile will be associated with only one computing resource. The RTGrid is
accessed through a web portal, so no software needs to be installed in the PC of
the scientist using the RTGrid.
Simulations are divided into linac head simulations, performed using BEAMnrc,
and patient/phantom geometry, performed using DOSXYZnrc. Input files spe-
cifying the MC simulation parameters may be uploaded through the RTGrid
server, or DICOM and DICOM-RT files may be sent to a DICOM server, and
input files produced based on the information bin the DICOM and DICOM-RT
files. A number of independent ‘jobs’ are created, each suitable for executing on
a node of the appropriate computing environment. The random numbers in the
input files are varied between the jobs. The jobs are submitted to the computing
resources, and the progress of the job execution can be monitored via the web
portal. Optionally, the simulation can be completed when a certain percentage,
e.g. 95% of jobs have been completed, to avoid the whole simulation waiting for
a small number of jobs that have not been executed. The RTGrid itself does not
provide tools for visualising or analysing the simulated doses, preferring to leave
this to dedicated tools.
The RTGrid has been used in a number of research projects. Cuﬄin et al. (2010)
used the RTGrid for MC based prediction of EPID treatment verification images.
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Millin and Lewis (2010) used the RTGrid as part of a MC based verification
system for verification of stereotactic radiotherapy and stereotactic radiosurgery
treatment plans.
2.5.3.6 Monte Carlo on GPUs
GPUs are computer components designed for graphical operations, which con-
tain thousands of processing units on a single chip. NVIDIA12 markets a number
of GPUs that use the Compute Unified Device Architecture (CUDA)13, an Ap-
plication Programming Interface (API) that allows the GPU to be programmed.
Alternatively, the Open Computing Language (OpenCL)14 may be used to pro-
gram GPUs from different manufacturers. The cross-vendor support of OpenCL
limits the tailoring of the code to the specific architecture of the hardware be-
ing used. Tian et al. (2015) found several comparisons of computation problems
implemented on CUDA and OpenCL platforms. CUDA based implementations
were found to be faster in most cases, but Tian et al. (2015) expect that the
specific problem type and size will influence whether CUDA or OpenCL will be
faster.
A common term in computing is a thread, which is the smallest sequence of
instructions that can be executed independently. The processing units on a GPU
execute threads in groups, known as warps. The execution of all threads in
a warp is started together, and the results from a warp are read back at the
same time. Reading the data back from the whole warp must wait for the last
thread to complete. This is not an issue if all threads are performing very similar
tasks, as is common in graphics rendering. For MC transport, different types
12NVIDIA Available at: http://www.nvidia.co.uk/page/home.html (Accessed: 28 November
2016).
13CUDA Available at: http://www.nvidia.com/object/cuda_home_new.html (Accessed: 28
November 2016).
14OpenCL Available at: https://www.khronos.org/opencl/ (Accessed: 28 November 2016).
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of interactions require different calculations, which may take different lengths
of time to calculate. This issue is termed thread divergence, and avoiding it is
challenging, but key to maximising the performance of GPUs for MC.
Jia et al. (2010) ported the DPM (section 2.5.1.6) code to NVIDIA GPUs using
the CUDA platform, which they called gDPM v1.0. To port the code they had
to consider that double precision arithmetic is not available on the GPU, how
the processors of the GPU accesses memory both internally and externally to the
GPU, and how to accumulate dose while avoiding concurrent writing to memory.
gDPM v1.0 was able to decrease calculation time by a factor of 5-6 compared to
DPM on a CPU.
gDPM v2.0 (Jia et al., 2011) made further improvements, chiefly by batching
the transport of similar particles together so the parallel nature of the warps
could be used more effectively. Single precision was used throughout, as it was
shown not to affect the accuracy of MC, a new faster random number generator
was employed, and improvements in the interpolation of cross-sectional data were
made. This allowed gDPM v2.0 to realise an increase in execution speed by a
factor of 70-80 compared to DPM.
A further enhancement gDPM v3.0 (Townson et al., 2013) can read phase space
files, and sort the particles therein, to allow simulations to be batched into warps.
This allowed a head and neck case to be simulated in less than a minute, while
performing a simulation for the same case with BEAMnrc and DOSXYZnrc took
2.6 hours for the linac simulation and 5.8 hours for the patient simulation. There
was some disagreement between the two simulations however, with 97% of points
being within either 2%, or having a point within 2 mm with the same dose.
Hissoiny et al. (2011a) developed a MC code specifically for GPUs, based on
PENELOPE, called GPUMCD. This algorithm batched the simulation of similar
particles to allow a warp to only consider one type of particle at a time, before
gDPM v2.0 had implemented this feature. GPUMCD was able to achieve a
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speed increase of 27 times over PENELOPE. GPUMCD as described by Hissoiny
et al. (2011a) used only mono-energetic beams, but it was stated that further
work would allow simulations using poly-energetic spectra required for realistic
treatment plans, and phase space files. GPUMCD has since been used for low-
energy Brachytherapy seed dosimetry (Hissoiny et al., 2011b), and adapted to
dose calculations in strong magnetic fields (Hissoiny et al., 2011c).
Jahnke et al. (2012) ported the electro-magnetic transport functionality of GÉ-
ANT4 to a GPU. They used pre-calculated random numbers rather than calculat-
ing them on the fly. For electrons and positrons, steps were simulated separately,
rather than simulating all steps for a particles sequentially. This avoided ‘thread
divergence’, increasing the efficiency of simulation on a GPU.
2.6 Comparisons of Monte Carlo and analytical
algorithms
2.6.1 Phantom Studies
Many groups have studied the differences between analytical algorithms and MC
simulations in heterogeneous phantoms. Krieger and Sauer (2005) studied the
differences in the doses calculated in a heterogeneous slab phantom, for PB and
CC algorithms implemented in Helax15, the forerunner of Oncentra, and MC
doses calculated with XVMC (section 2.5.1.6). For point doses, they found CC
and MC agreed with measurements within 3%, but the PB algorithm predicted
doses up to 14% higher than expected in regions of low density (polystyrene). For
profiles through the phantom, the PB algorithm generally over-estimated the dose
in low density regions, although it under-estimated the dose near to water-density
regions surrounding the low-density regions. In water-equivalent material, near
15Nucletron, Veenendaal, Netherlands, superseded by Oncenrta MasterPlan
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low density regions, the PB algorithm generally over-estimated the dose. The CC
algorithm agreed well with measurement in water-equivalent regions, even near
low density regions. In the low density regions, CC generally under-estimated
the dose, but was closer to measurement than was the PB dose. MC agreed well
with measurement throughout.
Knöös et al. (1995) compared the EGS4/PRESTA code with the PB algorithm
in a heterogeneous phantom. For beams passing parallel to regions of low density
(cork, used as a substitute for lungs) the PB dose was 2-5% higher than the
MC dose. This was attributed to the inability of the PB algorithm to account
for changes in lateral scatter - due to the spatially invariant pencil beam kernels
used in the algorithm. For beams passing through the low density regions, the
PB algorithm over-estimated the dose by up to 14% for 18 MeV beams. It was
however noted that the dose calculated by PB returned to the correct level shortly
after the beam re-entered the water density material.
Arnfield et al. (2000) compared doses calculated by a power law method (sec-
tion 2.4.2), an implementation of the CC algorithm and the PEREGRINE MC
dose calculation system, in a heterogeneous phantom. Differences in low density
regions for the CC algorithm of 5% were reported.
2.6.2 Clinical Studies
Several workers have published comparisons of dose distributions generated by
conventional radiotherapy planning systems and those produced by various MC
dose calculation packages. However, due to the large computational load involved
in producing each MC plan, the number of cases cited in each study is relatively
small and therefore the statistical weight of these studies is low. For example, Ma
et al. (2000) initially demonstrated agreement between MC and measurements in
various ‘phantom’ test objects within 2%. They then compared PB with MC
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for two clinical example cases (prostate and spinal column) and demonstrated
reasonable agreement (within 4%) in homogeneous tissue regions but significant
discrepancies in the presence of inhomogeneities (e.g. 20% to the spinal cord).
Wang et al. (2002) compared PB with MC in nine cases - four head and neck cases
and five lung cases. In the lung cases, calculated doses to tumour volume and
lungs were up to 10% lower in MC than PB, whereas doses to the spinal cord were
in generally good agreement. Francescon et al. (2000) compared CC with MC in
two anatomical cases – mediastinal and breast. They reported good agreement
(within 3%) between these methods in the cases studied, but acknowledged that
the plans cited involved fairly large field sizes (~10 cm x 10 cm). Greater discrep-
ancies would be expected if smaller fields were involved, due to the sensitivities
of these fields on the focal spot size used in the dose calculation method.
2.6.3 Oesophageal Studies
While there have been hundreds of studies comparing analytical algorithms with
MC simulations, there have been relatively few performed for oesophageal treat-
ment plans. To demonstrate this, a search was performed of the bibliographic
database SCOPUS16 for abstracts containing the phrases “treatment plan”, “Monte
Carlo” and “lung”; over 380 articles were found to match these search criteria.
Replacing “lung” with “head AND neck” found 150 articles. However, replacing
“lung” with “*esophag*” found only 26 articles. Of the articles found, only four
(Wills et al., 2009; Irvine et al., 2004; Haga et al., 2014; Jang et al., 2006) involve
comparisons of doses from different calculation methods for oesophageal RT.
Wills et al. (2009) compared 15 oesophageal plans calculated with the PB and
CC algorithms on Oncentra MasterPlan, as well as comparing plans re-optimised
using the CC algorithm against those optimised using the PB algorithm. The
dose to the PTV decreased by less than 1% when re-calculating the plans using
16SCOPUS. Available at: https://www.scopus.com/ (Accessed: 20 August 2017).
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the CC algorithm, and OAR doses were found to agree to within 2%. For type
B algorithms, a proposal was made to reduce the volume of the PTV that was
required to receive 95% of the prescription dose (V95%), based on the percentage
of PTV overlapping the lungs. This was due to the dependence of the change
in PTV V95% on the overlap between PTV and lung. No comparison was made
with MC simulations.
Irvine et al. (2004) compared 10 lung plans and 10 two-phase oesophageal plans
calculated with the PB and CC algorithms implemented in Helax version 6.1,
but did not use MC calculated doses. In the two phase oesophageal technique
used, the first phase plan used two beams, one anterior and one posterior; the
second phase consisted of three beams, an anterior beam, and two posterior lateral
obliques. It was found that the minimum dose to the PTV decreased by up to
23% when the PB plan was re-calculated with the CC algorithm (using the MU
from the PB calculation). The under-dosage was attributed to low density tissue
within the PTV, a decrease in the scattered dose from the low density region
surrounding the PTV, and a secondary build up at the intersection of low and
high density materials. No comparison was made with MC simulations.
Haga et al. (2014) compared the doses calculated by the superposition/convolution
algorithm in the Pinnacle TPS with the XVMC MC package implemented within
Monaco v3.3 (Elekta), for 15 patients treated with VMAT plans. Of the 15 pa-
tients, one had oesophageal cancer, five were prostate cancer cases, five were lung
cancer cases, three were head and neck cases and one was a rectal cancer case.
For the oesophageal case, the agreement between the analytical algorithm and
the MC simulation was within 2% for the PTV and lung, but the analytical al-
gorithm underestimated dose to the spinal cord by approximately 5% compared
to MC. As this study involved only a single oesophageal case, it is unclear how
applicable to other oesophageal cases this result is.
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Jang et al. (2006) compared doses for a number of thoracic plans, including four
lung and four oesophageal IMRT plans, as calculated by the Corvus system17 ver-
sion 4 or Pinnacle versions 6.0i or 6.2b with doses from MC simulations. For the
lung and oesophageal IMRT cases Pinnacle agreed with measurement to within
5% or 5 mm in the high and medium dose regions, but differences of 10% were
found in lose dose regions in the lungs. The MC simulations showed no differences
(compared with measurement) in the low dose regions, and agreement was within
5%/5 mm for the majority of measurement points. For comparisons of point
doses between Pinnacle and MC simulation, agreement was within 2%. Com-
parisons of DVHs for Pinnacle and MC simulated doses were presented for two
lung IMRT cases. The DVHs were very similar for the cord and combined lungs
for both cases. In one case the DVH for the PTV showed MC calculated higher
doses than Pinnacle. The differences found between Pinnacle and measurement
in the low dose regions were attributed to differences in the modelling of MLC
transmission.
The proximity of the lungs and vertebrae to the oesophagus present difficulties
in accurate dose calculation for this treatment region. However, there are rel-
atively few published comparisons of analytical algorithms and MC simulations
for oesophageal RT treatment plans, in contrast to other treatment regions. In
those studies that did examine oesophageal plans, fewer than five cases calcu-
lated with MC were considered. Studies using larger numbers compared different
analytical algorithms, without using MC simulations. With the development of a
Grid-based MC computation facility discussed in section 3.2.2, it will be feasible
to undertake a higher powered study to compare dose distributions generated by
both PBE and CCE with the MC alternatives, in an effort to provide a definitive
study of these dose calculations in oesophageal RT.
17North American Scientific, Chatsworth, CA, USA
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2.7 Summary
In this chapter, the basic interactions between radiation and matter that are im-
portant in radiotherapy energy ranges have been reviewed. The characteristics
of photon beams from linacs have been presented, to illustrate the difficulties
in modelling these analytically. Various analytical approaches to dose calcula-
tions have been reviewed, and the PBE and CCE algorithms as implemented
in Oncentra v4.3 have been discussed. An overview of common MC codes has
been presented, and methods to use HPC or HTC resources to decrease execution
times for MC simulations have been reviewed. Finally, differences found between
analytical algorithms and MC simulations has been presented.
BEAMnrc and DOSXYZnrc are specifically aimed at RT, and the physical models
used have been optimised for the energies and materials of interest in RT. As such,
they are the most used MC codes in RT, based on the number of publications. Its
accuracy and active user base make it an ideal choice for this work. The RTGrid
involves no specialist hardware, such as high end GPUs, or dedicated computing
clusters. It does not require costly software, unlike SMCP, which depends on
Varian Eclipse. The RTGrid requires only a Linux server, and Windows Desktop
PCs using HTCondor. It has proven validity following work undertaken and
published by our group (Cuﬄin et al., 2010; Millin and Lewis, 2010). The RTGrid
is therefore a good choice for a computing platform on which to perform the MC
simulations for this work. The next chapter will describe the use of the RTGrid
to perform MC simulations with BEAMnrc and DOSXYZnrc.
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Chapter 3
Pilot study
3.1 Chapter aims
In this chapter the protocol followed in our centre for production of oesophageal
RT plans will be described. The implementation of the RTGrid in Velindre Cancer
Centre for performing MC on distributed computing resources will be described,
as it was configured at the start of the project. The changes that were made to
the RTGrid to allow this work will then be discussed. The production of a CT
ramp, OesRAMP, to convert CT data into the material and density information
for MC simulations will be described. The adaptation of the existing BEAMnrc
linac model to allow plans with EDWs to be simulated will be discussed. The
approach to removing CT contrast from CT data will be presented. Finally, the
simulation of 12 oesophageal cases will be described, and the results of these
simulations will be used to calculate the number of oesophageal cases to simulate
in the main study, for the required statistical power.
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3.2 Materials and methods
3.2.1 Oesophageal planning protocol
In this work oesophageal plans produced following the Velindre protocol for rad-
ical oesophageal plans, based on the SCOPE1 protocol, have been used. The
protocol issued to centres involved in the SCOPE1 trial called for a RT pre-
scription of 50 Gy in 25 fractions, each of 2 Gy, delivered over five weeks (i.e.
one fraction per weekday, with no RT over the weekend). For this work, only
oesophageal plans with a prescription of 50 Gy in 25 fractions were selected.
The SCOPE1 protocol also included detailed guidance on outlining OARs such
as the heart, as well as the Gross Tumour Volume (GTV) and margins to be
applied to the GTV. The GTV was to be delineated on a CT scan, and the
use of PET was encouraged. A number of margins were to be applied to the
GTV, including two Clinical Target Volumes (CTVs). A CTV is the GTV plus
a margin to account for the spread of the disease that cannot be detected, so
will not be included in the GTV. First, the CTV-A was produced by outlining
the oesophagus on slices 2 cm superior and up to 2 cm inferior of the GTV (but
no further than the gastro-oesophageal junction, if this was within 2 cm of the
GTV). From the CTV-A, the CTV-B is produced by growing a 1 cm margin in
all directions within the plane of the CT slice. Finally, the PTV is produced by
growing a margin of 1 cm superior and inferior, and 0.5 cm in all directions in the
plane of the CT slice of the CTV-B. A margin known as a Planning Reference
Volume (PRV) was to be added to the spinal cord to account for the uncertainties
in the position of this OAR. Again, only oesophageal plans with these volumes
were selected for this work, to exclude palliative plans, or plans produced to a
different protocol.
Prior to SCOPE1, oesophageal cancer was commonly treated by a two-phase RT
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plan. Initially, a two-beam plan was delivered, with the beams irradiating the
patient from the front (‘anterior’) and the back (‘posterior’), known as the first
phase plan. This would be delivered for a certain number of fractions, then the
treatment plan would be changed to a three field plan avoiding the spinal cord,
known as the second phase plan, to be used for the remaining fractions. By using
a single phase, multi-beam technique, the dose to the heart could be reduced
more easily (Cominos et al., 2005). Also, a single phase plan was postulated to
be better for the OARs, as the dose they received would be spread over the whole
course of radiotherapy. In the two phase approach, the spinal cord would receive
the dose just in the first phase, reducing the amount of recovery time for the
healthy tissue. The SCOPE1 protocol mandated a single phase approach, but
allowed the number and arrangement of beams to be determined on a case by
case basis. This is the approach adopted at Velindre for all CFRT oesophageal
treatment plans, so all plans included in this work are single phase plans.
The DVH parameters that are reported for oesophageal plans in Velindre are: -
• PTV V95%: The volume, as a percentage, of the Planning Target Volume
receiving 95% of the prescription dose;
• PTV D99%: The dose, in Gray, received by 99% of the Planning Target
Volume;
• GTV D100%: The dose, in Gray, received by 100% of the Gross Tumour
Volume;
• heart V80% The volume, as a percentage, of the heart receiving 80% of
the prescription dose;
• Cord PRV D1cc: The dose, in Gray, received by 1 cubic centimetre of
the Planning Organ at Risk Volume for the Spinal Cord;
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• Combined Lung V20 Gy: The volume, as a percentage, of the combined
lungs receiving 40 Gy;
• Liver V30 Gy: The volume, as a percentage, of the liver receiving 30 Gy
(if included in the treatment field);
• Individual Kidney V20 Gy: The volume, as a percentage, of the each
kidney receiving 20 Gy(if included in the treatment field);
Since the liver and kidneys are not included in the treatment field, or indeed the
CT scan for all oesophageal treatments, these were excluded from consideration.
All other DVH parameters were investigated in this work.
3.2.2 RT Grid at Velindre
The RTGrid was introduced in section 2.5.3.5, as a system designed to allow MC
simulations to be run on distributed computing platforms. Details of how the
RTGrid is used in Velindre will be presented, along with adaptations made to aid
in this work.
The RTGrid at Velindre uses HTCondor1 as the distributed computing resource
on which MC simulations, using BEAMnrc, are run. HTCondor (previously
known as Condor) is a workload management system that executes programs
on a pool of computers while those computers are idle. It is an example of a
HTC resource, as discussed in 2.5.2. HTCondor uses the concept of a slot; an
executable is run within a slot, the more slots available, the more jobs can be run
simultaneously. For computers with Intel CPUs each core of the CPU provides
two slots to HTCondor, due to the Hyper-Threading technology of Intel CPUs.
Therefore, a PC with a quad-core Intel CPU will be able to run eight HTCondor
1HTCondor. Available at: https://research.cs.wisc.edu/htcondor/ (Accessed: 21 November
2016).
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jobs simultaneously. The HTCondor pool in Velindre Cancer Centre currently
has approximately 200 slots, so can in theory run 200 jobs simultaneously. If a
single MC simulation was split between all slots, this would provide a increase
in efficiency that would exceed even that of VMC++
(
which demonstrates an in-
crease in efficiency of 150 compared to EGS4 (section 2.5.1.6)
)
. The availability
of these slots varies depending on how many PCs are in use, or switched off. It is
common that only a few tens of slots will be available during working hours, but
200 will be available overnight, or at weekends.
There are five key elements to the RTGrid, illustrated in Figure 3.1:
1. Web portal
2. Web services
3. MySQL database
4. Experiment manager
5. Computational resources
The Web services, MySQL database and the experiment-manager run from a
single server. The Web portal can be accessed on a web browser from the users’
computers and is used to stop and start experiments. The distributed resources
are computers throughout the Medical Physics department at Velindre Cancer
Centre, although the HTCondor Manager is also installed on the RTGrid server.
All communications between the Web Services and experiment-manager are per-
formed by updating the MySQL database. The use of a database for communic-
ation facilitates the updating of information about many different experiments
concurrently.
The RTGrid provides four ‘portlets’, for the administration of Users, Resources
(i.e. HTCondor), Profiles and Experiments (an individual simulation is termed
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RTGrid 
Server
RTGrid Web PortalInput Files Uploaded Results Files Downloaded
Web Services
RTGrid MySQL Database
Experiment Manager
HTCondor Pool
Figure 3.1: Original configuration of the RTGrid at Velindre Cancer Centre.
an experiment). The RTGrid is designed to support many different types of
MC simulation on many different types of computation platform. The profiles
describe the specifics of a simulation with a given MC package (i.e. BEAMnrc),
using a given resource (i.e. HTCondor). Profiles are defined by a Job Submission
Description Language (JSDL) document. This is an XML file describing the
programs to be executed, the parameters passed to the executables, the resources
they can be run on etc. In addition two shell scripts, pre.sh and post.sh, are run
at the start and end of the simulation respectively, to prepare the experiment,
and to perform any post-processing steps. A second XML file, called a profile
extension, may be used to specify information that is outside the scope of the
JSDL file. An example used by some RTGrid profiles (though not employed in
this work) would be to specify DICOM peer information in the extension.xml file,
used by a post.sh to export results to, in DICOM format.
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Files Transferred
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HTCondor Pool
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File-System
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downloaded via scp
Figure 3.2: RTGrid, as configured for this project.
When the RTGrid is started, the experiment-master process is started, to monitor
changes in the RTGrid database, and start an experiment-manager process for
each individual experiment. This also updates the database, for changes in the
state of the related experiment.
In order to perform a simulation, a ‘watch’ process is started, which monitors the
file system for new DICOM and DICOM-RT files. The DICOM and DICOM-RT
files describing a treatment plan are sent from a client PC to a dcm4chee2 server,
which writes the DICOM and DICOM-RT files to the file system (Figure 3.2).
The creation of these files is detected by the watch process, which creates an
entry in the database for the new experiment. The experiment-master updates
the web portal, so that the experiment is visible in the web portal. In the current
2dcm4chee Image Manager and Archive. Available at: http://www.dcm4che.org/ (Accessed:
19 December 2016).
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implementation, nothing further will happen without user interaction - the user
must start the experiment via the web portal.
The experiment-master ‘spawns’ an experiment-manager for each new experi-
ment. The experiment-manager executes the pre.sh, which will create the jobs
to execute on the HTCondor pool, to match the job as laid out in the JSDL file.
In this profile, this is achieved via a number of Python3 scripts in the profile,
which create the BEAMnrc and DOSXYZnrc input files from the DICOM and
DICOM-RT data. The experiment-manager will update the database with the
number of jobs created, and jobs are copied to the HTCondor resources. As the
jobs are completed, the HTCondor process on the client computer will return the
output to the HTCondor server, and the database will be updated, so that the
experiment-manager can update the web portal to show progress (Figure 3.3).
Initially a ‘pre-test’ simulation is performed, with one job per beam and 10000
histories per job. The results of these jobs are used to calculate the number of
histories that will be needed for 2% statistical uncertainty at the isocentre. From
this, the number of jobs that the simulation should be split into to keep the jobs
to approximately two hours each in calculated. Typically 30-50 jobs are used per
oesophageal plan. Since the time to simulate 10000 histories in the pre-test is
used in the calculation, this can be affected if the PC used at this stage is unusu-
ally slow or fast, so jobs may not take two hours as intended. As for the pre-test,
during the main simulation the web portal will be updated with progress as the
jobs move from submitted, to running to finished.
HTCondor will suspend the job being executed on a PC when that PC starts to
be used, i.e. HTCondor detects keyboard or mouse activity; if it cannot be started
on the same PC within a set time, the HTCondor server will submit the job to a
different available slot. As all jobs must finish before a simulation is completed,
the completion of a simulation may be delayed by a single job. A setting in the
3Python Software Foundation. Python Language Reference, version 2.7. Available at
http://www.python.org
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RTGrid profile can be used to complete the simulation if a set percentage of the
jobs, e.g. 95%, have been completed. This feature was not used in this work, in
case the outstanding 5% of jobs all related to the same beam, and this resulted in
poor statistical uncertainties for this beam. As most simulations were performed
overnight or at weekends, not enabling this feature did not result in problems in
this work.
Figure 3.3: Screenshot of RTGrid, showing the progress of an experiment.
After simulation, the SSH is used to download the .3ddose files, egsphant files and
logs. SSH is called from a Python script, so the same files are downloaded each
time for consistency. The 3ddose is then calibrated in terms of dose, correcting
for back-scatter. The dose is converted from Monte Carlo, Dose To Material
(MC DMat) to Monte Carlo, Dose To Water (MC DWtr), and both set of dose
files converted to DICOM-RT. Python scripts used to call CERR (Deasy et al.,
2003) scripts to create .cerr files for PBE, CCE and both types of MC dose. This
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facilitated the production of DVH data using the same method, as recommended
by authors such as Alexander et al. (2007). Using CERR for the DVH production
also allowed the DVH production to be automated, which would not have been
possible in Oncentra.
3.2.3 BEAMnrc on RTGrid
DOSXYZnrc is capable of using various inputs, called sources, which may be
point sources, phase space files, simulations of linac from BEAMnrc or others.
The profile used on the RTGrid for this work use ISOURCE9, which uses a
BEAMnrc linac compiled to a .dll file. DOSXYZnrc is able to call the .dll file to
‘request’ an input particle. As with SMCP in section 2.5.3.3, this avoids copying
large phase space files to HTCondor slots.
The jobs write .pardose files, rather than .3ddose files, which are a more com-
pact way of storing dose data. Once the .pardose files are copied back to the
RTGrid/HTCondor server, they are converted to .3ddose files.
3.2.3.1 Naming convention for structures
In order to facilitate analysis, it was decided to enforce a naming convention for
all Regions Of Interest (ROIs) in the DICOM-RT Structure Set file prior to MC
simulation. A script was written in Python to check each ROI for each case prior
to submitting it to the RTGrid. If a case was found to have an ROI that did
not match the desired naming convention, the code either tried to substitute a
recognised name based on a look up table, or submission would be prevented until
a suitable substitution was added to the look up table. For example, if an ROI
named ‘Left Lung’ was encountered, and there was an entry in the look up table
relating ‘Left Lung’ to ‘Lung_Left’ (the preferred name for the left lung ROI),
the ROI would be renamed in the DICOM-RT file to ‘Lung_Left’. If however a
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ROI with a variation that had not been predicted, e.g. ‘Haert’, the DICOM and
DICOM-RT files would not be copied to a staging area used to store data prior to
uploading to the RTGrid, and an error logged. Once the look up table had been
amended to link ‘Haert’ to ‘Heart’, the substitution would be performed, and the
DICOM and DICOM-RT files copied to the staging area.
3.2.4 Developmental work required
In order to simulate oesophageal plans on the RTGrid, the following changes
needed to be made to the profile: -
1. changes to allow MC simulations using Velindre CT scans;
2. changes related to the oesophageal radiotherapy technique used at Velindre;
3. changes relating to reproducing the Oncentra approach to dose calculation,
to allow appropriate comparisons to be made.
3.2.4.1 CT Ramp
Radiotherapy dose calculations use CT scans of patients, which are maps of Houn-
sfield Units (HU), a quantity related to relative attenuation coefficients (Equa-
tion 3.1). BEAMnrc calculations require the simulation geometry to be repres-
ented as maps of the material composition and density, e.g. in an egsphant file
that describes the geometry using two matrices, one listing the material for each
voxel, and the other listing the mass density (rather than electron density) for
each voxel. (A separate file lists the interaction cross sections for different energy
ranges for the materials specified in the egsphant files). MC treatment planning
therefore requires a method to convert HU to materials and densities — this is
known as a CT ramp. ICRU (1992) lists the material compositions and interac-
tion data for approximately 100 tissues found in the human body. The CT ramp
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(a) Illustration of the CIRS 062M phantom. (b) CT Scan of the CIRS 062M phantom.
Figure 3.4: The CIRS 062M phantom, which features inserts which mimic the electron
densities of tissues of the body.
used in this work was created based on the Stoichiometric method of Schneider
et al. (1996), as described by Vanderstraeten et al. (2007). The ramp in this work
will be termed OesRAMP.
Stoichiometry is the calculation of relative quantities of chemicals in a compound
or mixture. The basic steps in this approach are:-
1. Scan a range of test materials of known elemental composition with the CT
scanner protocol of interest, to determine the HU of the test materials;
2. Determine the attenuation coefficients of the test materials;
3. Use an iterative fitting method to determine parameters in the relation
between attenuation coefficients and material composition;
4. Use these parameters to predict the HU for standard tissues, based on their
elemental composition.
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H = 1000
 µ
µwater
− 1
 (3.1)
The first step was to scan the CIRS 062M phantom4 in the CT scanner at Velindre
Cancer Centre, using the CT protocol used for oesophageal patients – ‘RTChest-
Contrast’. This CT scan included the HU for inserts of known densities and
elemental composition (Figure 3.4). Equation 3.1 shows the relation between
HU and the attenuation coefficient, µ. Since both µ and µwater vary with the
energy spectrum of the incoming radiation beam, the HU values will vary too.
Equation 3.2 describes the total attenuation coefficient, µ, of a material that is
a mixture of elements with elemental weights wi, atomic numbers Zi and atomic
masses Ai, where: -
• ρ is the mass density;
• NA is Avagadro’s Constant, 6.022× 1023 mol−1;
• Kph, Kcoh and KKN are energy dependent parameters that characterise
different interaction cross-sections, Kph for photoelectric absorption, Kcoh
for coherent scattering including the binding correction, and KKN for the
Klein-Nishina coefficient,
µ = ρNA
n∑
i=1
(
wi
Ai
(
KphZ4.62i +KcohZ2.86i +KKNZi
))
(3.2)
Equations 3.1 and 3.2 may be applied to each insert of the CIRS 062M phantom.
Since we are only interested in the attenuation relative to water, Equation 3.2 can
be rearranged as Equation 3.3, leaving two fitting parameters, k1 = Kph/KKN and
k2 = Kcoh/KKN . Code was written in Python to extract the HU for the various
inserts from the CT scans, look up the appropriate elemental weights, atomic
4Computerized Imaging Reference Systems, Inc.
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number and atomic masses of the inserts, and calculate the fitting parameters k1
and k2. This was performed by a function to minimise the difference between
the published densities of the CIRS materials and the values calculated from
Equation 3.3. The values that this method yielded were Kph/KKN = 2.14 × 10−5
and Kcoh/KKN = 7.42× 10−4. These compare favourably with the values reported
Vanderstraeten et al. (2007) (Table 3.1). In addition, the value of Kcoh/KKN calcu-
lated is a positive number, and Vanderstraeten et al. (2007) state that a negative
value of Kcoh/KKN is unphysical.
µ = ρNAKKN
n∑
i=1
(
wi
Ai
( Kph
KKN
Z4.62i +
Kcoh
KKN
Z2.86i + Zi
))
(3.3)
The densities of the different inserts were plotted against the calculated HU (Fig-
ure 3.5). This yielded three distinct portions of the graph; air and lung, soft
tissue and bony tissue. As the equations fitted to the first two portions of the
graph were very similar they were combined into a single fit covering air, lung and
soft tissue (Equation 3.4). The R2-squared value for this equation was 0.9998,
showing that there was little deviation between the equation and the measured
data. The CT ramp was therefore defined by the two equations, applying Equa-
tion 3.4a below HU value of 55 and Equation 3.4b above 55, where 55 is the HU
value where the two equations give the same mass density value. This enabled
HU to be converted to a density.
Mass Density = 9.931× 10−4 ×HU + 1.0185 for HU ≤ 55 (3.4a)
Mass Density = 5.287× 10−4 ×HU + 1.0445 for HU > 55 (3.4b)
To close the loop, for the inserts of CIRS 062M phantom, the HU were calculated
from Equation 3.4, and the calculated HU plotted against the mean measured HU.
If the approach is correct, the data should lie along the line y=x. To test this, the
equation y=x was fitted to the data, and the R2-value calculated. The R2-value
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Figure 3.5: Hounsfield Unit calibration curve, for the RTChestContrast protocol,
showing fitting parameters for the air and lung region, the soft tissue region, the bone
tissue region, and the combined air, lung and soft tissue regions.
was 0.9992, demonstrating the ability of the method to recover the data used
to generate the CT Ramp, verifying that the work was done without significant
error (Figure 3.6). For each insert in the CIRS 062M phantom there was a range
of HU values measured. The error bars in Figure 3.6 are the standard deviations
of the ranges of HU measured for each insert.
Equation 3.4 is a continuous function converting HU to density. A method to
convert HU to material is still required; this will not be a continuous function,
but a conversion of a continuous variable to a discrete series of materials. Vander-
straeten et al. (2007) recommend 14 discrete materials, or bins, in the ramp, and
this approach was followed in this work.
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Figure 3.6: Comparison of calculated and measured HU for CIRS 062M phantom.
The error bars are the standard deviations of the ranges of HU measured for each insert.
The HU boundaries as given in Table 3 of Vanderstraeten et al. (2007) were
initially used to determine the boundaries to be used in this work, by converting
HU to densities using the ramp in Vanderstraeten et al. (2007), then converting
these back to densities using OesRAMP. These HU values were used to visualise
which regions of a CT slice would be treated as each material, for the central CT
slice of each patient in the pilot study, and the CT of the CIRS phantom. It was
seen that the conversion to material was not always correct. This is illustrated in
Figures 3.7 and 3.8. Both show the density (a) of the voxels in a slice through an
egsphant file, and then for AIR (b), LUNG (c), ADIPOSE (d), MUSCLE (e) and
the ten bone bins combined (f). The voxels converted to the material of interest
are shown in white, and all the other voxels are shown as black.
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In Figure 3.7(c) it can be seen that many voxels outside the lung have been set to
LUNG, whereas in Figure 3.8(c) the only voxels set to lung are in the lung, or a
small ’halo’ around the surface of the patient. This is due to the CT scan having
a higher resolution than the egsphant file, which matches the resolution of the
dose calculation, 3 mm × 3 mm. This causes the the voxels at the patient surface
to include some air and some soft tissue, and appear to be an average of the two
HU values, which is set to LUNG. As this affects only a single layer of voxels,
the effect on the dose calculation can be neglected. Other cases exhibited other
related issues, such as voxels in the lung being set to AIR, and voxels in bones
being set to MUSCLE. To correct these incorrect assignments, the HU values
used as the boundaries were adjusted until AIR, LUNG, ADIPOSE, MUSCLE
and BONE1 showed no obvious issues.
The width of the bone bins from Vanderstraeten et al. (2007) was approx 0.9 g.cm−3,
which is equivalent to 170 HU for OesRAMP (c.f. 150 HU for the ramp of Vander-
straeten et al. (2007), which has a different gradient). The boundaries of the ten
bone bins were set based on the interface of MUSCLE and BONE1 as the starting
point, then regularly spaced at 170 HU. The upper limit of BONE10 was set to
4000, as this is above the maximum HU the scanner would produce, to avoid the
code encountering a runtime error if it tried to interpolate a value outside the
defined boundaries.
The HU and densities defining OesRAMP were then included in the source code
for ctcreate.exe. This is not the ctcreate from BEAMnrc, but a program written
in C5 as part of RTGrid development (Downes, 2010), which creates the egsphant
file from CT files. When this ctcreate.exe is called with the appropriate option,
OesRAMP is used in the creation of the egsphant file.
5The C Programming Language. Available at: http://www.open-std.org/jtc1/sc22/wg14/
(Accessed: 25 November 2016).
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(a) Plot of density in sample slice. (b) Voxels converted to Air shown as white,
other materials shown as black.
(c) Voxels converted to Lung shown as white,
other materials shown as black.
(d) Voxels converted to Adipose shown as
white, other materials shown as black.
(e) Voxels converted to Muscle shown as white,
other materials shown as black.
(f) Voxels converted to any bone bins shown as
white, other materials shown as black.
Figure 3.7: Plots showing material assignment based on incorrect boundaries, plus
plot of density for comparison.
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(a) Plot of density in sample slice. (b) Voxels converted to Air shown as white,
other materials shown as black.
(c) Voxels converted to Lung shown as white,
other materials shown as black.
(d) Voxels converted to Adipose shown as
white, other materials shown as black.
(e) Voxels converted to Muscle shown as white,
other materials shown as black.
(f) Voxels converted to any bone bins shown as
white, other materials shown as black.
Figure 3.8: Plots showing material assignment based on final boundaries, plus plot of
density for comparison.
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Vanderstraeten Ramp Mass Density (g.cm−3) OesRAMP—initial OesRAMP—adjusted
HU Lower HU Upper Lower Upper HU Lower HU Upper HU Lower HU Upper
null -900 null 0.104 null -921 -1024 -950
-900 -100 0.104 0.904 -921 -115 -950 -165
-100 20 0.904 1.024 -115 6 -165 0
20 100 1.024 1.104 6 113 0 100
100 250 1.104 1.165 113 228 100 270
250 400 1.165 1.255 228 399 270 440
400 550 1.255 1.345 399 569 440 610
550 700 1.345 1.435 569 739 610 780
700 850 1.435 1.525 739 909 780 950
850 1000 1.525 1.615 909 1079 950 1120
1000 1150 1.615 1.705 1079 1250 1120 1290
1150 1300 1.705 1.795 1250 1420 1290 1460
1300 1450 1.795 1.885 1420 1590 1460 1630
1450 null 1.885 null 1590 null 1630 4000
Table 3.2: Table of the boundary values used to distinguish different tissues types,
for OesRAMP.
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3.2.4.2 EGS4DAT file
To complement the CT Ramp, a file containing the interaction cross-sections for
the materials in the ramp is required. For BEAMnrc/DOSXYNnrc, this inform-
ation is held in a file with the extension .egs4dat. BEAMnrc is supplied with
sample .egs4dat files for elements commonly found in linac heads, and certain
human tissues, matching those used by the standard BEAMnrc CTRAMP, i.e.
air, lung, soft tissue, and bone. In order to perform simulations using the 14-bin
ramp, an .egs4dat file containing interaction cross-sections for the 14 materials
of interest had to be created. This was done using ‘egs gui’, a program within
BEAMnrc (Figure 3.9). For AIR, LUNG, ADIPOSE and MUSCLE the ICRU
density files were used. For the bone bins, the approach of Schneider et al. (2000)
was used, in which the weight of elements for bone tissue was interpolated between
red/yellow marrow and skeleton cortical bone, for the densities of the centre of
the bone bins (Table 3.2).
3.2.4.3 SPR calculation
The absorbed dose to a given material, Dmat may be converted to the absorbed
dose to water, Dwtr, using Bragg-Gray cavity theory, defined by Equation 3.5,
where SPRwtr,mat is the unrestricted Stopping Power Ratio (SPR), water to ma-
terial (a restricted SPR is one restricted to energy losses below a certain cut-off
energy). Bragg-Gray cavity theory is applicable when a small volume of water,
small enough not to perturb the fluence of charged particles, is substituted for a
volume of the material being irradiated.
Dwtr = Dmat × SPRwtr,mat (3.5)
SPRRZnrc (Kosunen and Rogers, 1993) was used to perform simulations using the
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Figure 3.9: Screenshot of egs_gui, used to create .egs4dat file.
same MC linac model used for the oesophageal simulations, to calculate the SPR
values for the 14 materials used in this work. These were compared with standard
values taken from Siebers et al. (2000), the results are shown in Figures 3.10 and
3.11.
3.2.4.4 Simulation of Enhanced Dynamic Wedge
EDW fields have been simulated on the RTGrid using the component module
‘EDW’, by Downes (2010). The component module was written for BEAM-
nrc 2007, and BEAMnrc 2010 was used in this work. Therefore the differences
between the cm.macros and cm.mortran files for the Jaws CM for BEAMnrc
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Figure 3.10: Comparison of calculated and published SPR values, for a 6 MV beam
from the Varian 2100 linac model.
2007 and BEAMnrc 2010 were studied, and the changes to the cm.macros and
cm.mortran were reproduced for the EDW Component Module.
3.2.4.5 Calibration of linac model
The values produced in the .3ddose file from DOSXYZnrc are energy deposited
per unit mass, normalised to the number of incident particles, i.e. electrons incid-
ent on the target. It is therefore common to perform a simulation for 100 MU,
find the energy deposited per unit mass, per incident particle, at a reference point
at which the dose from 100 MU is known, and use this value to produce a calibra-
tion value. This calibration value can then be applied to subsequent simulations
to convert from the values in the .3ddose file to Gy per MU. Chetty et al. (2007)
3.2 Materials and methods 102
S
ie
b
e
rs
 A
ir
 
A
ir
S
ie
b
e
rs
 L
u
n
g
 
Lu
n
g
S
ie
b
e
rs
 T
is
su
e
 
A
id
p
o
se
M
u
sc
le
B
o
n
e
1
S
ie
b
e
rs
 S
o
ft
 b
o
n
e
 
B
o
n
e
2
B
o
n
e
3
B
o
n
e
4
B
o
n
e
5
B
o
n
e
6
S
ie
b
e
rs
 C
o
rt
. 
B
o
n
e
 
B
o
n
e
7
B
o
n
e
8
B
o
n
e
9
B
o
n
e
1
0
0.0
0.2
0.4
0.6
0.8
1.0
1.2
S
P
R
 v
a
lu
e
s
Figure 3.11: Comparison of calculated and published SPR values, for 10 MV beam
from the Varian 2100 linac model.
caution against using a single voxel to produce the calibration value, to avoid the
calibration value being affected by the statistical uncertainty of the value in a
single voxel. In this work, simulations were performed with 100 MU delivered to
a cubic water phantom of side 20 cm, at 90 cm Focus to Source Distance (FSD)
for a 10 cm by 10 cm field. The dose values were plotted between 5 cm and 15 cm
deep on the central axis. A curve was fitted to the values, and the value of the
curve at 10 cm deep used in the production of the calibration values. By fitting
a curve to many voxels, the effect of the statistical uncertainty will be averaged
out.
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3.2.4.6 Backscatter correction
The method used to calibrate the linac model described in section 3.2.4.5 will not
account for radiation scattered from the jaws into the MU chamber. Consider the
definition of Output Factor (OPF) as the ratio of dose at a reference point from
a given field to that from a 10 cm × 10 cm field (British Institute of Radiology,
1996); this FSF will have three components, head scatter, phantom scatter and
backscatter. The head scatter is the change in radiation at the reference point
due to the collimators occluding more or less of the effective radiation sources in
the head (such as target, flattening filter, collimator faces). The phantom scatter
is the change in radiation at the reference point due to the change in the volume
of the phantom being irradiated as the collimators are moved in or out of the
beam. The backscatter effect is due to radiation being scattered from the upper
surface of the collimators into the monitor chamber, changing the signal measured
by the chamber relative to the 10 cm × 10 cm collimator settings. Closing the
collimators will lead to an increased signal, so 100 MU will be reached with less
radiation fluence impinging on the chamber from above. The backscatter effect
will not be accounted for in the calibration method, so a method must be found
to correct for this in order for the calibration to give accurate doses across field
sizes.
Verhaegen et al. (2000) found that the backscatter contribution was 2 − 3% for
static fields, for linacs that were affected by it, but stated that EDW fields would
show larger backscatter contributions. Furthermore, Verhaegen et al. (2000)
found that the source of the backscatter effect was backscattered electrons from
the secondary collimators, not the MLCs.
Yu et al. (1996) and Duzenli et al. (1993) found that Varian 600C linacs have
little or no backscatter effect, due to the copper plated steel exit window of the
mica ionisation chamber, which absorbs the backscattered radiation; Varian 2100
linacs, which have a kapton monitor chamber, did demonstrate a backscatter
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effect.
Hounsell (1998) showed that Elekta Precise linacs do not demonstrate a backs-
catter effect, due to the presence of steel absorber above the flying wedge.
Measuring the contribution of backscatter is challenging. Some authors used the
telescopic technique (Yu et al., 1996), to isolate all radiation but narrow beam,
so that the measured dose is proportional to Bremsstrahlung generated in the
target. Others use variation of charge integration or pulse counting technique, to
analyse the signal from the monitor chamber as a function of pulses from Pulse
Forming Network (Lam et al., 1998).
For linacs that do demonstrate the backscatter effect, there are a few approaches
to dealing with it. Popescu et al. (2005) placed a scoring plane above the collimat-
ors, and performed a simulation which describes the radiation leaving the patient
invariant portion of the linac head (i.e. the components above the phase space file
are fixed for all photon fields for a given energy). The phase space file produced is
then used as a input to subsequent simulations, in which the energy deposited in
the monitor chamber from the backscattered radiation is produced, as well as the
dose deposited in a phantom or patient geometry. For a given field, the dose in
the monitor chamber due to radiation incident from above can be found from the
initial simulation, combined with the dose due to the backscattered radiation.
This can be compared with the dose accumulated in the monitor chamber for
reference conditions, and so the absolute dose from the MC can be determined.
This is an attractive approach, as it mimics what occurs in the linac. However,
the simulation based on a phase space file above the jaws does not fit with the
ISOURCE9 beam library based approach used in this work.
Liu et al. (2000) performed simulations of a Varian 2100 linac head with various
collimator settings, then used the results to produce equations describing the
backscatter from each pair of jaws, and the masking effect of the upper jaws on
backscatter from the lower jaws. This method was able to predict the change in
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output due to backscatter to within 0.5% of measured data. The equations are
applicable (after suitable validation) to other Varian 2100 linacs without having to
reproduce the simulations. The approach of Liu et al. (2000) was adopted in this
work. Simulations were used to create three equations. Equation 3.6 describes
the backscatter from each y−jaw, Ry(y), which follows a third order polynomial.
Equation 3.7, is a linear equation describing the backscatter from the x−jaws,
Rx(x). Equation 3.8 is another third order polynomial describing the shielding
effect of the y−jaws on the backscatter from the x−jaws, Py(y). These can be
used to calculate the relative backscatter, Sc,b(x, y), from any field of collimator
settings x and y, and Equation 3.9 used to calculate the change in dose due to
backscatter, relative to a reference field.
Ry(y) = 1.54× 10−2 − 8.45× 10−2y + 4.47× 10−5y3 (3.6)
Rx(x) = 0.40× 10−3 − 1.87× 10−2x (3.7)
Py(y) = 3.95× 10−2y − 3.55× 10−5y3 (3.8)
Sc,b(x, y) =
[1 +R(x0, y0)]
1 +R(x, y) (3.9)
3.2.4.7 Reproducing TPS approach
The changes to the RTGrid profile to perform the MC simulation in a way that
mimics the TPS are:
• intra-venous contrast must be treated as water equivalent;
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• a 5 cm extension must be added superiorly and inferiorly to account for
scatter outside the CT scan;
• the CT couch top, and other objects outside the external contour must be
treated as air.
Intra–venous contrast is frequently used to aid in the delineation of the GTV
in oesophageal radiotherapy. An iodine–based contrast agent is injected shortly
before the CT scan is acquired, so that the contrast agent enters the circulatory
system. Due to the iodine content, the contrast agent has a higher electron
density than that of soft tissue, so regions with a high concentration of iodine
will be enhanced (appear more white) on the resulting CT scan. For certain
tumours, including oesophageal tumours, the increased blood flow to the tumour
will help the radiation oncologist to outline the tumour on the CT scan. It is
common for larger blood vessels, notably the aorta, and the heart to have a high
concentration of iodine, and appear enhanced on the resulting CT scan. As the
iodine is filtered from the body, the kidneys and bladder may also have a high
concentration of iodine, and appear enhanced.
In addition to changing the appearance of the CT scan, the change in the elec-
tron density in regions of high iodine concentration will alter the attenuation
of radiotherapy treatment beams as calculated by treatment planning systems.
This would be acceptable if the iodine was present during treatment, but it will
have been removed from the blood stream by the body long before treatment
starts. Therefore, the presence of the iodine must be corrected for prior to radio-
therapy dose calculations, or the dose calculated will be incorrect. The standard
method for doing this in Oncentra (and other treatment planning systems) is
to outline regions of high enhancement, and mark these areas as having a bulk
density representing soft tissue. In Velindre, a bulk density of 1 g/cc is used (i.e.
the enhanced regions are assumed to be water density). An alternative approach
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(a) CT slice before masking has been performed. Heart has regions of en-
hancement, due to presence of contrast, with variations in pixel values.
(b) CT slice after masking has been performed. Pixel values have been
replaced with a value representing water density. Masked regions appear
uniform.
Figure 3.12: Masking of intra-venous contrast in CT slice.
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might be to use a slightly higher bulk density, more representative of soft tissues
such as the heart.
In Oncentra, the bulk density can be thought of as being applied internally to
the code; i.e. regions outlined as contrast will be treated as water equivalent
only during the dose calculation, the CT DICOM files are not altered by this
process. Since this work aims to perform MC based on DICOM and DICOM-
RT files exported from the treatment planning system, a method was needed
to treat regions of contrast as water equivalent in the MC, with ideally no user
involvement.
One possibility would be a windowing technique, in which CT pixels within a
certain HU range could be set to water equivalence. This method would be
difficult, as the HU of the contrast regions coincides with that of trabecular bone
(approximately 1250), as shown in Figure 3.13, so the method could treat bone as
water equivalent, which would not be appropriate. This shows that any reliable
approach would need to incorporate some knowledge of the organs or tissues
in which the regions of enhancement were located. It was therefore decided to
use the regions of contrast outlined in the planning system to determine what
regions should be treated as contrast in the MC simulation. This approach has
the advantage that exactly the same voxels will be treated as water in each dose
calculation (Figure 3.12). The downsides are that the regions outlined as contrast
are defined within a DICOM-RT Structure Set file, which the RTGrid has not
needed in order to perform simulations before.
The basic methodology used is as follows:
• include the DICOM-RT Structure Set in the files uploaded to the RTGrid
for a simulation;
• alter the RTGrid profile to read the Structure Set file;
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Figure 3.13: Histogram of Hounsfield Unit values within region of intra venous con-
trast, with HU of material inserts from CIRS 062M phantom for reference.
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• for each structure with the bulk density set to 1 g.cm−3, iterate over the
contours;
• for each contour, determine which CT pixels are within the contour, and
change the pixel value to the pixel value appropriate for water density;
• save the modified CT files;
• use the modified CT files to create egsphant file, not the originals.
As an aside, this approach would also allow bolus defined at the planning stage
to be accounted for, as the bolus will have a bulk density of 1 g.cm−3 applied.
This is not relevant for oesophageal plans, but is common in breast radiotherapy,
and other treatments in which the PTV is close to the skin surface.
3.2.4.8 Superior and inferior extension
When performing a CT scan to be used for RT planning, it is common to only scan
a portion of the body. This reduces the radiation dose from the CT scan to healthy
tissue away from the tumour. However, this means that the treatment planning
system will not be able to account for tissue outside the CT scan provided. Any
tissue that will be irradiated, and any nearby OARs, must be included in the CT
scan, to allow the dose in this region to be calculated, and the dose assessed by
an oncologist. Some of the absorbed dose in the PTV or OARs may be due to
radiation scattered from the tissue at the extremes of the scanned region. The
calculated dose must be independent of the superior and inferior boundary of the
CT scan, i.e. including additional slices should not alter the quoted dose within
the PTV due to the additional scatter.
It may be difficult to set the boundaries of the CT scan to achieve this independ-
ence, while not scanning tissue unnecessarily. The solution provided by Oncentra
is to allow a ‘virtual’ superior and inferior extension to be applied. In these
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extended regions, the superior or inferior slice is ‘copied’, to provide additional
scatter, out to a user defined distance. If, as for Head and Neck radiotherapy, the
CT scan includes the superior aspect of the head, the superior extension would
be set to 0 cm. For scans of the thorax and pelvis, it is common practice to set
both the superior and inferior extensions to 5 cm. Oncentra will not calculate
dose inside this ‘virtual’ region, but will account for scatter from this region into
the scanned region. This approach may not be accurate in regions where the
superior (or inferior) slice is not representative of the tissue outside the scan. For
example, if the superior slice includes the shoulders, but outside the CT scan the
patient outline narrows sharply to the neck. However, using an unrepresentative
cross-section is expected to be better than not accounting for tissue outside the
CT scan at all.
As with assigning a bulk density the iodine contrast, this correction is ‘internal’
to the dose calculation of Oncentra, the superior and inferior extension is not
included in the files exported from Oncentra. Therefore a method was needed to
mimic this approach for the MC simulations. Code was written in Pythonto parse
the egsphant file, alter the number and boundaries of the voxels in the Superior-
Inferior direction. The superior-most slice of the density matrices is then copied
and appended to the top of the matrix. The inferior-most slice is similarly copied
and appended to the bottom of the density matrix. This process was repeated
for the material matrix. The modified data was written to the egsphant file,
and the modified file used in the MC simulations. A complementary function was
written to reverse these changes after the simulation, and to alter the .3ddose files
(which take the same dimensions as the density and material matrices from the
.egsphant file). This ensured that the dimensions of the files from the simulation
match those of the DICOM-RT Dose files from the TPS.
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3.2.4.9 Accounting for the treatment couch
The CT scan will invariably include the couch top of the CT scanner – the CT
images will show the couch that the patient lay on during the CT scan. This
will not be present during treatment (the patient will be lying on a different
couch on the linac), so must be ‘ignored’ during the dose calculation (and the
effect of the linac couch top should be included). For Oncentra, the CT couch
is commonly removed from consideration by outlining the patient, but not the
couch, and defining this outline as the external volume. The external volume is
a special ROI; all pixels outside this volume are assumed to be air by Oncentra,
regardless of the HU values.
Again, the solution that most closely mimicked the approach of Oncentra was
felt to be the most suitable. The external contour was read from the DICOM-RT
Structure Set file, a mask was constructed that was unity for all values inside the
external contour, and zero for all pixels outside the contour (following the method
used for masking contrast). If there is more than one contour per slice, a mask is
generated per contour, and then the masks combined using an element-wise OR
statement. The mask was then inverted, and used to change the pixel values for
those pixels that are outside the external contour to -987, the mean of the upper
and lower boundaries of the AIR bin shown in Table 3.2.
The standard practice in Velindre for accounting for the linac couch is to apply
a simple attenuation correction factor to the MU for beams passing through the
treatment couch. This is performed outside the planning system, so will not be
included in either the doses calculated by Oncentra, or the doses from the MC
simulations.
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3.2.4.10 Post processing
After the MC simulation was complete, the 3ddose files produced by DOSXYZnrc
were downloaded from the RTGrid via scripts using SSH, along with associated
files such as .egsphant file, DICOM CT files and log files. The un-calibrated
.3ddose files were calibrated by applying calibration factors derived following the
method in section 3.2.4.5, and a factor to account for backscatter as described in
section 3.2.4.6. The files, now quoting dose in terms of energy deposited per unit
mass of material, were copied, and the SPR values discussed in section 3.2.4.3
applied, to convert to dose deposited per unit mass of water. The .3ddose files
were converted to DICOM-RT files, using code provided by Tony Teke of British
Columbia Cancer Agency, Vancouver Island Centre6.
3.2.4.11 Calculation of Dose Volume Histogram parameters
For the four sets of DICOM-RT Dose files (PBE, CCE, MC DMat and MC DWtr),
DVH parameters for the 12 cases in the Pilot Study were calculated using a
Matlab7 script that called functions from CERR.
3.2.5 Validation
In order to ensure that the MC simulations (including the generation of BEAMnrc
and DOSXYZnrc input files from DICOM and DICOM-RT files by the RTGrid),
and the post-processing tasks were being performed correctly, validation checks
were performed. This involved performing simulations in water phantoms, and
comparing these with commissioning data acquired at Velindre Cancer Centre
for a Varian 2100 linac. It is common practice when performing such verification
6Private Communication
7MATLAB 7.13, The MathWorks Inc., Natick, MA, 2011
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simulations to prepare an egsphant file with high resolution voxels in regions of
interest (i.e. along the central axis, for producing a PDD), and coarse voxels in the
regions in which the dose will not be examined, but provide scatter to the beam
axis. This approach reduces calculation time, compared with using high resolution
voxels throughout the phantom. However, in order to test the functionality of
the RTGrid, the method used by the RTGrid to create the egsphant files had
to be followed, i.e. they were produced from the DICOM CT files. Since the
DICOM CT files must have equally spaced voxels within a plane, the egsphant
used in this work also had to have equally spaced voxels. Even using the RTGrid,
simulating a cubic phantom of side 50 cm at 1 mm resolution, for tens of test
fields would have taken an excessive amount of time. It was decided to perform
simulations of fields of 7 cm by 7 cm and smaller in a 150 mm by 150 mm by
150 mm cube, of voxel size 1.5 mm by 1.5 mm by 1.5 mm. For fields up to 12 cm
by 12 cm, a cubic phantom of side 200 mm and cubic voxels of side 2.0 mm was
used. For fields up to 15 cm by 15 cm, a cubic phantom of side 300 mm and cubic
voxels of side 3.0 mm was used. This would provide sufficient phantom material
around the beam edges to provide scatter. The smallest phantom could be used
to confirm the field edge was modelled accurately, and the larger field sizes in the
larger phantoms could be used to show that a range of field sizes were modelled
accurately.
The measurements were performed for commissioning of the linac prior to this
work. They were acquired in a 50 cm by 50 cm by 50 cm plotting tank (water filled
tank, which uses a motorised system to position a measuring device anywhere in
the water tank). The measurements were performed with Scanditronix Photon
Field Detector (Scanditronix-Wellhofer, Germany), which is a p-type silicon diode
detector.
The MC parameters used for this validation work, and all subsequent simulations
are shown in Table 3.3.
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Option Parameter
Boundary Crossing Algorithm EXACT
Electron-step algorithm PRESTA-II
Spin effects On
Bremsstrahlung angular sampling Simple
Bremsstrahlung cross sections BH
Bound Compton scattering Off
Pair angular sampling Simple
Photoelectron angular sampling Off
Rayleigh scattering Off
Atomic relaxations Off
Electron impact ionisation Off
Table 3.3: BEAMnrc and DOSXYZnrc transport
options used in simulations throughout this work.
3.2.5.1 Open field depth dose curves
PDDs were produced at 6 MV and 10 MV, for 5 cm by 5 cm, 10 cm by 10 cm
and 15 cm by 15 cm fields, in varying sizes of phantom, as described above. In
order to improve the statistical uncertainty, multiple copies of the same field were
produced in the same DICOM-RT plan. The RTGrid then performed a simulation
for each beam, using different random numbers for each, and the resulting .3ddose
files combined. For each field, a plot of the measured PDD normalised to DMAX is
shown as a continuous blue line, and the MC values, also normalised to DMAX are
shown as green crosses. A second plot, showing the percentage difference between
the measured and simulated values is included. This also shows the statistical
uncertainty of the MC simulation as error bars, to allow the comparison of the
statistical uncertainty and any discrepancy between measurement and simulation
to be performed. Results in the first 5 mm are not presented, as the measurements
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in this region not reliable, due to the lack of CPE.
For the 5 cm by 5 cm fields at 6 MV and 10 MV (Figure 3.14), virtually all
simulated values are within 1% of measurement, aside from the shallowest and
deepest points. The difference for the very deepest points can be attributed to
the simulation having no material beyond 150 mm deep to provide backscatter,
whereas the water phantom used for the measurements extended to approximately
500 mm deep.
The results for the 10 cm by 10 cm fields at 6 MV and 10 MV (Figure 3.15), show
that the simulations are again within 1% of the measured values, aside from the
deepest 20 mm of the phantom. This behaviour in the deepest 20 mm could be
due to a flaw in the simulation, or the different backscatter conditions present for
the measurement. However, as both 6 MV and 10 MV plots demonstrate similar
behaviour, and the PDD for the 15 cm by 15 cm fields in a larger phantom show
good agreement at 200 mm deep (Figure 3.16), the backscatter is the more likely
explanation.
For the 15 cm by 15 cm fields at 6 MV and 10 MV (Figure 3.16), again agreement
between simulation and measurement is within 1% until approximately 50 mm
from the deepest point in the simulated phantom. As this is a repeat of the
behaviour from other field sizes and phantom sizes, this can be explained by the
difference in backscatter between measurements and simulation.
Overall, these results show that PDD can be accurately simulated for both 6 MV
and 10 MV, for field sizes between 5 cm and 15 cm, for open fields.
3.2.5.2 Open field profiles
As for the PDDs, beam profiles were produced for 6 MV and 10 MV, for 5 cm by
5 cm, 10 cm by 10 cm and 15 cm by 15 cm field sizes, in varying size phantoms.
Profiles were compared at 5 cm and 10 cm deep for all field sizes. Due to the
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larger phantom size used for the 15 cm by 15 cm beams, profiles at 20 cm deep
are also presented. As for the PDD comparisons, for each profile two plots have
been produced. The first shows measurements as a continuous blue line and MC
results as green crosses, and the second shows differences between the two results,
and the statistical uncertainty in the MC results.
For the 6 MV, 5 cm by 5 cm field (Figure 3.17), for both 5 cm and 10 cm deep, and
in both directions (X-direction and Y-direction), the MC results are within 1% of
the measurements, except in the penumbra where the dose drops sharply. It can
be seen that the shape of the MC beam edge follows that of the measurements.
Figure 3.18 shows the results for the 6 MV, 10 cm by 10 cm field. The MC results
are typically within 1% of the measurements, with a few points in the ‘shoulders’
of the profile being outside 1%, but well within 2%.
For the 6 MV, 15 cm by 15 cm field (Figure 3.19), most MC results are within
1% of measurement, even at 20 cm deep.
For the 10 MV, 5 cm by 5 cm field (Figure 3.20), the MC results are within 1%
of the measurements, except in the penumbra. However, it can be seen that the
shape of the MC beam edge follows that of the measurements. Since the 5 cm by
5 cm fields were simulated in a phantom with voxels of side 1.5 mm, these fields
show the penumbra to the highest resolution used in this work.
Figure 3.21 shows the results for the 10 MV, 10 cm by 10 cm field. Once again,
the MC results are typically within 1% of the measurements, with a few points
being just outside 1%.
For the 10 MV, 15 cm by 15 cm field (Figure 3.22), most MC results are within
1% of measurement, and all are within 2%, even at 20 cm deep.
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3.2.5.3 Enhanced Dynamic Wedge field depth dose curves
An advantage of EDW fields is that their PDDs are the same as those for the
equivalent open field, so results will not be duplicated here.
3.2.5.4 Enhanced Dynamic Wedge field beam profiles
Beam profiles were produced for 6 MV and 10 MV, for 5 cm by 5 cm, 10 cm
by 10 cm and 15 cm by 15 cm field sizes, in varying size phantoms, for the
four EDW wedge angles, 15o, 30o, 45o, and 60o. For brevity, only the results
for 10 cm by 10 cm fields are presented. The corresponding results for 5 cm by
5 cm and 15 cm by 15 cm fields are discussed in Appendix B. Verhaegen and Liu
(2001) found the agreement between simulation and measurement to be within
two standard deviations, with a standard deviation on the MC results of 1%.
Therefore, agreement between simulation and measurement within 2% shall be
considered the desired agreement.
For the 6 MV, 15o EDW, 10 cm by 10 cm field (Figure 3.23), results are typically
within 1% of the measurements, with all points for the profiles in the X-direction
being within 2% of measurements, which agrees with the results from Verhaegen
and Liu (2001). For the profiles in the Y-direction, the direction of the wedge,
some points in the ‘toe’ of the wedge are outside 2%, but this is comparable with
the results of Verhaegen and Liu (2001).
Figure 3.24 shows the results for 6 MV, 30o EDW, 10 cm by 10 cm field. Again
results are well within 2% aside for a small region in the toe of the wedge.
Figures 3.25 and 3.26 show the results for 6 MV, 10 cm by 10 cm fields for 45o
EDW, and 60o EDW. Again results are within 2%, apart from differences in the
toe of the wedges. However, overall agreement between MC and measurement is
within the desired tolerance.
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The results for the equivalent 10 MV fields (Figures 3.27, 3.28, 3.29 and 3.30) are
comparable to those for the 6 MV fields, agreement is typically within 1% - 2%,
except for the toe of the wedge, with discrepancies in the toe region increasing
with wedge angle. However, the results for 45o EDW, and 60o EDW at 10 MV
are better than the equivalent 6 MV field sizes.
Overall, the agreement for EDW fields is comparable to the results of Verhaegen
and Liu (2001), outside the very toe end of the EDW fields. This is expected from
the original work on the component module used for EDW simulations (Downes,
2010). Furthermore, when different fields are combined in a clinical plan, the
effect of a single field will be reduced.
3.2.5.5 Check of absolute dose
The Absolute Dose at the isocentre for most fields in Tables 3.4 and 3.5 show
most fields are accurate to within 1%. Some of the smallest and largest fields
show differences between 1% and 2%, with the worst result of 2.3% for the 15 cm
by 15 cm 60o EDW field at 6 MV. This field is larger than a typical field used for
oesophageal plans. Overall, these results show good agreement between simula-
tion and measurement.
3.2.6 Case selection criteria
Radical RT treatment plans created in Velindre are entered into a custom task
management system, which includes the treatment site of the plan, and the date
the plan is due by. Structured Query Language (SQL) was used to extract a list
of all oesophagus plans in this system, ordered by the due date. The pilot study
comprised the first 12 cases meeting the following criteria:
• the CT was performed at Velindre Cancer Centre, using the
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5 cm by 5 cm
Field Raw Cal Factor Liu MC Dose Expected Dose % Diff
Open 8.76E-17 1.22E-16 1.00 0.722 0.710 1.8
15 EDW 8.41E-17 1.22E-16 1.00 0.690 0.687 0.5
30 EDW 8.01E-17 1.21E-16 1.00 0.664 0.663 0.2
45 EDW 7.60E-17 1.19E-16 1.00 0.643 0.632 1.7
60 EDW 6.91E-17 1.18E-16 1.00 0.588 0.585 0.6
7 cm by 7 cm
Field Raw Cal Factor Liu MC Dose Expected Dose % Diff
Open 9.16E-17 1.22E-16 0.998 0.755 0.751 0.5
15 EDW 8.68E-17 1.22E-16 0.998 0.712 0.716 -0.6
30 EDW 8.14E-17 1.21E-16 0.997 0.675 0.679 -0.5
45 EDW 7.52E-17 1.19E-16 0.997 0.637 0.633 0.6
60 EDW 6.62E-17 1.18E-16 0.996 0.563 0.566 -0.5
10 cm by 10 cm
Field Raw Cal Factor Liu MC Dose Expected Dose % Diff
Open 9.67E-17 1.22E-16 1.000 0.795 0.795 0.0
15 EDW 8.88E-17 1.22E-16 0.999 0.728 0.736 -1.1
30 EDW 8.12E-17 1.21E-16 0.999 0.672 0.677 -0.7
45 EDW 7.21E-17 1.19E-16 0.998 0.609 0.610 -0.1
60 EDW 6.10E-17 1.18E-16 0.998 0.518 0.520 -0.3
12 cm by 12 cm
Field Raw Cal Factor Liu MC Dose Expected Dose % Diff
Open 9.98E-17 1.22E-16 1.000 0.820 0.817 0.3
15 EDW 8.95E-17 1.22E-16 1.000 0.733 0.742 -1.2
30 EDW 8.02E-17 1.21E-16 0.999 0.664 0.668 -0.7
45 EDW 7.00E-17 1.19E-16 0.999 0.592 0.589 0.4
60 EDW 5.71E-17 1.18E-16 0.999 0.484 0.489 -0.9
15 cm by 15 cm
Field Raw Cal Factor Liu MC Dose Expected Dose % Diff
Open 1.02E-16 1.22E-16 1.000 0.840 0.844 -0.5
15 EDW 8.86E-17 1.22E-16 1.000 0.726 0.741 -2.0
30 EDW 7.66E-17 1.21E-16 1.000 0.634 0.647 -2.1
45 EDW 6.50E-17 1.19E-16 1.000 0.549 0.552 -0.6
60 EDW 5.08E-17 1.18E-16 0.999 0.431 0.441 -2.3
Table 3.4: Comparison of absolute doses from Monte Carlo compared with measure-
ments, at 6 MV, for different fields, where Raw is the uncorrected value from the MC
simulation, Cal Factor is the calibration factor, Liu is the backscatter correction for the
field, MC Dose is the raw MC value multiplied by the Cal Factor and Liu Factor, the
Expected Dose is the dose calculated from dosimetry tables in Velindre, and %diff is
the difference between the MC and expected doses, expressed as a percentage.
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5 cm by 5 cm
Field Raw Cal Factor Liu MC Dose Published Dose % Diff
Open 2.24E-16 2.79E-16 0.997 0.806 0.798 1.0
15 EDW 2.17E-16 2.75E-16 0.997 0.791 0.776 2.0
30 EDW 2.08E-16 2.75E-16 0.997 0.760 0.755 0.8
45 EDW 1.99E-16 2.73E-16 0.997 0.733 0.725 1.1
60 EDW 1.84E-16 2.69E-16 0.997 0.687 0.679 1.2
7 cm by 7 cm
Field Raw Cal Factor Liu MC Dose Published Dose % Diff
Open 2.35E-16 2.79E-16 0.998 0.842 0.835 0.8
15 EDW 2.24E-16 2.75E-16 0.998 0.814 0.802 1.5
30 EDW 2.11E-16 2.75E-16 0.998 0.770 0.768 0.3
45 EDW 1.97E-16 2.73E-16 0.997 0.725 0.725 0.0
60 EDW 1.76E-16 2.69E-16 0.997 0.658 0.659 -0.1
10 cm by 10 cm
Field Raw Cal Factor Liu MC Dose Published Dose % Diff
Open 2.44E-16 2.79E-16 1.000 0.875 0.875 0.0
15 EDW 2.27E-16 2.75E-16 0.999 0.826 0.820 0.8
30 EDW 2.10E-16 2.75E-16 0.999 0.763 0.766 -0.3
45 EDW 1.91E-16 2.73E-16 0.999 0.700 0.702 -0.3
60 EDW 1.64E-16 2.69E-16 0.998 0.613 0.612 0.1
12 cm by 12 cm
Field Raw Cal Factor Liu MC Dose Published Dose % Diff
Open 2.50E-16 2.79E-16 1.001 0.893 0.895 -0.2
15 EDW 2.29E-16 2.75E-16 1.000 0.832 0.825 0.8
30 EDW 2.08E-16 2.75E-16 1 0.757 0.758 -0.1
45 EDW 1.84E-16 2.73E-16 0.999 0.676 0.681 -0.8
60 EDW 1.56E-16 2.69E-16 0.999 0.580 0.579 0.1
15 cm by 15 cm
Field Raw Cal Factor Liu MC Dose Published Dose % Diff
Open 2.55E-16 2.79E-16 1.003 0.910 0.919 -0.9
15 EDW 2.26E-16 2.75E-16 1.002 0.818 0.824 -0.8
30 EDW 2.00E-16 2.75E-16 1.000 0.729 0.738 -1.3
45 EDW 1.74E-16 2.73E-16 1.000 0.637 0.645 -1.4
60 EDW 1.41E-16 2.69E-16 1.000 0.526 0.529 -0.7
Table 3.5: Comparison of absolute doses from Monte Carlo compared with measure-
ments, at 10 MV, for different fields, where Raw is the uncorrected value from the MC
simulation, Cal Factor is the calibration factor, Liu is the backscatter correction for the
field, MC Dose is the raw MC value multiplied by the Cal Factor and Liu Factor, the
Expected Dose is the dose calculated from dosimetry tables in Velindre, and %diff is
the difference between the MC and expected doses, expressed as a percentage.
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‘RTChest3mm_Contrast’ protocol for which OesRAMP is defined;
• the scan orientation was Head First Supine (i.e. face up, head towards the
linac gantry);
• the SCOPE trial volumes GTV, CTV-A, CTV-B and PTV were present;
• the linac model used in Oncentra was ‘Varian_2100_1217’, a Varian Clinic
2100CD with the Millennium 120-leaf MLC;
• the plan was prescribed to 50 Gy in 25 fractions;
• the plan used a CFRT technique, not a IMRT or VMAT technique;
• no metal implants in the CT, determined by bulk densities defined with
density greater than 1
12 cases were used to ensure the pilot study would be at least 10% of the main
study; it would have been impractical to identify and simulate 120 cases matching
the above criteria. Over time, the linac model used for oesophageal plans in
Velindre Cancer Centre changed from a Varian Clinac 2100CD with an 80-leaf
MLC, to the model used for this work, to an Elekta Synergy linac.
3.3 Results
To present the results of the 12 simulations used in the pilot study, the concept
of the table-graphic, or slopegraph, (Tufte, 2001) has been adapted. The table-
graphic is a combination of tabulated data, and a graphical representation of the
data. It allows the rank of data to be visualised for the different dose calculation
methods, and the change in each dataset to be seen. Also, the slope of the lines
from one dataset to the next indicates the overall trend, as well as highlighting
any cases that do not follow the general trend.
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For each DVH parameter as defined in SCOPE1 (aside from the kidneys and liver,
because they are not always involved), two table-graphics have been produced.
The first compares the DVH parameter from the PBE dose calculations with
the MC DWtr calculations, as PBE reports dose to water. The second compares
PBE, CCE and MC DMat. CCE reports dose to material (section 2.4.5.3), so
it is natural to compare it with and MC DMat. Even though PBE and CCE
report dose to different media, it has become commonplace to compare dose from
these two algorithms; PBE and CCE are compared here as a control, to place
the differences from CCE to MC DMat into context. In each table-graphic, lines
are used to join the results for the same case calculated with different methods;
the line is coloured blue if the value falls, red if the value rises, and black if the
value remains the same. Grey lines are used to link labels with points - in many
cases the data points are too close together to allow labels to be close to the data
points.
Figure 3.31(a) shows that the PTV D99% for the MC DWtr calculations has a
greater spread of values than the PBE calculations. It can also be seen that
there is a general trend for the PTV D99% to be lower in the MC DWtr cal-
culation. However, the magnitude of this change is variable, as shown by the
trend-lines crossing over one another in many cases. Similarly Figure 3.31(b)
shows the greater spread of PTV D99% as calculated with CCE than those with
PBE. In many cases the reduction in PTV D99% when recalculating PBE with
CCE is reproduced when re-calculating with MC DWtr. However, there are some
exceptions to this, such as cases #5 and #12.
Figure 3.32(a) also shows the overall trend is for PTV V95% to decrease when re-
calculated with MC DWtr compared to the PBE distribution. The spread in values
for MC DWtr is again wider that the spread in values for PBE. Figure 3.32(b)
shows the overall trend is for PTV V95% to decrease when re-calculated with
CCE compared to the PBE distribution. This trend is often continued when
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(b) PBE versus CCE versus MC DMat for PTV D99%
Figure 3.31: Table-graphics comparing PTV D99% values for PBE, CCE, MC DMat
and MC DWtr.
3.3 Results 142
PBE MC DWtr
75
80
85
90
95
100
P
T
V
 V
9
5
%
 (
%
)
#1, PTV V95=100.0%
#1, PTV V95=97.2%
#2, PTV V95=98.6%
#2, PTV V95=82.5%
#3, PTV V95=100.0%
#3, PTV V95=98.3%
#4, PTV V95=100.0% #4, PTV V95=93.0%
#5, PTV V95=99.6%
#5, PTV V95=89.9%#6, PTV V95=99.7%
#6, PTV V95=77.3%
#7, PTV V95=99.6%
#7, PTV V95=92.7%#8, PTV V95=99.9%
#8, PTV V95=94.2%#9, PTV V95=100.0%
#9, PTV V95=88.7%
#10, PTV V95=98.7%
#10, PTV V95=84.1%
#11, PTV V95=98.8% #11, PTV V95=80.5%
#12, PTV V95=99.6%
#12, PTV V95=78.8%
(a) PBE versus MC DWtr for PTV V95%
PBE CCE MC DMat
75
80
85
90
95
100
P
T
V
 V
9
5
%
 (
%
)
#1, PTV V95=100.0%
#1, PTV V95=97.0%
#2, PTV V95=98.6%
#2, PTV V95=85.0%
#3, PTV V95=100.0%
#3, PTV V95=98.9%
#4, PTV V95=100.0%
#4, PTV V95=91.1%
#5, PTV V95=99.6%
#5, PTV V95=91.8%
#6, PTV V95=99.7%
#6, PTV V95=84.1%
#7, PTV V95=99.6%
#7, PTV V95=95.0%
#8, PTV V95=99.9%
#8, PTV V95=94.7%
#9, PTV V95=100.0%
#9, PTV V95=88.7%
#10, PTV V95=98.7%
#10, PTV V95=85.4%
#11, PTV V95=98.8%
#11, PTV V95=81.3%
#12, PTV V95=99.6%
#12, PTV V95=80.6%
(b) PBE versus CCE versus MC DMat for PTV V95%
Figure 3.32: Table Graphics comparing PTV V95% values for PBE, CCE, MC DMat
and MC DWtr.
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comparing the CCE values with those from MC DMat. One case, case #12, shows
an increase in PTV V95% from DMat compared to CCE (note the red line), but
the overall trend is evident.
Figure 3.33(a) does not show a clear overall trend, almost as many values of
GTV V100% decrease when re-calculated with MC DWtr as increase. Statistical
calculations can be used (section 3.4) to reveal if there is a real difference between
the two sets of data, or whether the changes are random. As there is no clear
pattern emerging from these 12 cases, it may be expected that a very large number
of cases would be required to demonstrate a difference. Likewise, Figure 3.33(b)
does not show an obvious trend when comparing results from MC DMat with
those from CCE. There does seem to be a small reduction in most values of GTV
D100% when comparing results from PBE with those from CCE.
Figure 3.34(a) shows that there is very little change in heart V80% when re-
calculating PBE plans versus MC DWtr plans. The order of the cases, when
ranked by heart V80% for PBE is very similar to the order when ranked by
heart V80% when re-calculating MC DWtr. Similarly, Figure 3.34(b) shows very
little variation in the three dose calculation methods, PBE, CCE and MC DMat.
This is a useful result from a clinical point of view, regardless of dose calculation
method, the heart V80% is consistent (accurate). Therefore, clinical experience
based on doses calculated with the PBE algorithms is still valid when using the
CCE algorithm or MC methods. However, there is likely to be no interesting
behaviour to investigate for heart V80% in this work.
Figure 3.35(a) shows that most values of Cord D1cc increase when re-calculated
with MC DWtr compared with the original PBE dose. For Figure 3.35(b), com-
paring PBE and CCE, there is a small reduction in Cord PRV D1cc in each case.
When comparing CCE and MC DMat there is not such a clear trend, a small
majority of cases show a decrease in Cord PRV D1cc, but some show no change
and some show a small increase. Based on the variation in these results, it is
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(b) PBE versus CCE versus MC DMat for GTV V100%
Figure 3.33: Table Graphics comparing GTV V100% values for PBE, CCE, MC DMat
and MC DWtr.
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Figure 3.34: Table Graphics comparing heart V80% values for PBE, CCE, MC DMat
and MC DWtr.
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#6, Cord D1cc=39.5 Gy
#6, Cord D1cc=38.9 Gy
#7, Cord D1cc=35.1 Gy #7, Cord D1cc=34.3 Gy
#8, Cord D1cc=37.5 Gy
#8, Cord D1cc=36.9 Gy
#9, Cord D1cc=37.8 Gy #9, Cord D1cc=37.5 Gy
#10, Cord D1cc=36.8 Gy #10, Cord D1cc=36.1 Gy
#11, Cord D1cc=33.9 Gy #11, Cord D1cc=33.3 Gy
#12, Cord D1cc=37.5 Gy
#12, Cord D1cc=37.3 Gy
(b) PBE versus CCE versus MC DMat Cord D1cc
Figure 3.35: Table Graphics comparing Cord D1cc values for PBE, CCE, MC DMat
and MC DWtr.
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not likely that a comparison can be performed that will have a high statistical
power (i.e. greater than 90%) to detect a true difference in the dose calculation
methods.
Figure 3.36(a) shows that most values of lung V20 Gy reduce when produced
with MC DWtr compared to the original PBE calculation. Figure 3.36(b) shows
most values of lung V20 Gy reduce when recalculated with CCE compared to the
original PBE, but there are a number of cases showing the opposite behaviour.
The values of lung V20 Gy from the MC DMat data show small increases for most
cases, but there are some with no real change, and one with a slight reduction.
3.4 Discussion
3.4.1 Discussion of selected cases
Figure 3.37 shows a comparison of the DVHs for CCE and MC DMat dose cal-
culations, for the PTV, heart, combined lungs and the spinal cord PRV, for case
#10. This case had one of the largest decreases in PTV V95% and PTV D99%.
The most striking aspect of the graph is how similar the DVH plots are for the
different dose calculation methods. The largest deviations between the DVH
plots occur for the Cord PRV, which demonstrates differences in the region of
the graph depicting doses of 5-30 Gy. For the PTV, the MC DMat plotted line is
slightly to the left of the plotted line for the CCE algorithm, showing a reduction
in coverage for the MC DMat case. This does not appear to be a systematic shift
in the plotted line, as there is not a constant offset between the two curves. The
DVH lines are very similar for the heart, which agrees with the results in Fig-
ure 3.34, which demonstrates consistent heart V80% values for the different dose
calculation methods. For the combined lungs, the DVH shows that the MC DMat
calculation results in a higher dose to the lungs in the 15-20 Gy regions of the
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(b) PBE versus CCE versus MC DMat for Combined Lung V20 Gy
Figure 3.36: Table Graphics comparing V20 Gy values for Combined Lung for PBE,
CCE, MC DMat and MC DWtr.
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graph.
Figure 3.38 shows a comparison of the DVHs for CCE and MC DMat, for case
#12. This was the only case to show an increase in PTV V95% for the MC DMat
calculation compared to the CCE algorithm. Once more, the DVH plots for the
different dose calculation methods are very similar to one another. The PTV
DVH plot for the MC DMat calculation exhibits a slightly steeper curve than that
for the CCE algorithm. The plotted line for the MC DMat calculation indicates a
higher dose in the 60-100% volume region, but a lower dose in the region below
40% of the volume, compared to the CCE algorithm. The DVH plots for the
heart are very similar. The DVH plots for the combined lungs shows that the
MC DMat method is calculating slightly higher doses in the 20-40% volume region,
and below 5% volume, compared to the CCE algorithm. The DVH plots for the
cord PRV again show differences in the region of the plot with pronounced steps.
These steps are due to the small volume of the cord PRV and the finite size of the
voxels used in the DVH calculation. As the dose reduces to the right of the DVH
graph, fewer voxels are treated to given dose level; if the change in the volume
treated to given dose level is large compared to the total OAR volume, steps will
be produced in the DVH. Similarly, the differences in the plotted lines for the
two dose calculation methods in this region relate to changes in the dose to a
comparatively small number of voxels.
By definition, DVH plots hold no information about where in an ROI the doses
are, so comparisons of DVH plots cannot determine where the changes in dose
are occurring. For this, comparisons of isodose plots must be used.
Figure 3.39 shows isodose plots for case #10, the same case for which the DVH
is shown in Figure 3.37. Comparing the isodoses for CCE in Figure 3.39(a) with
those for MC DMat in Figure 3.39(b), it can be seen that both demonstrate a ‘hole’
in the 95% isodose (47.5 Gy isodose in the legends of Figures 3.39(a) and (b)) in
the bronchus, the small low density region on CT, anterior of the cross-hairs. For
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the MC DMat method, the smaller red contour (i.e. the 95% isodose) almost fills
the area of the bronchus on this slice; as the larger red contour wholly encloses this
contour, this indicates that the dose within the smaller red contour is below 95% of
the prescribed dose. For the CCE algorithm, the area of the bronchus not covered
by the 95% isodose is much smaller. This leads to the lower PTV V95% observed
for the MC DMat in this case, compared with the CCE algorithm. The dose to a
small, low density regions such as this will be dominated by scattered radiation
from the surrounding soft tissue regions; the difference in dose calculated by the
two methods in this region is due to the improved modelling of lateral scatter of
the MC method, compared with the CCE algorithm.
Figure 3.40 shows isodose plots for case #12, which is the same case for which
the DVH is shown in Figure 3.38. In Figure 3.40(a), the 95% isodose resembles
a T-shape. Where the PTV overlaps the heart, the lateral extent of the isodose
covers the PTV. Where the PTV overlaps the lungs, the lateral extent of the
95% isodose is narrower than the PTV. In Figure 3.40(b) it can be seen that the
coverage of the PTV by the 95% isodose where the PTV overlaps the lungs is
improved (although the PTV is not completely covered). It is hypothesised that
differences in the modelling of the forward scattered radiation between the CCE
and MC DMat calculations for beams entering through the heart and spinal cord
cause the differences seen in this case.
3.4.2 Calculation of sample size
Whitley and Ball (2002) discuss a method for calculating sample sizes, so that
the study may have the desired statistical power, following the method of Altman
(1999). The three factors that determine the sample size are the p-value, the
power i.e. the probability of correctly identifying a difference where one genuinely
exists, and the size of the effect, e.g. the difference in the means of two populations.
The smaller the desired p-value, the larger the required sample size; similarly the
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Figure 3.37: Comparison of DVH parameters for CCE and
MC DMat, for case #10 of the 12 cases used in the pilot study.
smaller the effect that is being investigated, the larger the required sample size.
Conversely, the larger the desired power, the larger the required sample size.
The power of the test is the probability that the test will produce a significant
difference, at a given level of significance.
Whitley and Ball (2002) relate these three parameters to sample size using Equa-
tions 3.10a and 3.10b, where d is called the Standardised Difference (the factor of
2 applicable when undertaking a paired study comparing different techniques on
the same sample group). A key parameter in Equation 3.10b is the Cp,power, the
critical value, defined by Equation 3.11, where PDF is the Gaussian Probability
Density Function.
d = Target DifferenceStandard Deviation (3.10a)
N = 2
d
× Cp,power (3.10b)
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Figure 3.38: Comparison of DVH parameters for CCE and
MC DMat, for case #12 of the 12 cases used in the pilot study.
Cp,power =
(∫ p/2
0
PDF +
∫ 2(1−power)
0
PDF
)2
(3.11)
The DVH parameters for the CCE and MC DMat distributions are shown in
Table 3.6. For each DVH parameter, the differences between the values from the
CCE and MC DMat dose distributions are calculated, then the mean and standard
deviations of the 12 values found for each DVH parameter. Table 3.7 shows the
sample size calculation for each DVH parameter, using the mean differences as an
estimate of the target difference, using a p-value of 0.05 or 0.01, and powers of 0.8
and 0.9 as appropriate. The values of Cp,power are calculated from Equation 3.11,
cross-checked against Whitley and Ball (2002), where they have been tabulated.
The PTV D99% has a relatively small mean differences between the values for
CCE and MC DMat, compared with the standard deviation. Therefore, if a p-
value of 0.05 is desired, then even the relatively modest power of 0.8 would require
N=98.8, which should be rounded up to 100. This would be a very large number
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of oesophageal plans to find and simulate. Repeating the analysis for PTV V95%
leads to a recommended sample size of 40 (36.1) for a power of 0.8 and 50 (48.6) for
a power of 0.9, (this calculation is also depicted in the Nomogram in Figure 3.41).
40 cases on top of the initial 12 cases used for the pilot study is feasible, additional
cases may not be possible due to the number of existing clinical cases available.
The sample size calculated for the GTV V100% is huge, approaching 700 (659.1).
This is not unexpected, as Figure 3.33 showed no clear trend, so a very large
number of comparisons would be needed to detect a signal amongst the noise,
and it is unlikely that such a small difference would be clinically significant. It is
not feasible to find 700 oesophageal cases using a consistent approach to simulate,
as Velindre plans approx 50 oesophageal cases per year, and techniques change
over time.
Performing the calculation for the heart V80% using various values of p-value
and power shows that relatively few cases are needed for even high power and
low p-value. Referring back to Figure 3.34, this is probably due to a consistent,
if small, reduction in heart V80% when changing from the CCE to the MC DMat.
The sample size calculated for the Cord PRV D1cc is also very large, around 250
(249.6). This is to be expected, as Figure 3.35 shows little variation in Cord PRV
D1cc between the CCE to the MC DMat dose distributions.
Due to the mean change in Lung V20 Gy being larger than the standard deviation
in the mean, only 25 cases would be required for a comparison with 95% power
and a p-value of 0.01.
3.5 Conclusions
The RTGrid has been used to simulate RT treatment plans for oesophageal can-
cers. To allow this, a CTRamp, OesRAMP, was produced from scans of a CIRS-
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062M phantom. The EDWComponent Module was incorporated into the RTGrid
Profile, to allow the simulation of plans including Varian EDW fields. Code was
developed to remove the high density intra-venous contrast from CT scans, ignore
data on the CT scan outside the external contour. Separate code was developed
to create artificial volumes at the superior and inferior extent of the CT scan, so
that the MC simulation followed the approach of the TPS calculations.
A group of 12 oesophageal plans were simulated, and DVH parameters calculated
from the MC dose distributions. Parameters commonly reported from the DVHs,
such as PTV V95%, were compared for the CCE and MC, and sample size cal-
culations were performed. From this analysis, 40 clinical cases will be used for
the main body of the work, to investigate the coverage of the PTV with the 95%
isodose. Other DVH parameters for oesophageal plans will be analysed, but may
not be statistically significant at the same level.
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(a) 95% isodose calculated from CCE dose distribution.
(b) 95% isodose calculated from MC DMat dose distribution.
Figure 3.39: Screen-shots comparing 95% isodose coverage of PTV in CT slice.
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(a) 95% isodose calculated from CCE dose distribution.
(b) 95% isodose calculated from MC DMat dose distribution.
Figure 3.40: Screen-shots comparing 95% isodose coverage of PTV in CT slice.
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Chapter 4
Main study
4.1 Introduction
Following the sample size calculation in the last chapter (section 3.4), 40 oesopha-
geal case were simulated with the RTGrid. These were the next 40 cases identified
following the approach describe in section 3.2.6. This chapter will describe the
measures calculated for these 40 cases, and the analysis of these measures, to
determine if differences between doses calculated with the CCE algorithm and
MC simulations are statistically significant. Finally, situations where MC is of
most of benefit will be identified.
4.2 Materials and methods
As for the cases in the Pilot Study, after simulation and calibration, the doses
calculated by MC were held within CERR format files for analysis. The methods
of analysis are described below.
4.2.1 Dose Volume Histogram parameters
The DVH parameters described in section 3.2.1 were calculated and analysed for
the four dose calculation methods for all cases.
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4.2.2 Conformity indices
DVH parameters such as PTV V95% are commonly used metrics to describe either
how the dose distribution covers a target volume, or how the dose distribution
avoids organs at risk. In the production of the DVH, the 3D dose distribution
is reduced to a single line. A dose volume parameter is a single point along
this line. Compressing the information from a 3D distribution to a single value
allows different plans to be compared easily, but a lot of information is lost. Two
plans may have the same PTV V95%, but the shapes of the V95% may be quite
different. One plan may have the 95% isodose tightly conforming to the PTV, in
the the other the 95% isodose may include a lot of tissue in addition to the PTV.
To address the shortcomings of DVH parameters, while preserving the conveni-
ence of summarising a 3D distribution as a single value, a conformity index may
be used. A conformity index is a value that describes how well two volumes agree.
Hanna et al. (2010) describes the use of conformity indices for comparing target
volumes outlined on the same set of images by multiple observers, as well as com-
paring the volume defined by a given isodose with that of a target volume. From
the pilot study, it is known that the PTV V95% varies enough between different
calculation methods in oesophageal radiotherapy to be worth investigating. It
follows that conformity indices describing the coverage of the PTV by the 95%
isodose may also produce interesting results.
4.2.2.1 RTOG Index
The RTOG Conformance Index (RTOG-CI) was introduced by the RTOG in
Shaw et al. (1993), and is given by Equation 4.1, where PIV is the Prescription
Isodose Volume and TV is the Target Volume. This was used in Shaw et al. (2000)
for the assessment of plan quality for radiosurgery. The advantage of the RTOG-
CI is its simplicity; there is little ambiguity in the ratio of two volumes. This is
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particularly important when trying to implement the calculation in a computer
program, to avoid details of the implementation affecting the calculated value.
The main disadvantage is that no account is taken of the overlap of the two
volumes being assessed. In principle, the isodose volume of interest could wholly
miss the target volume, but the RTOG Index could still exceed unity if the isodose
volume is larger than the target volume.
RTOG-CI = PIV
TV
(4.1)
4.2.2.2 Jaccard Index
An example of an index that does account for the overlap between two volumes
is the Jaccard Concordance Index (Jaccard-CI), defined in Hanna et al. (2010) as
Equation 4.2, where A and B are the volumes of two structures being compared.
According to Gwynne et al. (2012), the Jaccard-CI was originally defined in 1901,
and has been known by various terms including the conformity index and the
conformity index. In this work, it will be referred to as the Jaccard-CI.
Jaccard-CI = A ∩B
A ∪B (4.2)
4.2.2.3 Dice Similarity Coefficient
A similar coefficient to the Jaccard-CI is Dice Similarity Coefficient (Dice-CI),
defined in Hanna et al. (2010) by Equation 4.3.
Dice-CI = 2(A ∩B)
A+B (4.3)
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4.2.2.4 van’t Reit Conformation Number
Another measure is the van’t Reit Conformation Number (Reit-CI), defined in
van’t Riet et al. (1997) as Equation 4.4, where VT,ref is the volume of the target
receiving a dose greater than or equal to a reference dose, VT is the volume of the
target and Vref is the volume of tissue receiving a dose greater than or equal to a
reference dose. This may be re-written as Equation 4.5, where the terms A and
B have the same meanings as in Equation 4.2 and Equation 4.3. The first term in
the Reit-CI describes how much of the target volume is covered by the reference
isodose. The second term describes how much tissue (target or otherwise) is
covered by the target isodose. It can be seen that a low value may be due to the
reference isodose covering little of the target, or the reference isodose covering a
large volume of tissue outside the target. The same is true of the Jaccard-CI or
Dice-CI, although this is less apparent from the equations.
Reit-CI = VT,ref
VT
∗ VT,ref
Vref
(4.4)
Reit-CI = A ∩B
A
∗ A ∩B
B
(4.5)
4.2.2.5 Discordance Index
Kepka et al. (2007) described a Discordance Index (DI-CI), which they applied to
analysing the variation in delineated volumes for nodal volumes in lung cancer ra-
diotherapy. DI-CI was defined according to Equation 4.6, where V I is the Volume
of Intersection of two volumes, and DV is the Delineated Volume, i.e. the volume
of the reference outline. DI-CI was intended to supplement a concordance index,
(defined differently to the Jaccard Concordance Index), but Kepka et al. (2007)
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found that there was no statistical difference in the two endpoints. Equation 4.7
shows the equation expressed in terms of the intersection between volumes.
DI-CI = (1− V I
DV
) ∗ 100% (4.6)
DI-CI = (1− A ∩B
DV
) ∗ 100% (4.7)
4.2.2.6 Geometric Miss Index
Another measure, which unlike most other indices increases as the agreement
between two volumes decreases, is the Geometric Miss Index (GMI). Muijs et al.
(2009) defined the GMI according to Equation 4.8. A GMI of 0 indicates that
the one volume is completely enclosed by the other; a GMI of 1 indicates that
the volumes have no overlap.
GMI = A− A ∩B
A
(4.8)
4.2.3 Mean Distance to Conformity
Jena et al. (2010) introduced the concept of a Mean Distance to Conformity
(MDC), defined as the average distance that points on one surface must be moved
to achieve perfect conformity with another surface. It can be computed as a single
statistic, describing the average magnitude of the movement a point to achieve
conformity. Alternatively, two statistics may be calculated, the first for points
that must be moved outwards to the reference surface, and a second statistic for
points that must be moved inwards towards the reference surface. As Jena et al.
(2010) discussed the MDC for comparing two outlined volumes, they dubbed
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this over or under-contouring. Carrington et al. (2016) have used the MDC for
comparison of target volumes and isodose surfaces.
Jena et al. (2010) compared the MDC values with a conformity index (defined
in the same way as the Jaccard Conformity Index, Equation 4.2), and found the
MDC to be more sensitive to errors in conformity that was the conformity index.
4.2.4 Tumour Control Probability
The Tumour Control Probability (TCP) is the probability that the dose delivered
to a tumour will either eradicate the tumour cells, or kill enough of the cells that
the tumour will no longer threaten the life of the patient. It is not generally
possible to calculate the TCP for a given patient, but models can be created from
studies of groups of patients, and these models can be used to compare different
treatment approaches. It this work, a published model for calculation of TCP
for oesophageal cancer will be used to compare the effect of the different dose
distributions from the different calculation methods.
4.2.5 Generation of measures
Having outlined the measures that will be compared for the 40 cases in the study,
the methods used to generate these measures will be discussed.
4.2.5.1 Generation of Dose Volume Histogram parameters
The DVH parameters reported for oesophageal plans in Velindre Cancer Centre
were calculated for all 40 cases, following the method described in section 3.2.4.11.
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4.2.5.2 Generation of conformity indices
Calculation of the various conformity indices involved a two step process. Firstly,
Matlab scripts were used to open the CERR (Deasy et al., 2003) files created
previously (section 3.2.2), call existing functions from CERR to create a volume
from the 95% isodose, and save this to the CERR file. Secondly, functions within
CERR Trial Addition (Gwynne et al., 2012) were used to calculate RTOG-CI,
Jaccard-CI, Dice-CI, Reit-CI, GMI and DI-CI conformity indices.
4.2.5.3 Generation of Mean Distance to Conformity
The method used to calculate the MDC values follows that for the Conformity
Indices, again using functions within CERR Trial Addition.
4.2.5.4 Generation of Tumour Control Probability
Geh et al. (2006) developed an equation to calculate TCP for oesophagus can-
cer, based on outcome data, demographic data (age, gender) and treatment data,
including radiotherapy dose. In their work, the dose was taken to be the prescrip-
tion dose, so no account was taken of how the prescription isodose conformed to
the target. Carrington et al. (2015) used the model from Geh et al. (2006), but
used the DVH data for different treatment techniques and prescriptions to predict
TCP and gastric toxicity. In this work, DVH data from CERR were used to allow
calculation of the TCP value for each volume element. In order to assess the effect
on the final analysis, in addition to calculating the TCP with the median values
of the parameters and the recommended values of the coefficients from Geh et al.
(2006), each of the parameters were replaced in turn with the minimum or max-
imum value, and the coefficients replaced in turn by either 90% or 110% of the
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published values, and the highest and lowest TCP values produced were recorded.
This produced three measures, TCP-Median, TCP-Min and TCP-Max.
4.3 Results
4.3.1 Correlations and multiple testing
In section 4.2, several measures to compare the different dose calculation methods
have been proposed. When several tests are performed on the same data, the
statistical results, notably the p-values, cannot be presented in isolation from
each other. Put simply, if a sufficiently large number of tests are performed
on a dataset, one of the tests will appear to be significant purely by chance.
This is a common issue in fields such as radiomics (Yip and Aerts, 2016) and
genomics, which frequently perform many tests on the same dataset. A number of
authors have described approaches to correct p-values in multiple testing scenarios
in these fields. Authors including Mu et al. (2015) and Orlhac et al. (2014)
recommend grouping measures that are strongly correlated with one another, (i.e.
Pearson correlation co-efficient greater that 0.8), and only including one measure
per group in the analysis. Once the correlated measures have been identified,
and all but one measure per ‘group’ have been excluded, Yip and Aerts (2016)
describe two approaches to handling multiple testing. These approaches are a
family-wise error rate controlling method such as the Holm-Bonferroni approach,
and a false discovery rate controlling method such as the Benjamini-Hochberg
approach. Both of these methods to correct the p-values require that the measures
involved are independent.
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4.3.1.1 Correlations between measures
For each of the 17 measures (six CI, six DVH parameters, two MDC values
and three TCP values), the correlation co-efficient with every other measure was
calculated (Table 4.1). This shows that the Dice-CI, GMI, Jaccard-CI, Reit-CI
and RTOG conformity indices are strongly correlated (0.8 was used as the cut-
off, but the results are relatively insensitive to the cut-off value; using 0.75 or
0.85 would have lead to the same conclusions). This correlation implies that the
measures may provide redundant information, so only one should be used in the
final analysis.
It is interesting that the RTOG is strongly correlated with other CIs (except DI-
CI), given that RTOG is a relatively crude measure; it does not account for the
overlap of the volumes compared, only their size. This may be because the PTV
and V95% have a high degree of overlap, so accounting for this does not truly
provide extra information. It is also interesting that PTV V95% is not strongly
correlated with any of the CIs, or the MDC values, as all describe coverage of PTV
by 95% isodose. This shows that the CIs and MDC values do contain different
information to the PTV V95% values. The DI-CI is weakly correlated with the
other conformity indices, probably because, as stated by Muijs et al. (2009), it is
designed to be a complementary measure to a Jaccard-CI like conformity index.
It is not surprising that the three related approaches to calculating TCP are
correlated with one another.
From Table 4.1 , the correlated groups are: -
• Dice-CI, GMI, Jaccard-CI, Reit-CI and RTOG. All except Jaccard-CI will
be excluded from further analysis;
• TCPMEDIAN , TCPMIN , TCPMAX . All except TCPMEDIAN will be ex-
cluded from further analysis.
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4.3.1.2 Holm-Bonferroni method
In a family-wise error rate controlling method, the critical p-value is modified,
such that the probability of there being one (or more) false positive results in the
family of tests is less than the critical p-value. McDonald (2014) states that the
most common family-wise error rate controlling method is the Bonferroni method.
In the Bonferroni method, the p-value of interest, e.g. 0.05, is divided by the
number of tests. Assuming ten tests, the critical value would be 0.05/10 = 0.005,
and only individual tests with a p-value less than 0.005 are considered significant
at the 0.05 level. The Bonferroni method is simple to apply, but for large numbers
of tests the resulting critical value may be so low as to be impossible to meet.
A less stringent method is the Holm-Bonferroni method (Holm, 1979), also known
as the Bonferroni Step Down method. In this approach, the p-values for individual
tests are calculated, and the tests ranked by p-value, smallest to largest. The first
p-value is multiplied by the number of tests N . If the result is less than the critical
p-value, e.g. 0.05 the test is significant at that level. For the second test, the p-
value is multiplied by N−1, and compared with the critical value. This continues
until a non-significant test is found. This is based around the principle that if a
single test is performed and the p-value shows it to be significant, performing a
subsequent test should not retrospectively alter the previous finding. However,
as each new test is performed, the p-value calculated must take account of the
preceding tests.
4.3.1.3 Benjamini-Hochberg method
An alternative approach to the family-wise error rate controlling approach is the
false-discovery rate controlling approach. An example of this is the Benjamini-
Hochberg method, proposed by Benjamini and Hochberg (1995). In this method
an acceptable false positive rate, is set, e.g. 10%. Tests are ranked from smallest
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to largest p-value, and the p-value is compared to the Benjamini-Hochberg critical
value, rank
N
∗M , where N is the number of tests and M is the acceptable false
positive rate. The largest p-value that is less than the Benjamini-Hochberg critical
value is significant, as are all smaller p-values – even if they were larger than
the critical value for their rank. This approach is suitable when performing an
initial analysis, to decide which measures will be investigated in more detail by
subsequent experiments, so false positives will be dealt with later. If a single
false positive would be unacceptable, a family-wise error rate controlling method
would be more appropriate.
The Holm-Bonferroni method will be used in this work to correct the p-values
calculated for the various measures.
4.3.2 Testing for Gaussian distribution
Having calculated a given measure for each case, for different dose calculation
methods, an important question to ask is whether the mean or median of the
two datasets are compatible. Since the same plans have been calculated with two
methods, this is a matched pair problem. There are three approaches for finding
differences in a paired sample for interval data (Bland, 2000):
• normal distribution, for samples with more than 100 items
• paired t-test, for samples with less than 100 items, where the differences
follow a Gaussian distribution
• Wilcoxon matched pairs test, for samples with less than 100 items, where
the differences do not follow a Gaussian distribution
Therefore, three questions must be answered for each dataset being compared:
1. Do the differences in a measure form an interval scale?
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2. Are there enough items for the normal distribution to be used?
3. Do the differences follow a Gaussian distribution?
An interval scale is a scale in which differences between two points has a precise
meaning, which does not change with the point on the scale. A difference of
1 m/s is the same at 10 m/s or 50 m/s, so speed is an interval scale. Compare
this with an ordinal scale, a numerical scale in which differences between two
points may not be the same at different points on the scale. An example of an
ordinal scale is the American Association of Anaesthesiologists (ASA) physical
status classification system, a system for describing the fitness of a patient prior
to surgery. In this scale, while a performance score of two is better than a score
of one, the difference between a score of one and two is not necessarily equivalent
to the difference between a score of five and six. Considering these examples, the
differences in Dose Volume Histogram parameters, and other measures used in
this chapter, lie on an interval scale.
The second question, does the sample have more than 100 items, is trivial; there
are 40 items, so use of the normal distribution for analysing the differences in the
sample is not suitable.
The third question, do the differences follow a Gaussian distribution can be
answered in a number of ways: -
1. By visualising the data, to see if it follows a Gaussian curve;
2. By calculating the skewness and kurtosis of the distribution, and see if they
are compatible with that of a Gaussian distribution;
3. By using a more formal test for Gaussian distribution, such as the Shapiro-
Wilk test.
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Taking PTV V95% for CCE versus MC as an example, a histogram of the dif-
ference data was plotted, and a Gaussian with the same mean and standard
deviation overlaid on this (Figure 4.1). It can be seen that the data do not con-
form well to a Gaussian; the distribution is asymmetric about the mean, and has
some values more the three times the standard deviation from the mean. It is
worth noting that the distribution is not symmetric around zero. A second graph
was plotted, known as a quantile-quantile, or QQ, plot (Figure 4.2). In a QQ
plot, the quantiles of the sample distribution are plotted against the theoretical
quantiles, in this case for a Gaussian distribution. If the sample data follows a
Gaussian, the data in a QQ plot will lie along the red line (this is analogous to
plotting logarithmic data on a logarithmic scale, producing a straight line). From
Figures 4.1 and 4.2, the data do not appear to follow a Gaussian.
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Figure 4.1: Comparison of distribution for differences in PTV V95% calculated from
CCE and MC DMat dose with Gaussian distribution.
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Figure 4.2: Quantile-quantile plot for differences in PTV V95% calculated from CCE
and MC DMat doses.
To confirm this, the skewness and kurtosis of the differences were calculated.
The skewness was calculated as 4.2 by the ‘stats’ module of the Scipy package1,
whereas a Gaussian distribution would have a Skew of 0. The p-value calculated
was much less than 0.01, implying very strong evidence of a difference between
this distribution and a Gaussian. The kurtosis was calculated as 3.2 by the
‘stats’ module of the Scipy package, whereas a Gaussian distribution would have
a kurtosis of 0. The p-value calculated was much less than 0.01, implying very
strong evidence of a difference between this distribution and a Gaussian.
The Shapiro-Wilk test (Shapiro and Wilk, 1956) calculates a statistic, often
named W, which tests whether a random sample comes from a Gaussian dis-
tribution. The Shapiro-Wilk statistic and associated p-value were calculated for
each measure, using the ‘stats’ module of the Scipy package for Python. Taking
1Jones E, Oliphant E, Peterson P, et al. SciPy: Open Source Scientific Tools for Python,
2001-, Available at: http://www.scipy.org/ (Accessed 2016-12-16)
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PTV V95% as an example, the Shapiro-Wilk statistic calculated was 0.8, the p-
value calculated was 0.001, so the null hypothesis (that the data is Gaussian)
can be rejected, i.e. the data is non-Gaussian.
This excludes the paired t-test as an analysis method for the PTV V95%, CCE
versus MC comparison, leaving the Wilcoxon matched pairs test, the non para-
metric analogue of the paired t-test, as the preferred method.
The same approach was applied to all measures (aside from those eliminated in
section 4.3.1 due to being correlated with other measures). The results of the tests
for Gaussian are shown in Table 4.2. For most measures, the kurtosis, skewness
and Shapiro-Wilk all pointed to the same outcome. However, for PTV V95%
and MDCOver, the results of the different tests for Gaussian distribution were
inconsistent. For both of these measures, the histogram and QQ plots of the data
were used to determine if the data was Gaussian or not.
4.3.3 Wilcoxon matched pairs test
For each measure where the differences between the CCE and MC data were
shown to be non-Gaussian, the Wilcoxon matched pairs test was performed using
the Scipy package for Python. The results are shown in Table 4.3.
4.3.4 Paired T-test
For each measure where the differences between the CCE and MC data were
shown to follow a Gaussian distribution, the paired t-test was performed using
the Scipy package for Python. The results are shown in Table 4.3.
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Test Name Test Applied Test Statistic p-value Critical p-value Modified p-value Significant
TCPMedian Paired t-test 13.5  1.0× 10−3 1.0× 10−3  1.0× 10−3 True
MDCUnder Wilcoxon 17.0  1.0× 10−3 1.0× 10−3  1.0× 10−3 True
Combined Lungs V20 Gy Paired t-test −6.0  1.0× 10−3 1.0× 10−3  1.0× 10−3 True
Heart V80% Wilcoxon 41.0  1.0× 10−3 1.0× 10−3  1.0× 10−3 True
PTV V95% Wilcoxon 42.5  1.0× 10−3 1.0× 10−3  1.0× 10−3 True
Jaccard Wilcoxon 103.0  1.0× 10−3 1.0× 10−3  1.0× 10−3 True
Discord. Index Paired t-test 3.5 1.2× 10−3 1.0× 10−3 6.0× 10−3 False
PTV D99% Paired t-test 3.5 1.3× 10−3 1.0× 10−3 5.2× 10−3 False
Cord PRV D1cc Paired t-test 2.7 1.1× 10−2 1.0× 10−3 3.3× 10−2 False
MDCOver Wilcoxon 261.5 4.6× 10−2 1.0× 10−3 9.2× 10−1 False
GTV D100% Paired t-test 1.0 3.1× 10−1 1.0× 10−3 3.1× 10−1 False
Table 4.3: Results for whether CCE and MC DMat give significantly different values,
tested by either T-test or Wilcoxon Matched Pairs test.
4.3.5 Significant results
Once the test statistics and p-values were calculated as described above, the
Benjamini-Hochberg method was used to correct the calculated p-values. The
original and corrected p-values are shown in Table 4.3, which shows that the
differences in the measures DI-CI, PTV D99%, Cord PRV D1cc, MDCOver and
GTV D100% between CCE and MC DMat are not significant. The absence of a
statistically significant difference between the doses calculated by CCE and MC
for these parameters, based on investigation of 40 cases, gives confidence that
CCE is accurate for these parameters. These parameters will not be discussed
further.
4.3.6 Boxplots
Boxplots, or box and whisker plots, are a way of visualising the distributions of
data. The boxplot shows various statistical measures in the following way:
• The First Quartile, or 25th percentile, is represented by the bottom of the
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box;
• The Third Quartile, or 75th percentile, is represented by the top of the box;
• The Mean of the distribution is represented by a red square;
• The Median, or Second Quartile, or 50th percentile, of the distribution is
represented by a horizontal red line;
The whiskers of the boxplot may be defined in various ways, but in this work the
following approach is used:
• The Upper cap, or line at the end of the whisker, is the highest datum
within 1.5 times the Inter-Quartile Range (IQR);
• The Lower cap is the lowest datum within 1.5 times the IQR;
• Points outside 1.5 times the IQR, i.e. outliers, are plotted as a ’+’ symbol;
Boxplots are useful alternative to histograms when comparing multiple datasets,
as several boxes can be plotted side by side. This makes boxplots a useful tool
for comparing the distribution of measures, such as PTV V95%, for the four
different dose calculation methods PBE, CCE, MC DMat and MC DWtr. As for
the table-graphics of section 3.3, two graphs are produced for each measure: the
first compares PBE and MC DWtr and the second compares PBE, CCE and
MC DMat.
Figure 4.3(a) compares the PTV V95% for PBE and MC DWtr. It can be seen
that PTV V95% for PBE has a very small spread of values, with a mean value
of nearly 100%. The boxplot for the MC DWtr simulations shows a drop in the
mean and median, and a marked increase in the IQR of values. Figure 4.3(b)
compares the PTV V95% for PBE, CCE and MC DMat. CCE also shows a drop
in the mean and median compared to the PBE results, and a marked increase
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in the IQR of values. The MC DMat results show a reduction in the mean and
median values compared with the PBE data, of the order of the IQR.
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Figure 4.3: Boxplots comparing PTV V95% for PBE, CCE, MC DMat and MC DWtr.
Figures 4.4(a) and (b) compare the values for the heart V80% for the different
calculation methods, and shows that the mean, median and IQR values are com-
parable across the different dose calculation methods. The Wilcoxon test shows
that the difference in heart V80% between CCE and MC DMat is significant
(Table 4.3). This is due to a consistent trend downward trend in the majority of
cases, as shown in the table-graphic of Chapter 3 (Figure 3.34).
Figures 4.5(a) and (b) compare the values for the lung V20 Gy for the different
calculation methods. Figure 4.5(a) shows a reduction in the mean and median
values from the PBE to the MC DWtr, just as Figure 4.5(b) shows a reduction in
the mean and median values from the PBE to the CCE dose calculation meth-
ods. There is an increase in the mean and median values from the CCE to the
MC DMat, which may be due to the beam penumbra broadening further in low
density materials in the MC simulations compared to the analytical algorithms.
Figure 4.6(a) shows that the mean and median values for the Jaccard-CI decreases
between the PBE and MC DWtr, but that the decrease is small compared to the
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Figure 4.4: Boxplots comparing heart V80% for PBE, CCE, MC DMat and MC DWtr.
IQR. The mean and median values for the PBE and CCE are comparable, as
shown in Figure 4.6(b), but there is a decrease in the mean and median values of
the Jaccard-CI between the CCE and MC DMat dose calculation methods.
Figure 4.7(a) shows that a clear reduction in the mean and median values of the
MDC-Under between PBE and MC DWtr. Figure 4.7(b) shows that a large re-
duction in the mean and median values of the MDC-Under between the PBE and
CCE algorithms, but an increase between the CCE and MC DMat dose calculation
methods.
Figure 4.8(a) shows that a large reduction in the mean and median values of
the TCP-Median between PBE and MC DWtr. Figure 4.8(b) shows that a large
reduction in the mean and median values of the TCP-Median between PBE and
CCE, and a further reduction between CCE and MC DMat. This behaviour is
consistent with the equivalent graphs for TCP-Min and TCP-Max, so this result
is not dependent on the values of the parameters used in the TCP model.
4.4 Discussion 181
PBE MC DWtr
Dose Calculation Method
0
5
10
15
20
25
30
35
D
V
H
 C
o
m
b
in
e
d
 L
u
n
g
s 
V
2
0
G
y
 (
p
e
rc
e
n
t)
(a) PBE and MC DWtr
PBE CCE MC DMat
Dose Calculation Method
0
5
10
15
20
25
30
35
D
V
H
 C
o
m
b
in
e
d
 L
u
n
g
s 
V
2
0
G
y
 (
p
e
rc
e
n
t)
(b) PBE, CCE and MC DMat
Figure 4.5: Boxplots comparing Combined lung V20 Gy for PBE, CCE, MC DMat
and MC DWtr.
4.4 Discussion
4.4.1 Discussion of selected cases
Figure 4.9 shows a comparison of the DVHs for CCE and MC DMat, for case #9
(i.e. the ninth case in the group of 40 cases used in the main body of the study).
For the PTV, the plotted line for MC DMat calculated dose is slightly higher at
the 95% level, but lower elsewhere, compared with the CCE calculated dose. For
the cord PRV, there are differences where there are steps in the plotted lines, as
seen in section 3.4.1. For the heart, the dose from MC DMat is generally lower
than the dose calculated by the CCE algorithm. For the combined lungs, the
there is very little difference between the two dose calculation methods.
Figures 4.11 (a) and (b) show the 95% isodose (47.5 Gy, legend within Figures)
for the CCE and MC DMat dose calculation, for case #9. It can be seen in
Figure 4.11(b) that the coverage of the PTV by the 95% isodose is better in the
region overlapping with the lungs, compared with Figure 4.11(a). As in the cases
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Figure 4.6: Boxplots comparing Jaccard-CI for PBE, CCE, MC DMat and MC DWtr.
discussed in section 3.4.1, the superior modelling of scatter in the MC simulations,
compared with the CCE algorithm results in the differences seen in these regions.
However, the coverage where the PTV overlaps with the bone of the vertebra is
better of the CCE case Figure 4.11(a) than the MC DMat case Figure 4.11(b).
There are also ‘holes’ in the 95% isodose throughout the PTV. These ‘holes’
are directly anterior of the lateral edges of the vertebra, so it is likely that the
differences observed are due to differences in the modelling of attenuation in high
density tissues between the CCE and MC DMat dose calculation methods.
Figure 4.10 shows a comparison of the DVHs for CCE and MC DMat, for case
#37. For the PTV, the plotted line for MC DMat demonstrates lower coverage
than that for the CCE algorithm. For the cord PRV, the DVH plots deviate
below 90% of the volume, while there is god agreement for the high dose region.
The DVH for the heart and combined lungs show good agreement, although the
dose calculated by MC DMat is generally higher that that from CCE for the heart,
while the reverse is true for the combined lungs.
Figures 4.12 (a) and (b) show the 95% isodose (47.5 Gy isodose line, legend within
figures) for the CCE and MC DMat dose calculation, for case #37, which showed
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Figure 4.7: Boxplots comparing Under Mean Distance to Conformity for PBE, CCE,
MC DMat and MC DWtr.
a large difference in PTV V95%, produced by CERR. Figures 4.12 (a) and (b)
both show poor coverage where the PTV overlaps the right lung (left side of the
image). Figure 4.12 (b) shows that the coverage of the PTV for the MC DMat
is poorer than for the CCE algorithm, particularly where the PTV overlaps with
the high density vertebra. This suggests poorer agreement between the CCE and
MC dose calculations is related to non-soft tissue regions in the PTV. Visually,
the differences are not large, but as this behaviours is repeated over several slices,
the combined effect produces one of the largest changes in PTV V95%.
4.4.2 Correlation with PTV material
It has been shown that re-calculating oesophageal radiotherapy plans with MC
gives a value for PTV V95% that is significantly different to that obtained with
the original CCE calculation. For sections 3.4.1 and 4.4.1, differences occur in
regions where the PTV overlaps lung or bone. It would be useful if a prediction
could be made regarding which cases would benefit the most from MC simulation.
From examining isodoses for outliers, the composition of the PTV appears to be
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Figure 4.8: Boxplots comparing Tumour Control Probability Median for PBE, CCE,
MC DMat and MC DWtr.
a factor. Could the percentage of the PTV that is lung, for example, predict
whether MC should be used?
A common tool for measuring the effectiveness of the predictive power of a test is
the Receiver Operator Characteristic (ROC) curve. A predictive test that aims
to answer a true or false question may have four outcomes: -
1. The test gives a positive result, when the result should be positive (a true
positive);
2. The test gives a positive result, when the result should be negative (a false
positive);
3. The test gives a negative result, when the result should be negative (a true
negative);
4. The test gives a negative result, when the result should be positive (a false
negative).
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Figure 4.9: Comparison of DVH parameters for CCE and MC DMat,
for case #9 of 40.
The ratio of true positive test results to the ‘real’ number of positive outcomes
is known as the sensitivity. A related quantity is the specificity, which the the
ratio of the true negative test results to the ‘real’ number of negative outcomes.
Ideally a test will have 100% sensitivity, so correctly identifies all true outcomes,
and 100% specificity, so will not incorrectly identify any false outcomes as true.
However, many tests in which a threshold value is used to make a true or false
prediction will not behave in this ideal way; as the threshold is varied to improve
the sensitivity, the specificity may be compromised. By plotting the sensitivity
(or True Positive Rate) against 1-specificity (also known as the False Positive
Rate) as the threshold value is varied, a ROC curve is produced. A ROC curve
may be used to determine the effectiveness of a test, to compare different tests,
and choose a suitable threshold. Figure 4.13 shows three ROC curves used to
predict if the change in PTV V95%, is greater than 5%. The first curve uses the
percentage of air or lung in the PTV. The second curve uses the percentage of
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Figure 4.10: Comparison of DVH parameters for CCE and
MC DMat, for case #37 of 40.
bone in the PTV. The third curve uses the percentage of air, lung or bone in the
PTV; this is equivalent to the percentage of the PTV that is not soft tissue.
An ideal test will have a point at the top left extreme of the plot, sensitivity =
1, and 1 - specificity = 0. A test which is no better that random will have points
lying along the x = y line. It can be seen than none of these three parameters
predicts a 5% change in PTV ideally, but all three are better than random. A
way to compare these tests is to calculate the Area Under the Curve (AUC). An
ideal test will have an AUC of 1, a test that is no better than random will have
a AUC of 0.5. A test with an AUC of less than 0.5 has higher false positive and
false negative results than would be expected by a random guess. In this case the
logic of the test can be reversed to give an AUC greater than 0.5, so the test has
predictive ability.
Comparing the three AUC values, the percentage of PTV that is either air, lung
or bone is the best test. However, the point on the ROC curve closest to the
4.4 Discussion 187
top left corner is not necessarily the best value. Consider a screening test for
cancer. One approach to setting the threshold used in the test would be strike the
best balance between sensitivity and specificity. However, choosing a threshold
value such that the false negative rate is minimised would mean that number of
patients with cancer that is ‘missed’ by the test is minimised. Even if this comes
at the expense of a lower sensitivity, i.e. more false positive results meaning more
patients without cancer are referred for further tests, it is likely that this will be
the preferred approach.
Consider the three points in Figure 4.13, P1, P2 and P3. Using a threshold value
of 31% of PTV that is bone, will correctly identify 53% of the cases that will
see a 5% change in PTV V95%, without classifying any that do not need MC as
needing it. It will however ‘miss’ 47% of those that would benefit from MC.
P3 relates to applying a threshold of 39% to the PTV that is either Air, Lung
or Bones. This threshold identifies all cases that would have a greater than 5%
reduction in PTV V95%, but also includes 78% of those that would not. This is
not a particularity useful test, if that many cases are to be simulated with MC,
all cases may as well be.
P2 picks of 87.5% of those needing MC, and only 41% of those not needing MC.
This is still not ideal, but is a useful test, and could be used to aid prioritisation
of MC resources. It also suggests modification of this parameter (i.e. composition
of PTV plus a margin) may yield a more effective prediction.
Assuming that 10% reduction in PTV is the criteria used to determine if MC is
required, then P4 in Figure 4.14 picks up 68% of those requiring MC, and none
where CCE is sufficient. P5 identifies all cases requiring MC, and only 37% of
those that do not require MC, using the percentage of the PTV that is air, lung
or bone greater than 62% as the threshold. It is therefore recommended that if
a PTV has greater than 62% of the volume consisting of air, lung or bone, then
MC simulation should be used where available.
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4.4.3 Comparison of results with other published work
As discussed in section 2.6.3, there are few studies comparing different calculation
methods for oesophageal RT treatments. Wills et al. (2009) found a reduction in
PTV V95% of 9% when comparing the PB and CC algorithms for oesophageal
plans. This agrees with the results presented in Figure 4.3(b). Wills et al. (2009)
found that the doses to the OARs changed by less than 2% between the two
calculation algorithms, which agrees with the comparisons of the PBE and CCE
DVH parameters for the heart V80% in Figure 3.34, cord PRV D1cc in Figure 3.35,
and lung V20 Gy in Figure 3.36. As no MC simulations were included in the work
of Wills et al. (2009), no comparison can be made with the results obtained in
the current work for MC calculations.
Irvine et al. (2004) found that the minimum dose to the PTV reduced by up to
23% when the PB plan was re-calculated with the CC algorithm. Although there
was substantial variation between the 10 cases examined, the PTV minimum dose
always decreased when re-calculating with the CC algorithm. The minimum dose
to the PTV was not examined in the current work, as it is not a parameter re-
quired by the SCOPE1 trial. The most comparable parameter in the current work
is the PTV D99% (the minimum dose to the PTV could be called PTV D100%,
the minimum dose received by 100% of the PTV volume). Figure 3.31(b) shows
qualitative agreement with the results of Irvine et al. (2004); the PTV D99% al-
ways decreases when re-calculating with CCE, and there is substantial variation
in the magnitude of the reduction. No reductions in PTV D99% of 20% were
obtained in this work; the largest reduction shown in Figure 3.31(b) is approx-
imately 15%. D99% and D100% are different parameters, so these differences in
the results are not contradictory.
As in the work of Wills et al. (2009), Irvine et al. (2004) compared the ‘classic’
PB and CC algorithms, rather than the enhanced versions used in this work
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(section 2.4.6). As the work of Irvine et al. (2004) did not involve comparisons
with MC calculated doses, no comparison can be made with the results obtained
in the current work for MC calculations.
Haga et al. (2014) found differences in the PTV of less than 2% between the
analytical algorithm used and the MC simulation, for the single oesophageal case
examined. This agrees with the mean changes in PTV found in the current
work between CCE and MC DMat calculations, as presented in Table 3.6 and
Figure 4.3(b), although there is substantial variation between cases in the current
work. Haga et al. (2014) found differences in the mean lung dose of less than 2%,
while the results in the current work (Table 3.6 and Figure 4.5(b)) show differences
within 1% for heart V80% . This may be due to the differences in the measures
used for lung, V20 Gy versus mean dose.
Haga et al. (2014) found differences in the maximum dose to the spinal cord of
5%. The most comparable parameter in this work is the Cord PRV D1cc. The
mean change in Cord PRV D1cc between the CCE and MC DMat calculations
presented in Table 3.6 was 0.05 Gy, or approximately 1.3%, and the analysis in
Chapter 4 revealed no significant change in the Cord PRV D1cc when comparing
CCE and MC DMat calculations. This may reflect that the absolute maximum
dose to an OAR is a less stable parameter than D1cc. The maximum dose for a
MC simulation is likely to be affected by the statistical fluctuations in the voxels.
Haga et al. (2014) only examined a single oesophageal case, so these results cannot
be extrapolated to other patients.
Jang et al. (2006) compared doses at discrete points rather than comparing DVH
parameters, so direct comparison of results cannot be performed. Despite finding
point differences of up to 10%, the DVHs presented for the lung cases show
good agreement between Pinnacle and MC simulations. The DVHs presented in
sections 3.4.1 and 4.4.1 also show the DVH graphs appear very similar despite
differences being found for individual DVH parameters, and differences being
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apparent for isodose distributions.
No comparisons can be made with the results presented in Table 4.3, showing
which of the PTV parameters were found to change significantly between the
CCE and MC DMat calculations, as no know studies have taken the approach
used in the current work, for oesophageal or other treatment sites.
4.5 Conclusion
40 oesophageal cases have been simulated on the RTGrid. For all cases a number
of measures (DVHs parameters, Conformity Indices, Mean Distance to Conform-
ity values and TCP values) have been calculated for the four different sets of doses
produced, PBE, CCE, MC DMat and MC DWtr. For measures that were correl-
ated with other measures, all but one from each ‘group’ were excluded. For each
remaining measure, the differences in the values calculated from the CCE and
MC DMat dose distributions produced a distribution of values; each distribution
was tested to determine if it was a normal distribution. For normally distributed
data, the paired t-test was used to test if the differences were significant or not;
for non-normal distributions, the Wilcoxon paired test was used.
For each of the t-tests and Wilcoxon tests, the p-value was calculated. Due to the
number of measures analysed, the Holm-Bonferroni method was used to adjust
the critical p-values. It was found that differences in TCP-Median, MDC-Under,
combined lungs V20Gy, heart V80% PTV V95% and Jaccard-CI were statistically
significant. The measures DI-CI, PTV D99%, Cord PRV D1cc, MDCOver and GTV
D100% between CCE and MC DMat were not found to be significant.
Boxplots were used to visualise the differences in the measures for different dose
calculation methods, and shown that the PTV V95% fell between PBE and CCE,
and then fell further for the MC DMat dose calculation.
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Isodose plots show qualitatively that the agreement is poorer between different
dose calculation methods in regions of lung, bone, or other non-soft tissue regions.
It was found that the composition of the PTV shows some utility for predicting
those cases that would benefit the most from MC. It is recommended that if the
percentage of non-soft tissue voxels in the PTV exceeds 62%, MC should be used
where available (P5 in Figure 4.14).
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(a) 95% isodose calculated from CCE dose distribution.
(b) 95% isodose calculated from MC DMat dose distribution.
Figure 4.11: Screen-shots comparing 95% isodose coverage of PTV in CT slice, for
case #9 of 40.
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(a) 95% isodose calculated from CCE dose distribution.
(b) 95% isodose calculated from MC DMat dose distribution.
Figure 4.12: Screen-shots comparing 95% isodose coverage of PTV in CT slice, for
case #37 of 40.
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Figure 4.13: Receiver Operator Characteristic curves for the use of PTV composition
to predict a change in V95% greater than 5%.
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to predict a change in V95% greater than 10%.
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Chapter 5
Conclusions
5.1 Conclusions
This work has examined the effect of the method of dose calculation on RT plans
for oesophageal cancer. Oesophageal RT treatment plans created at Velindre
Cancer Centre following the SCOPE protocol were used for this study. The plans
had been created using the Oncentra MasterPlan TPS, and calculated using the
PBE algorithm. These plans were then re-calculated using the CCE algorithm,
and MC simulations performed. For these MC simulations the BEAMnrc and
DOSXYZnrc codes were chosen due to their accurate physical models for the en-
ergy ranges and materials of interest to photon beam RT, and their active user
base. The RTGrid was used to execute BEAMnrc and DOSXYZnrc simulations
on an HTCondor pool. This allowed existing PCs in the Medical Physics depart-
ment to be used overnight when they were (for the most part) unused. This was
a cost-effective approach to accessing a computing platform capable of executing
up to 200 ‘jobs’ in parallel.
Before oesophageal RT treatment plans could be simulated on the RTGrid, a
number of changes needed to be made to the profile used to create the jobs
executed on the HTCondor pool. A CTRamp, OesRAMP, was produced from
scans of a CIRS-062M phantom. The EDW component module was incorporated
into the RTGrid profile, to allow the simulation of plans including Varian EDW
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fields. Code was developed to remove the high density intra-venous contrast from
CT scans and to ignore data on the CT scan outside the external contour. Further
code was developed to create artificial volumes at the superior and inferior extent
of the CT scan, so that the MC simulation followed the approach of the TPS
calculations.
Initially, 12 oesophageal treatment plans were simulated, and DVH parameters
calculated from the MC dose distributions. Parameters commonly reported from
the DVHs, such as PTV V95%, were compared for the CCE and MC, and sample
size calculations were performed. From this analysis, it was decided to simulate 40
clinical cases for the main body of the work, primarily to investigate the coverage
of the PTV with the 95% isodose.
For these 40 oesophageal cases, four different dose calculation methods, PBE,
CCE, MC DMat and MC DWtr were considered. For each dose calculation method,
a number of measures (DVHs parameters, Conformance Indices, MDC values and
TCP values) were calculated. For those measures where the differences between
the CCE and MC DMat datasets followed a Gaussian distribution, the paired
t-test was used to test if the differences were significant. Where the differences
between the datasets were non-Gaussian, the Wilcoxon matched pairs test was
used to test if the differences were significant. Some of these differences may have
appeared to be significant by chance, due to the large number of comparisons
made. To correct for this effect, firstly any measures that were correlated with
other measures were excluded. Then, the Holm-Bonferroni method was used to
adjust the critical p-values for the statistical tests performed. It was found that
differences in TCP-Median, MDC-Under, combined lungs V20 Gy, heart V80%,
PTV V95% and Jaccard-CI were statistically significant.
Analysis of isodose plots showed that the agreement is poorer between different
dose calculation methods in regions of lung, bone, or other non-soft tissue re-
gions. It was found that if the percentage of non-soft tissue voxels in the PTV
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exceeds 62% this predicts those cases in which the PTV V95% would decrease
by 10% or more with a sensitivity of 68% and a specificity of 100%. It is there-
fore recommended that MC should be used where available in such cases (P5 in
Figure 4.14).
Comparing the results in this work for DVH parameters for the PTV for the
changes between the PBE and CCE algorithms, against other published results
found good agreement with Wills et al. (2009) and Irvine et al. (2004). The
differences observer for DVH parameters for the lungs and heart, comparing the
CCE and MC DMat dose calculations agreed with the results presented by Haga
et al. (2014), although the difference observed by Haga et al. (2014) for the max-
imum dose to the spinal cord between analytical calculation and MC simulation
(5%) exceeds any differences in this work for cord PRV D1cc. As no known work
has determined the statistical significance of a range of measures calculated for
analytical calculations and MC simulations, no comparisons of this aspect of the
work can be made with the literature.
In summary, the main findings of this work are as follows: -
• MC produces statistically significantly different PTV V95% compared to
CCE when planning CFRT for oesophageal cancer;
• It is necessary to consider using MC when performing outcome modelling,
as variation in TCP arising from different dose calculation methods is stat-
istically significant. This suggests that the differences in coverage of the
PTV by the 95% isodose will lead to clinically significant differences;
• The use of MC is indicated if non-soft tissue voxels make up > 60% of the
PTV.
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5.2 Further work
Possible areas for further study are presented below.
5.2.1 Extension to other treatment sites
For this work oesophageal treatment plans were chosen due to the significant
degree of heterogeneous material in the calculation region, and the paucity of
studies of this treatment site. Treatment plans for lung cancer are also performed
in regions of significant heterogeneities. While there have been a large number
of studies published comparing analytical and MC dose calculation methods for
lung RT, the sample size has often not been considered in the comparisons. Of
particular interest for future work would be trials involving dose escalation. In
such trials, the dose to the target is increased as high as possible (up to a limit)
while keeping the doses to OARs below set targets. Any inaccuracies in the dose
calculation for OARs could have a marked impact on the prescribed dose.
5.2.2 Automation of CTRamp creation and validation
During this work a CTRamp, OesRAMP, was created for a specific CT scan-
ner protocol, the ctcreate executable re-compiled with the material and density
boundaries that define the ramp, and the resulting egsphant files examined to
ensure the materials used matched the anatomical information. While aspects
of this task were automated, notably the generation of the fitting parameters
in Equation 3.3, other aspects were time consuming. It would be possible to
automate the whole process, for example: -
• For a CT scan of the CIRS-062 phantom, use the existing code to generate
the relation between HU and density for the CT scan of interest;
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• Compile a modified version of ctcreate.exe with a new CTRamp, relating
to the CT protocol of interest;
• Generate graphs plotting the CTRamp, and measured density versus cal-
culated density, to validate the CTRamp;
• Run the ctcreate executable for a reference CT scan, to generate an egsphant
file;
• Perform automated analysis on the egsphant file to ensure the boundaries
of the material bins have been set correctly, for example by testing the
material assigned to voxels within ROIs drawn on the CT;
• If material assignment is not satisfactory, adjust the boundaries used, re-
compile the ctcreate executable, re-create the egsphant file and repeat the
analysis of material assignment;
• Repeat this iterative process until material assignment is satisfactory.
This would streamline the process of producing CTRamps, and would facilitate
the study of RT plans for different treatment regions with MC.
5.2.3 Newer source models
As described in section 3.2.2, the RTGrid profile used in the current work performs
simulations with enough histories to achieve the required statistical uncertainty
for each beam. Therefore, for plans with six beams, the statistical uncertainty
at the isocentre will be better than that for a four beam plan. If the four beam
plan is simulated with sufficient histories, this implies that a six beam plan is
simulated with too many histories. Also, the feature of the RTGrid to end a
simulation once, for example, 95% of the jobs have completed was not used, in
case the 5% of jobs not performed all related to the same beam. (If a PC in
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the HTCondor pool is used intermittently, the execution of jobs assigned to this
PC will be repeatedly suspended, and restarted. If all jobs must finish before
a simulation is completed, the completion of a simulation may be delayed by a
single job, which is delayed by repeated suspension to execution.)
Using source model SOURCE21, by Lobo and Popescu (2010) would allow the
simulation of all the beams in a plan to be combined into a single simulation.
While this simulation would still be split into multiple jobs, the number of his-
tories used could be based on the statistical uncertainty to be set for the plan as
a whole. This would also allow the simulations to be ended after 95% (or other
suitable percentage) without fear of compromising the statistics for one beam.
As SOURCE21 is designed for dynamic treatments, adopting SOURCE21 would
allow the same profile to be used for CFRT as well as IMRT and VMAT.
5.2.4 Better predictive model for plans requiring Monte
Carlo
In section 4.4.2, methods to predict which oesophageal plans would benefit most
from MC were discussed. The percentage of voxels in the PTV which are not
soft-tissue showed some utility for predicting plans that would have large changes
in PTV V95%. It may be expected that the composition of voxels just outside
the PTV will in turn affect the dose calculated in the PTV. This is particularly
relevant for the dose just inside the PTV, which will affect the PTV V95%.
Therefore, investigation of the composition of the volume including the PTV plus
a margin as a predictor of the change in PTV V95% should be explored.
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Appendix B
EDW profiles
As discussed in Section 3.2.5.4, in this work beam profiles were produced for 6 MV
and 10 MV for three field sizes in varying size phantoms, for the four EDW wedge
angles, 15o, 30o, 45o, and 60o. The results for 5 cm by 5 cm and 15 cm by 15 cm
fields are presented below.
B.1 5 cm by 5 cm fields
Figure B.1 compares the measurement and MC simulation for a 5 cm by 5 cm,
6 MV beam with a 15o EDW wedge. For the profile in the X-direction, the
agreement between simulation and measurement is within 1% for all points. For
the Y-direction, some points in the beam ‘shoulders’ show a 1-2% discrepancy
between simulation and measurement, while all other points agree to within 1%.
The agreement of the shape of the beam shoulders and penumbra is visually very
good.
The measurement and MC simulation for a 5 cm by 5 cm, 6 MV beam with a
30o EDW wedge are compared in Figure B.2. For the profile in the X-direction,
the agreement between simulation and measurement is within 1%, aside from a
few points in the shoulders of the beam; the agreement for these points is within
2%. For the Y-direction all points agree to within 2%.
Figure B.3 compares the measurement and MC simulation for a 5 cm by 5 cm,
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6 MV beam with a 45o EDW wedge. For the profile in the X-direction, the
agreement between simulation and measurement is within 1%, aside for a few
points in the shoulders of the beam that are within 2% of measurement. For
the Y-direction all other points agree to within 3%; although agreement is better
away from the toe end on the wedge.
The measurement and MC simulation for a 5 cm by 5 cm, 6 MV beam with a
60o EDW wedge are compared in Figure B.4. For the profile in the X-direction,
again agreement is within 1%, aside from a few points in the shoulders of the
beam, which are within 2% of measurement. For the Y-direction the agreement
away from the toe end of the wedge is within 2%, although differences in the toe
of the wedge approach 4%.
Figure B.5 compares the measurement and MC simulation for a 5 cm by 5 cm,
10 MV beam with a 15o EDW wedge. The profiles in both the X-direction and
Y-direction show agreement within 1%, aside from a few points in the shoulders
of the beam. This behaviour is repeated in Figure B.6, which compares the
measurement and MC simulation for a 5 cm by 5 cm, 10 MV beam with a 30o
EDW wedge.
Figure B.7 compares the measurement and MC simulation for a 5 cm by 5 cm,
10 MV beam with a 45o EDW wedge. For the profile in the X-direction, the
agreement between simulation and measurement is within 1%, aside for a few
points in the shoulders of the beam that are within 2% of measurement. For the
Y-direction all other agree to within 3%; although agreement is better away from
the toe end on the wedge.
The measurement and MC simulation for a 5 cm by 5 cm, 10 MV beam with a
60o EDW wedge are compared in Figure B.8. For the profile in the X-direction,
the agreement between simulation and measurement is within 1%. For the profile
in the Y-direction, the agreement between simulation and measurement is within
3%, with the majority of points being within 2%.
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B.2 15 cm by 15 cm fields
Figure B.9 compares the measurement and MC simulation for a 15 cm by 15 cm,
6 MV beam with a 15o EDW wedge. For the profile in the X-direction, the
agreement between simulation and measurement is within 2%, aside from a few
points in the shoulders of the beam; the agreement for these points is within 3%.
For the Y-direction, the agreement away from the toe end of the wedge is within
2%, although differences in the toe of the wedge and the shoulders of the beam
approach 4%.
The measurement and MC simulation for a 15 cm by 15 cm, 6 MV beam with a
30o EDW wedge are compared in Figure B.10. For the profile in the X-direction,
the agreement between simulation and measurement is again within 2%, aside
from a few points in the shoulders of the beam where the agreement is within 3%.
For the Y-direction, the agreement away from the toe end of the wedge is within
2%, although differences in the toe of the wedge and the shoulders of the beam
approach 5%.
Figure B.11 compares the measurement and MC simulation for a 15 cm by 15 cm,
6 MV beam with a 45o EDW wedge. As for previous 15 cm by 15 cm EDW fields,
the agreement in the X-direction is within 2%, aside from a few points in the
shoulders of the beam where the agreement is within 3%. For the Y-direction,
the agreement away from the toe end of the wedge is within 2%. In the toe of the
wedge, the agreement is the worst of all fields compared, with differences between
simulation and measurement up to 6%.
The measurement and MC simulation for a 15 cm by 15 cm, 6 MV beam with a 60o
EDW wedge are compared in Figure B.12. The profiles in the X-direction show
the largest differences in the X-direction for all fields compared, with differences
of up to 4%. In the Y-direction, the differences are with 6%, with differences in
both the toe and heel ends of the wedge.
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Figure B.13 compares the measurement and MC simulation for a 15 cm by 15 cm,
10 MV beam with a 15o EDW wedge. For the profile in the X-direction, the
agreement between simulation and measurement is within 2%. For the Y-direction
the agreement away from the toe end of the wedge is within 2%, although there
are differences of up to 4% in the toe of the wedge.
The measurement and MC simulation for a 15 cm by 15 cm, 10 MV beam with a
30o EDW wedge are compared in Figure B.14. For the profile in the X-direction,
the agreement between simulation and measurement is within 2%, aside from
some points in the shoulders of the beams, which are within 3%. For the Y-
direction the agreement away from the toe end of the wedge is within 2%, although
there are differences of up to 5% in the toe of the wedge.
Figure B.15 compares the measurement and MC simulation for a 15 cm by 15 cm,
10 MV beam with a 45o EDW wedge. For the profile in the X-direction, the
agreement between simulation and measurement is again within 2%, aside from
some points in the shoulders of the beams, which are within 3%. For the Y-
direction the agreement away from the toe end of the wedge is within 2%, although
there are differences of up to 5% in the toe of the wedge.
The measurement and MC simulation for a 15 cm by 15 cm, 10 MV beam with
a 60o EDW wedge are compared in Figure B.16. Once again, the profile in the
X-direction shows that the agreement between simulation and measurement is
within 2%, aside from some points in the shoulders of the beams, which are
within 3%. For the Y-direction, agreement is within 3%, although the differences
are of a similar magnitude in the heel and toe. This is in contrast to most fields
where the heel end of the wedge is exhibits significantly better agreement than
the toe end.
Overall, agreement is very good, with most fields agreeing to within 3%, aside
from some larger discrepancies in the toe end of the wedge. The worst cases
occur for the 15 cm by 15 cm fields, with 45o or 60o wedges, for both 6 MV and
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10 MV. These fields exhibit discrepancies of 5-6%. The dose varies by a factor
of 2-2.5 between the heel and toe of the wedge in these beams. Wedges are used
to counteract dose gradients due to obliquities in the patient surface, or due to
beam arrangements. A variation in dose for factor of 2-2.5 would be an extremely
large variation to have arisen due to these effects, so it is not anticipated that
such wedges will be used in clinical oesophageal plans.
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Glossary
American Association of Anaesthesiologists (ASA) Association of physi-
cians organized to maintain and raise the standards of the medical practice
of anaesthesiology. Produced the ASA Physical Status Classification Sys-
tem, a system for describing the fitness of a patient prior to surgery. 172
Apoptosis Programmed cell death, the mechanism by which damaged cells are
killed. 2
Bremsstrahlung Braking Radiation, photons produced by the deceleration of
a charged particle. 17, 36, 37, 39, 48, 55, 57, 104
carbon ion Form of particle therapy, in which beams of carbon nuclei are used
to irradiate malignant tumours. The deposition of energy in matter for
particles is described by the Bragg curve, which has a pronounced peak,
known as the Bragg peak, just before the particle comes to rest. 10
Carcinogenesis The formation of cancer, in which normal cells transform into
cancerous cells. 10
Cell Cycle Series of changes in a cell in which the DNA is duplicated, and the
cell divides into two. 10–12
Central Processing Unit (CPU) The main piece of circuitry in a computer
that performs the instructions provided by computer programs. Often
known as the ‘chip’. 50, 64, 71, 81
Charged Particle Equilibrium (CPE) For radiation beam passing through
a material, the situation where the energy imparted to the electrons by the
radiation beam at a point is balanced by the energy deposited by electrons
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in the medium. When charged particle equilibrium is established, absorbed
dose is equal to collision Kinetic Energy Released per unit Mass. 38, 44,
116
Chemo-radiotherapy (CRT) Combination of chemotherapy and radiotherapy.
7, 8
Clinical Target Volume (CTV) Gross Tumour Volume plus a margin for sub-
clinical spread of disease. 79, 139
Collapsed Cone Algorithm (CC) Type B Dose Calculation algorithm used
in Oncentra MasterPlan. 15, 16, 24, 25, 28, 44, 46, 50–52, 72–75, 188
Collapsed Cone Enhanced (CCE) Enhanced version of the Collapsed Cone
Algorithm, which is faster than standard due to efficiencies in the calcu-
lation, while using a higher resolution head scatter grid. Throughout this
work, the Enhanced version of the Collapsed Cone Algorithm has been
used. iv, xvi–xviii, xxi, 51–53, 76, 77, 86, 113, 140–154, 156–158, 160, 169,
173–190, 192, 193, 196–198
Component Module (CM) A ‘building block’ used to create a model of the
linear accelerator for the BEAMnrc Monte Carlo code. 57, 58, 62, 100
Computed Tomography (CT) Form of x-ray imaging that produces a series
of cross-sectional images through the body, in which regions of high electron
density appear white, and regions of low electron density appear darker .
xiv, xvii, xviii, 8, 14, 15, 22, 48, 61, 67, 78, 79, 81, 88–91, 93–95, 99, 106–108,
110–114, 133, 139, 149, 156–158, 192, 193, 197, 199, 200
Condensed History (CH) In Monte Carlo, an approach to transporting lower
energy electrons in which multiple scattering events are modelled as a single
event, to save computation time. 54, 55, 57
Conformal Radiotherapy (CFRT) Type of radiotherapy in which radiation
beams are shaped to match the shape of the target, usually by Multi-Leaf
Collimators. 14, 16, 24, 25, 80, 139, 198, 201
deoxyribonucleic acid (DNA) Molecule that holds the genetic instructions
necessary for the growth, development, function and reproduction of liv-
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ing organisms. Has a double-helical structure, in which two strands wind
around each other, like a twisted ladder. 9, 11
Dice Similarity Coefficient (Dice-CI) Conformance Index for measuring how
one region of interest conforms to another, calculated as the ratio of twice
the intersection between the volumes to the sum of the volumes. 162, 163,
166, 168
Digital Imaging and COmmunications in Medicine (DICOM) A stand-
ard for transferring, viewing and storing digital images for medical use. 22,
23, 69, 83–85, 88, 108, 113, 114
Digital Imaging and COmmunications in Medicine, Radiotherapy Sup-
plement (DICOM-RT)
Extension to DICOM standard for Radiotherapy objects, such as structures,
radiotherapy plans and dose matrices. 22, 23, 64, 65, 67, 69, 84–88, 108,
111–113, 115
Discordance Index (DI-CI) Conformance Index for measuring how little one
region of interest conforms to another, calculated as the ratio of the inter-
section of the volumes to the volume of the reference object, subtracted
from 1. As the overlap volume increases, this index decreases. 163, 166,
168, 177, 190
Dose Volume Histogram (DVH) Graphical tool used in Radiotherapy to de-
scribe amount of dose being delivered to a volume. Histograms are usually
plotted cumulatively, so a point on the graph shows the volume receiving
up to or including the specified dose. iv, xvii, xviii, 15, 59, 66–68, 76, 80,
81, 87, 113, 140, 147, 149–152, 156, 160, 161, 165, 166, 168, 181, 182, 185,
186, 188–190, 197, 198
Double Strand Break (DSB) In radiobiology, a double strand break is a break
in both of the two helices in the structure of the DNA molecule, which is
much harder to repair than a single strand break. 9
electron-gamma-shower (EGS) A general purpose Monte Carlo code, used
extensively in Medical Physics, as well as other fields. 56–58
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Electronic Portal Imaging Device (EPID) Imaging device used on linear
accelerators, to produce an image from radiation passing through the pa-
tient. 65, 69
Energy fluence Amount of radiant energy per unit area, at a given position,
traversing a plane perpendicular to the beam. 46–49, 51, 52
Enhanced Dynamic Wedge (EDW) Method of producing a wedged isodose
distribution from certain Varian linacs, in which a collimator is driven across
the radiation beam. xv, xvi, xviii, xix, 21, 78, 100, 101, 103, 127–136, 156,
196, 204–207, 209–224
External Beam Radiotherapy (EBRT) Type of radiotherapy in which radi-
ation beams originating outside of the body are incident on the body. 4,
16, 28, 29, 32, 34
Field Size Factor (FSF) Absorbed dose at depth of maximum dose on the
beam axis for a 10 cm × 10 cm field, divided by dose at the same point for
a given field size. Inverse of the Output Factor. 47, 103
Floating Point Operations Per Second (FLOPS) Metric used for compar-
ing performance of supercomputers. 62
Focus to Source Distance (FSD) Distance from a reference plan in the linear
accelerator head containing the focus of the electron beam, to the surface
of the patient or phantom. 102
Geometric Miss Index (GMI) Measure describing how little two volumes over-
lap; GMI=0 implies one volume is completely enclosed in the other, GMI=1
implies no overlap between volumes. 164, 166, 168
Graphical User Interface (GUI) A type of user interface that allows users
to interact with electronic devices, particularly using a mouse to click on
icons, buttons and menus, as opposed to typing commands into a text based
interface. 66, 67
Graphics Processing Unit (GPU) Computing component designed to accel-
erate the creation and manipulation of images, and performing similar cal-
culations. May be dedicated to calculations, and not output an image to a
display device. 50, 70–72, 77
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Gross Tumour Volume (GTV) Volume identified as disease, normally by 3D
imaging. 79, 106, 139, 143, 154
High Performance Computing (HPC) A Computing paradigm focussing on
executing tightly coupled computing tasks that require high number of
Floating Point Operations per second. 62–64, 77
High Throughput Computing (HTC) A Computing paradigm focussing on
efficient execution of loosely coupled tasks. 62, 63, 77, 81
Hounsfield Units (HU) Value representing electron density in CT scan, relat-
ive to that of water. xiv, 88–91, 93–95, 108, 112, 199
Hydro-peroxy Radical A molecule that has unpaired valence electrons, and a
Oxygen-Oxygen bond, such as HO−2 . 10
Hypoxic State in which a region of the body is deprived of Oxygen. 10
Intensity Modulated Radiotherapy (IMRT) Type of Radiotherapy in which
Multi-Leaf Collimators move across the radiation beam during irradiation,
to produce dose distributions that cannot be achieved with Conformal Ra-
diotherapy. 46, 52, 68, 76, 139, 201
International Commission on Radiation Units and Measurement (ICRU)
Body that establishes international standards for radiation units and meas-
urement. 57, 99
Inter-Quartile Range (IQR) Measure of variability of data, based on dividing
rank-ordered data into four groups of equal size, and finding the difference
between the highest value in the third quartile and the highest value in the
first quartile . 178–180
Isodose Line of equal dose, tool used to display radiotherapy dose overlaid on a
Computed Tomography scan, or similar. xvii, 15, 20, 42, 59, 66, 149, 150,
156–158, 183, 190
Jaccard Concordance Index (Jaccard-CI) Conformance Index for measur-
ing how one region of interest conforms to another, calculated as the ratio
of intersection between the volumes to the union of the volumes. xvii, 162,
163, 166, 168, 179, 180, 182, 190, 197
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Job Submission Description Language (JSDL) An XML file describing the
programs to be executed, the parameters passed to the executables, the re-
sources they can be run on etc. in the RTGrid. 83, 85
kerma Kinetic energy released per unit mass. 38, 45
kilo-electron volts (keV) A unit of energy, usually used for to the energy of a
charged particle. An Electron will gain 1 eV, equal to 1.602 × 10−19 joule,
when accelerated through a potential of 1 volt. 1 keV is 103 eV. 30, 35, 57,
60
Linear Accelerator (linac) Treatment Machine used to deliver radiotherapy.
15, 16, 18, 20–22, 24, 37, 46, 55, 57–62, 65, 66, 71, 77, 78, 87, 99–101,
103–105, 113, 114, 139
Linear Energy Transfer (LET) Quantity describing the energy transferred
by an ionizing particle to the material traversed, per unit distance. 10
Mean Distance to Conformity (MDC) Method of comparing two volumes,
equal to the average distance that a point on one surface must be moved to
achieve perfect conformance with the other surface. 164–166, 168, 197
Medical Research Council (MRC) One of seven research councils in the United
Kingdom, the Medical Research Council co-ordinates and funds research
aimed at improving human health. 7
mega-electron volts (MeV) A unit of energy, usually used for to the energy
of a charged particle. An Electron will gain 1 eV, equal to 1.602 × 10−19
joule, when accelerated through a potential of 1 volt. 1 MeV is 106 eV. xiii,
29, 30, 32, 34, 57, 61, 73
Monitor Units (MU) A linac is calibrated such that a known signal from the
Monitor Chamber gives a known dose under reference conditions. Typically
100 MU will deliver 1 Gy at a reference point, under reference conditions.
21, 22, 41, 46, 66, 75, 101–103, 112
Monte Carlo (MC) Numerical Technique involving use of random numbers.
In this work, refers to calculation of radiotherapy dose distributions by
simulating the passage of photons and electrons through materials, where
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random number generation is used to account of probabilistic nature of
interaction between radiation and matter. iv, xv, xvi, xviii–xxi, 16, 24, 25,
28, 53, 54, 56–64, 66–78, 81–83, 86–88, 100, 104, 105, 108, 111–115, 117–
132, 134–138, 143, 150, 156, 160, 173, 175, 177, 179, 182–184, 187–189, 191,
196–201, 204–207, 209–224
Monte Carlo, Dose To Material (MC DMat) Absorbed dose calculated by
Monte Carlo simulation, calculated using the interaction cross-sections for
the material in the voxel or region of interest . xvi–xviii, xxi, 86, 113,
140–154, 157, 158, 169, 173, 174, 176–186, 189, 190, 192, 193, 197, 198
Monte Carlo, Dose To Water (MC DWtr) Absorbed dose calculated by Monte
Carlo simulation, scaled to give the dose as if the voxel were comprised of
water. xvi, xvii, 86, 113, 140–148, 178–184, 190, 197
Multi-Disciplinary Team (MDT) A group of health care workers who are
members of different disciplines. 8
Multi-Leaf Collimator (MLC) Series of thin collimators, which can be used
to shape the radiation beam. xii, 19, 21, 22, 27, 46, 47, 58, 62, 65, 67, 76,
103, 139
National Institute of Standards and Technology (NIST) Measurement stand-
ards laboratory in the United States of America. 57
Off Axis Factor (OAF) Ratio of the absorbed dose at a point away from the
beam axis, to the absorbed dose at a point on the beam axis at the same
depth. Depends on the energy of the beam, depth, and the field size. 41
Organ at Risk (OAR) Organs to which the radiation dose must be taken into
account during the treatment planning process. 14, 15, 22, 25, 75, 79, 80,
110, 149, 188, 189, 199
Output Factor (OPF) Ratio of absorbed dose at the depth of maximum dose
on the beam axis for a given field size, to the absorbed dose at the same
depth on the beam axis for a 10 cm by 10 cm field. 103
Oxygen Enhancement Ratio (OER) The ratio of doses needed to produce a
given effect in the presence and absence of oxygen. 10
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Pencil Beam Algorithm (PB) Type A Dose Calculation algorithm used in
Oncentra MasterPlan. 15, 16, 24, 25, 28, 44, 46, 49–53, 72–75, 188
Pencil Beam Enhanced Algorithm (PBE) Enhanced version of the Pencil
Beam Algorithm, which is faster than standard due to efficiencies in the
calculation, while using a higher resolution head scatter grid. Throughout
this work, the Enhanced version of the Pencil Beam Algorithm has been
used. iv, xvi, xvii, 50, 52, 76, 77, 86, 113, 140–148, 178–184, 188, 190,
196–198
Percentage Depth Dose (PDD) The PDD at a point in a water phantom is
the absorbed dose at that point divided by the absorbed dose at the depth
of maximum dose for the same field size, expressed as a percentage. PDD
applies only to the points along the beam axis. xv, 37–39, 41, 47, 114–120,
127
Personally Identifiable Information (PII) Any data that could potentially
identify a specific individual. 68
peta-electron volts (PeV) A unit of energy, usually used for to the energy of
a charged particle. An Electron will gain 1 eV, equal to 1.602 × 10−19 joule,
when accelerated through a potential of 1 volt. 1 PeV is 1015 eV. 60
Photo-electric effect (PE) Process by which a photon interacts will an elec-
tron bound to an atom, and the electron is ejected. 29, 31, 38
Pixel A portmanteau of Picture Element; one value on a regular grid in two
dimensional space; may be smallest addressable element in a display device.
48, 107, 108, 110, 112
Planning Reference Volume (PRV) A margin added to certain Organs at
Risk, to account for set-up uncertainties. 79, 80, 143, 147, 149, 154, 177,
181, 182, 188–190, 198
Planning Target Volume (PTV) Clinical Target Volume plus a margin for
set-up uncertainties. iv, xvi–xviii, 16, 25, 74–76, 79, 110, 139–143, 147, 149,
150, 152, 154, 156–158, 161, 168, 173–175, 177, 178, 181–195, 197, 198, 201
Positron Emission Tomography (PET) Functional imaging technique, used
to examine metabolic processes in the body. 8, 22, 79
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Prostate Specific Antigen (PSA) Screening test for Prostate Cancer. 3
Radiation Therapy Oncology Group (RTOG) Clinical cooperative group
for the purpose of conducting radiation therapy research and cooperative
clinical investigations in the USA. 68, 161, 162, 168
Radiotherapy (RT) Use of ionising radiation to treat disease, primarily cancer.
iv, 4, 8, 10, 13, 14, 22, 24, 74, 76–79, 110, 133, 154, 188, 196, 199, 200
Radiotherapy Trials Quality Assurance (RTTQA) Group funded by the
National Cancer Research Institute (NCRI), whom ensure that patients
in all NCRI radiotherapy trials are treated in accordance with the trial
protocol, and are treated according to nationally accepted standards. 8, 9,
23
Receiver Operator Characteristic (ROC) Plot of sensitivity of a test against
1-specificity, as a threshold used in the test is varied. Used to assess the
effectiveness of a test. 184–186
Region Of Interest (ROI) Organ, region, or group of tissues outlined prior
to Radiotherapy Treatment Plan production. Includes targets such as the
Planning Target Volume, and Organs At Risk. 87, 88, 112, 149, 200
RTOG Conformance Index (RTOG-CI) Conformance Index proposed by RTOG
for measuring how one region of interest conforms to another, calculated as
the the union of the two volumes divided by the volume of the first volume,
multiplies by the union of the two volumes divided by the volume of the
second volume. 161, 166
Secure SHell (SSH) Network protocol using cryptography to provide a secure
communications channel over an unsecured network. 67, 86, 113
Single Strand Break (SSB) In radiobiology, a single strand break is a break
in one of the two helices in the structure of the DNA molecule. 9
Stoichiometric Of or pertaining to the calculation of relative quantities of chem-
icals in a compound or mixture. 89
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Stopping Power Ratio (SPR) In Bragg-Gray cavity theory, the quantity that
relates the absorbed dose to a medium to the absorbed dose to water. xiv,
99–102, 113
Structured Query Language (SQL) Computer language used for the retrieval
and management of data stored in relational database management systems.
133
Tissue Air Ratio (TAR) The TAR at a point in a water phantom is the ratio
of the total absorbed dose at that point, divided by the total absorbed dose
at a point with the same distance from the source, but measured with the
phantom shifted so that this point is at the depth of maximum dose. Since
the dose at depth of maximum dose is wholly from primary photons, TAR is
a way of expressing the dose normalised in terms of primary dose. Despite
the name, the current definition does not involve measurement in air. 42
total energy released per unit mass (terma) Concept analogous to kerma,
but includes all energy released, not just kinetic energy, i.e. radiative energy
is included. 45
Treatment Planning System (TPS) Specialised type of Computer Aided Design
software, used to design Radiotherapy Treatment Plans. iv, 14, 15, 22, 24,
25, 37, 44, 61, 64–68, 75, 105, 111, 156, 196, 197
Tumour Control Probability (TCP) In Radiotherapy, the probability of killing
enough of the cancerous cells to control the tumour. iv, 165–168, 190, 197,
198
van’t Reit Conformation Number (Reit-CI) Conformance Index for meas-
uring how one region of interest conforms to another, calculated as the ratio
of the volumes of the two objects of interest. 163, 166, 168
Volumetric Modulated Arc Radiotherapy (VMAT) Type of Radiotherapy
in which the gantry rotates, the dose rate is varied, and Multi-Leaf Col-
limators move across the radiation field during delivery, to produce dose
distributions that cannot be achieved with Conformal Radiotherapy. 46,
67, 75, 139, 201
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Voxel A portmanteau of Volume Element; one value on a regular grid in three
dimensional space. iv, 23, 48, 50, 51, 64, 88, 94, 95, 102, 108, 111, 114, 120,
149, 189, 191, 197, 198, 200, 201
Wedge Factor (WF) Ratio of dose at a reference depth, often taken to be
depth of maximum dose, with and without a wedge in the beam. Depends
on energy of the beam, angle of wedge, and for dynamic beams the field
size. 41
Z Atomic number of an atom, or medium. 29, 30, 32, 34, 37, 53
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